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Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder 
involving selective degeneration of motor neurones. In a proportion of patients, 
ALS is caused by mutations in copper/zinc superoxide dismutase (S0D1), and 
mice expressing these mutants develop a syndrome that resembles human 
ALS. Using S0D1^^^^ transgenic mice, the role of glutamate-mediated toxicity 
and related intracellular pathways in motor neurone death has been 
investigated. GluR2 AMPA receptor subunits were decreased in spinal motor 
neurones of S0D1®®^  ^ mice before symptom onset. Since GluR2-lacking 
receptors are highly permeable to Ca^ ,^ a known trigger of excitotoxic neuronal 
death, this phenomenon may have a pathogenic role. In support of this, 
treatment with an AMPA antagonist, ZK-187638, ameliorated motor symptoms 
and prolonged the survival of S0D1®®^  ^mice. GluR2-lacking receptors are also 
permeable to zinc, which can be highly toxic. In situ hybridisation showed low 
expression of the zinc extruder ZnT-1 on motor neurones, which may contribute 
to their vulnerability to excitotoxicity. Expression of glutamate transporters on 
astrocytes may also contribute to excitotoxic motor neurone death. In transgenic 
mice and in astrocytes transfected with S0D1®®^ ,^ immunocytochemistry. 
Western blotting, in situ hybridisation and RT-PCR revealed down-regulation of 
GLT-1 protein, but not mRNA in astrocytes. However, the time-course in mice 
suggests that GLT-1 downregulation is not a primary pathological event. 
Activation of p38MAPK, a kinase putatively involved in glutamate mediated 
neurotoxicity, was observed in motor neurones at the onset of the disease, but
SB 239063, a p38MAPK inhibitor, did not ameliorate motor dysfunction or 
survival of mice.
Altogether the results suggest that AMPA receptor mediated excitotoxicity 
is a primary cause of motor neurone degeneration in ALS. These observations 
may contribute to the development of new therapeutic strategies for this 
devastating disease.
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In the spring of 1938, when Lou Gehrig, the star baseball player of the 
New York Yankees, was still only 34 and at the top of his career, his level of 
play fell off sharply. No one yet knew the terrible truth, but Gehrig's physical 
decline became more evident in the off-season, and in spring training the next 
year it became glaringly obvious. Gehrig moved like an old man: stiffly, slowly. 
He stumbled, his reflexes were slow, there was little speed or power in his 
swing. On June 1939, doctors at the Mayo Clinic in Rochester, Minnesota, 
diagnosed Lou Gehrig with a very rare form of degenerative disease: 
amyotrophic lateral sclerosis. There was no chance: he would ever play 
baseball again. Not only was his career over, but his life would soon be as well. 
On June 2, 1941 Lou Gehrig died at the age of 37.
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CHAPTER 1
OVERALL INTRODUCTION
23
Progressive muscular weakness affecting the motor system was a clinical 
condition well known to the physicians of 19*^  century and for years it was 
considered as a muscular disorder. In 1869 the famous French neurobiologist 
and physician Jean-Martin Charcot, studying the pathological features of this 
syndrome, described the characteristic alterations of the corticospinal tract and 
the loss of motor neurones in the bulbar nuclei and proposed the term 
amyotrophic lateral sclerosis. The term motor neurone diseases was introduced 
in the sixties to indicate a group of similar diseases of the motor system, that 
differed in terms of involvement of upper and lower motor neurones and of the 
topography of muscular weakness: amyotrophic lateral sclerosis (ALS), 
progressive bulbar palsy (PBP), progressive muscular atrophy (PMA), primary 
lateral sclerosis (PLS) and other minor syndromes. However, the term motor 
neurone disease (MND) is commonly used in the United Kingdom to indicate 
the ALS syndrome. In the United States, ALS is often known as Lou Gehrig’s 
disease after of the great baseball player who developed the disease in the 
1930s. Amyotrophic lateral sclerosis remains the most important of the motor 
neurone disorders, representing 85-90% of cases of this kind of pathologies
1.1 The motor system
Since motor neurone disease is manifested as a clinical condition affecting 
motor neurones, I shall review the principles of motor system in man.
24
Muscle contraction is the final event of the fine and highly elaborate motor 
control system. The motor pathways are pathways that originate in the motor 
cortex or in the brainstem and descend down the spinal cord to control the a- 
motor neurones. These large neurones in the ventral horns of the spinal cord 
send their axons out via the spinal roots and directly cause muscle contraction 
(Figure 1.1). The motor pathways can control posture, reflexes and muscle 
tone, as well as the conscious voluntary movements.
Motor cortex
Orophanngeal 
muscles
Bulbar
motor
neurone
Medulla
muscles
Somatic
motor
neurone
Spinal cord
Y" Medulla
Cervical 
spinal cord
Thoracic 
spinal cord
Lumbar 
 ^ spinal cord
Figure 1.1: The motor system
Adapted from Rowland LP and Shneider NA, N Engl J Med., 2001
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The primary motor cortex (also called Brodmann’s area 4) is located in the 
precentral gyrus of the frontal lobe and receives information from a number of 
surrounding areas. Firing of upper motor neurones (UMNs) controls the lower 
motor neurones (LMNs) of the spinal cord and brainstem. The cortical areas 
that project to the primary motor cortex are called somatosensory cortex, 
prefrontal cortex and premotor areas (Brodmann’s area 6), which are 
subdivided into the supplementary motor area (also called secondary motor 
cortex) and the premotor cortex. The somatosensory cortex is located in the 
post-central gyrus of the parietal lobe and provides information from the senses 
of touch and proprioception. This proprioceptive information is necessary for the 
proper guidance of movement. The remaining cortical areas that project to the 
primary motor cortex are located in the frontal lobe. Each of these regions is 
involved in the preparation of movement. The supplementary motor area and 
the premotor cortex are most active during the planning of movement, even 
when the movement is not executed, and are reciprocally connected to the 
primary motor cortex and each other. Input to the premotor cortex is primarily 
visual, whereas input to the supplementary motor cortex is primarily 
somatosensory. Each of these cortical regions is located just anterior to the 
primary motor cortex, with the supplementary motor cortex wrapping around 
into the longitudinal fissure separating the two hemispheres. Neuronal activity 
within the prefrontal cortex is associated, in particular, with sensory signals just 
preceding a movement. The prefrontal cortex receives projections from the 
posterior parietal cortex and projects to the secondary motor cortex and to the 
primary motor cortex. The prefrontal cortex may provide a mental
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representation of a stimulus to be the target of a movement and in addition may 
make the choice to initiate a voluntary response to that stimulus. Based on the 
diversity of information reaching the primary motor cortex, this region controls 
the complex and coordinated movement of several muscles.
The primary motor cortex has a distinct group of motor neurone in layer 5 
known as the giant pyramidal cell or Betz cells. However, this group of cell 
represents only a small portion of all the primary motor neurones in this layer. A 
single motor neurone in the primary motor cortex activates the contraction of a 
small group of skeletal muscles and control the force of contraction by varying 
its firing rate. Particular regions of the primary motor cortex control a particular 
region of the body and each region is additionally activated by adjacent regions 
of the cortex.
Axons from motor neurones in the primary motor cortex project downward 
through the brainstem to the ventral horn of the spinal cord where the activation 
of appropriate lower motor neurones occurs. Axons of the upper motor 
neurones are conveyed in the corticospinal tract of the pyramidal system. They 
descend to their destination within the lateral white matter of the spinal cord 
where they branch off to synapse primarily with interneurones, which play a 
crucial role in the final output, located within the ventral horn of the spinal 
segments where the lower motor neurones for the appropriate muscles are 
located. The corticospinal tract is divided into the lateral tract, which controls 
contraction of muscles in the extremities, and in the anterior tract, which 
controls axial and postural muscle contraction.
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Lower motor neurones are located in the anterior grey matter of the ventral 
spinal cord and in the motor nuclei of the brainstem. Their axons directly 
innervate the muscle fibers.
Large lower motor neurones, called a-motor neurones, are the principal 
lower motor neurones innervating the muscle fibers. Medium size motor 
neurones, known as p-motor neurones, innervate both muscle fibers and 
intrafusal fibers, y-motor neurones are small neurones innervating the intrafusal 
fibers only, a-motor neurones are the largest neurone types of the nervous 
system. They have long axons (up to 1 metre in same cases) and an extensive 
dendrite ramification, with dendrites that can reach 1 millimeter in length and 
extend well into the white matter, receiving thousands of synaptic contacts. One 
a-motor neurone innervates a single group of muscle fibers, generating a motor 
unit. Upon firing of the a-motor neuron, acetylcholine is released and binds to 
nicotinic acetylcholine receptors on the surface of muscle fibers, resulting in a 
rapid increase in intracellular calcium ion concentration, initiating the 
contraction. All of the muscle fibres in a motor unit contract at the same time 
and to their maximum. Each muscle is made up of many motor units and these 
motor units vary in their number of fibres (10 to 2000). The intensity of a muscle 
contraction therefore is determined by the number and size of the motor units 
activated.
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1.2 Diagnosis of amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis is one of the most devastating human 
disorders. It is an incurable fatal neuromuscular disease resulting from the 
selective degeneration of upper motor neurones in the motor cortex and lower 
motor neurones in the brainstem and spinal cord.
Diagnosis of ALS is often critical. In fact, many different clinical conditions 
may resemble ALS. To date, no one test or specific diagnostic marker can 
provide a definitive diagnosis of ALS, although the presence of upper and lower 
motor neurone signs in a single limb is strongly suggestive (Table 1.1). Thus, 
the diagnosis of ALS is primarily based on the symptoms and signs that the 
physician observes in the patient and on a series of tests to rule out other 
diseases. Criteria for clinical and pathological diagnosis have been defined 
during the ALS meeting held in El Escorial, Spain in 1994 and updated at Airlie 
House, Virginia four years later. However, these criteria unfortunately do not 
allow a presymptomatic diagnosis, which could be very useful in the future for 
effective therapeutic treatments.
Requirements for the diagnosis of ALS according to Airlie House guideline. 
The diagnosis of Amyotrophic Lateral Sclerosis requires:
A - the presence of:
1) evidence of lower motor neurone (LMN) degeneration by clinical, 
electrophysiological or neuropathologic examination.
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2) evidence of upper motor neurone (UMN) degeneration by clinical 
examination, and
3) progressive spread of symptoms or signs within a region or to other 
regions, as determined by history or examination,
together with
B - the absence of:
1) electrophysiological and pathological evidence of other disease 
processes that might explain the signs of LMN and/or UMN 
degeneration, and
2) neuroimaging evidence of other disease processes that might explain 
the observed clinical and electrophysiological signs.
A careful history, physical and neurological examination must search for 
clinical evidence of UMN and LMN signs in four regions (brainstem, cervical, 
thoracic or lumbosacral spinal cord) of the central nervous system (CNS). 
Ancillary tests should be reasonably applied, as clinically indicated, to exclude 
other disease processes. These should include electrodiagnostic, 
neurophysiological, neuroimaging and clinical laboratory studies. The clinical 
diagnosis of ALS, without pathological confirmation, may be categorized into 
various levels of certainty by clinical assessment alone depending on the 
presence of UMN and LMN signs together in the same topographical anatomic
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region in either the brainstem (bulbar cranial motor neurones) cervical, thoracic, 
or lumbosacral spinal cord (anterior horn motor neurones).
The terms Clinical Definite ALS and Clinically Probable ALS are used to 
describe these categories of clinical diagnostic certainty on clinical criteria 
alone;
Clinically Definite ALS
It is defined on clinical evidence alone by the presence of UMN, as well as 
LMN signs, in three regions.
Clinically Probable ALS
It is defined on clinical evidence alone by UMN and LMN signs in at least 
two regions with some UMN signs necessarily rostral to (above) the LMN signs.
Clinically Probable - Laboratory-supported ALS
It is defined when clinical signs of UMN and LMN dysfunction are in only 
one region, or when UMN signs alone are present in one region, and LMN signs 
defined by EMG criteria are present in at least two limbs, with proper application 
of neuroimaging and clinical laboratory protocols to exclude other causes.
Clinically Possible ALS
It is defined when clinical signs of UMN and LMN dysfunction are found 
together in only one region or UMN signs are found alone in two or more 
regions; or LMN signs are found rostral to UMN signs and the diagnosis of
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Clinically Probable - Laboratory-supported ALS cannot be proven by evidence 
on clinical grounds. Other diagnoses must have been excluded to accept a 
diagnosis of Clinically Possible ALS.
Clinically Suspected ALS
It is a pure LMN syndrome, wherein the diagnosis of ALS could not be 
regarded as sufficiently certain to include the patient in a research study. 
Hence, this category is deleted from the revised El Escorial Criteria for the 
Diagnosis of ALS.
Lower motor neurones Upper motor neurones
Symptoms Fatigue Weakness
Weakness Incoordination
Cramps Stiffness
Twitching of muscles 
Incoordination
Slowing of distal movement
Signs Weakness Spasticity
Fasciculations Brisk reflexes
Suppression of reflexes Babinski and Hoffman signs
Hypotonia Weakness
Atrophy Pseudobulbar effect
Table 1.1: Lower and upper motor neurone dysfunctions
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1.3 Clinical phenotype of amyotrophic iaterai scierosis
Amyotrophic lateral sclerosis is an unremitting, progressive, consistently 
fatal neurodegenerative disease. Upper and lower motor neurones, which 
control the movement of voluntary muscles, deteriorate and eventually die. 
When the motor neurones die, the brain can no longer initiate and control 
muscle movement. Because muscles no longer receive the input they need in 
order to function, they gradually weaken and deteriorate, producing deep 
atrophy of muscles.
In the beginning, ALS often displays asymmetrical symptoms and signs 
and may be quite focal, for example affecting the upper limbs with relative 
sparing of the lower limbs. The different extent and localization of involvement 
of motor system determines various early clinical features in different patients 
but ultimately, as the disorder progresses, the clinical expression of ALS is quite 
uniform, with extreme muscular wasting, spasticity and paralysis.
The clinical manifestation depends and varies on the basis of the 
combination of the UMN and LMN involvement. The different features are 
determined not only by the degeneration pattern but also by the stage of the 
disease and the body region involved.
Lower motor neurone involvement determines weakness and fatigue, 
associated to progressive muscular atrophy, fasciculation (muscular twitching 
and shaking of contiguous groups of muscle fibers) and fibrillation (muscular 
twitching and shaking involving individual muscle fibers acting without 
coordination), reduced muscle tone and absence of tendon reflex. Upper motor
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neurone involvement causes weakness, incoordination, stiffness and slowing of 
movement, with spasticity (persistent contraction of muscle), increased tendon 
reflexes and clonus (alternating contractions and relaxations). An abnormal 
reflex commonly called Babinski's sign (the large toe extends upward as the 
sole of the foot is stimulated in a certain way) also indicates upper motor 
neurone damage.
The commonest initial manifestation of ALS is asymmetric distal weakness 
and muscular atrophy, which determine difficulty in performing and coordinating 
fine movements such as buttoning clothes and picking up objects. Occasionally, 
the involvement of proximal limb muscles at the early stage of ALS may cause 
difficulty in walking, climbing stairs and carrying out heavy work. A consistent 
and appreciable loss of strength requires the loss of about 50% of motor 
neurones. Before this point, compensatory reinnervation from nearby motor 
neurones permits a good maintenance of function, although with enlargement of 
motor units. At this stage, the loss of motor neurones is noticeable only through 
electromyography. Patients often report fasciculation, cramps and spasms.
Signs of bulbar involvement often develop during the course of the 
pathology but may also represent an initial feature in some cases. Bulbar motor 
neurone degeneration leads to difficulty in swallowing (dysphagia) and speaking 
or forming words (dysarthria), associated to fasciculation of the tongue. Bulbar 
signs are often closely related to respiratory deficit, due to the involvement of 
diaphragmatic muscular weakness. This leads to a poor prognosis and to a 
shorter life expectancy. However, limbs onset is found in 75-80% of cases and 
bulbar onset is evidenced in only 20-25%.
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With the progression of the illness, the disease spreads to contiguous 
body segments. The upper motor neurone signs, which must be present in all 
defined case of ALS, are often quite difficult to recognize because of 
predominant muscle wasting determined by LMN involvement. The progressive 
loss of motor function results in increasing disability and paralysis, ultimately 
leading to a bed-bound state. Because the disease leaves cognitive abilities 
relatively unimpaired, patients are aware of their progressive loss of function. 
The usual course of ALS leads to death, occurring because of respiratory 
failure. In 50% of cases death occurs within 3 years from diagnosis.
“ALS is like a lit candle: it melts your nerves and leaves your body a pile of 
wax. Often it begins with the legs and works its way up. You lose control of your 
thigh muscles, so that you cannot support yourself standing. You lose control of 
your trunk muscles, so that you cannot sit up straight. By the end, if  you are still 
alive, you are breathing through a tube in a hole in your throat, while your soul, 
perfectly awake, is imprisoned inside a limp husk, perhaps able to blink, or cluck 
a tongue, like something from a science fiction movie, the man frozen inside his 
own flesh. This takes no more than five years from the day you contract the 
disease.”
Extract from “Tuesdays With Morrie” by Mitch Albom
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1.4 Neuropathology of amyotrophic lateral sclerosis
In the last years, ultrastructural and immunohistochemical studies 
performed on post mortem tissues have helped to better describe the 
neuropathology of ALS, defining its histopathological features and giving 
important clues about the pathogenesis of this devastating disease. Apart from 
some cases of accidental death of ALS patients at early stage of the disease, 
the bulk of post mortem examinations are conducted on tissues representing 
the final stage of the pathology. As a result, the alterations observed reflect a 
very advanced state of neuronal degeneration and give little information about 
the triggering events causing the cell death. It is also true that patients have 
different degrees of neuronal degeneration in different areas of their central 
nervous system. For example, many patients with aggressive form of bulbar 
onset ALS at time of death often have relatively spared motor neurones in the 
spinal cord. However, the analysis of these groups of motor neurones has not 
yet given any clear indication on the events that occur early in the pathology.
The degree of degeneration observable at autopsy in the motor cortex of 
ALS patients is quite variable and may not be always evident, even in the 
presence of clear upper motor neurone signs. In the most severely affected 
cases, there is an obvious loss of giant Betz cells in cortical layer 5 associated 
with an extensive astrogliosis. However, there are not good markers to 
distinguish upper motor neurones and other pyramidal cell types in the cortex. 
Thus, the identification of the Betz cell is often based on morphological and size 
criteria. Large pyramidal neurones are diminished in number in the motor cortex
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and in the surrounding regions somatosensory cortex, prefrontal cortex and 
premotor areas. Neurone cell bodies are atrophied (Kiernan and Hudson, 
1991), with shorter fragmented dendrites (Hammer et al., 1979). Intracellular 
alterations are rarely identified in the spared Betz cells in classical ALS. 
Occasionally ubiquitinated neurofilament inclusions are reported. More evident 
lesions are observable in familial ALS (FALS) cases associated with S0D1 
mutant.
Axonal degeneration of the descending corticospinal tracts results In clear 
demyelination of the tract. Thus, the spinal cord of ALS cases shows a typical 
bright pallor. An extensive gliosis is present, causing the typical sclerosis of 
lateral side of the spinal cord.
Loss of large motor neurones in the lower brain stem and spinal cord 
(lower motor neurones) is clearly observed at autopsy. As in the upper motor 
neurones of motor cortex, shrinkage and atrophy of cell body precede neuronal 
death (Kiernan and Hudson, 1991). This phenomenon is associated with 
alterations of axon and dendrite structure, which become thinner (Nakano and 
Hirano, 1987). Remaining motor neurones present several abnormalities: 
diffuse accumulation of phosphorylated neurofilaments is observed in the 
perikarya of motor neurones, especially in sporadic ALS (Hirano et al., 1984a), 
whereas focal accumulation is more common in familial cases (Hirano et al., 
1984b; Mizusawa et al., 1989). Since phosphorylated neurofilaments are 
normally present only in the distal axons, this unusual distribution may indicate 
an altered slow axonal transport of neurofilaments in affected motor neurones. 
Phosphorylated neurofilaments are also packed in axonal swellings called
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spheroids, together with peripherin and kinesin (Corbo and Hays, 1992; 
Toyoshima et al., 1998). Small spheroids, termed globules, are also observed in 
age matched controls and in normal aging nervous system but they are fewer in 
number and smaller than those observed in sporadic ALS patients (Hirano et 
al., 1984a). These features have not been described in familial ALS.
Cell bodies and proximal axons of spinal motor neurones show several 
types of inclusions with different shapes. Many of them are immunoreactive to 
ubiquitin (Leigh et al., 1988). This 76 amino acid polypeptide is involved in the 
non lysosomal ATP-dependent degradation of abnormal cytoplasmic proteins 
(ubiquitin-proteasome pathway) and in other cellular functions. The presence of 
ubiquitinated inclusions in the lower motor neurones is specific to ALS 
pathology, although characteristic inclusions in other neurodegenerative 
disorders (neurofibrillary tangles, Pick bodies) often are also ubiquitin 
immunopositive (Schiffer et al., 1991). The ubiquitinated inclusions found in ALS 
have been classified in two types: skein-like and Lewy body-like inclusions. 
Skein-like inclusions are a specific hallmark of ALS whereas Lewy body-like 
inclusions are not specific for ALS. Both the inclusions probably represent two 
different morphological stages of protein aggregations, from diffuse filamentous 
forms to dense and compact inclusions. Both skein-like and Lewy body-like 
inclusions contain tubules and filaments with diameters ranging from 15 to 25 
nm as determined by electron microscopy (Murayama et al., 1989; Mizusawa et 
al., 1991; Schiffer et al., 1991). In skein-like arrays, ubiquitin labelling is 
concentrated on abnormally formed 15-20 nm filaments and neurofilament 
immunostaining localized on 10 nm filaments adjacent or in continuity with the
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abnormal filaments (Migheli et al., 1994). Besides phosphorylated 
neurofilaments and ubiquitin inclusions, Lewy body-like inclusions also contain 
CDK5 kinase (Nakamura et al., 1997). More recently, dorfin, a RING finger-type 
E3 ubiquitin ligase, has also been localized in the inclusion bodies found in the 
motor neurones and neuronal processes of familial and sporadic ALS 
(Hishikawa et al., 2003).
Another type of intracellular inclusion is named hyalin conglomerate 
inclusions. They consist in large aggregates of phosphorylated and non 
phosphorylated neurofilaments associated with other cytoplasmic proteins and 
ubiquitin (Schochet et al., 1969; Leigh et al., 1989; Sasaki and Maruyama, 
1991). Identified in sporadic and familial ALS, they however seem to be less 
specific for ALS pathology since they have been found in other neurological 
disorders (Sobue et al., 1990).
Bunina bodies are eosinophilic granules originally observed in familial ALS 
that are also found in sporadic and Guamaniam ALS. They can be considered 
ALS specific and they are clearly distinguishable from the other inclusion 
bodies. Surrounded by endoplasmic reticulum fragments and other debries, it 
has been hypothesized that they can originate from lysosomes (Sasaki and 
Maruyama, 1993).
1.5 Genetics of amyotrophic lateral sclerosis
In 90-95% of ALS cases, there is no apparent genetic linkage (sporadic 
ALS) but in the remaining 5-10% the disease is inherited mostly in a dominant
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manner, with rare cases of recessive inheritance. The genetic form is named 
familial ALS or FALS. The clinical phenotype of sporadic and FALS is 
indistinguishable, although FALS patients do present some different features in 
the pathology, which are described in more detail in section 1.6.
In 1993, Rosen and colleagues reported that mutations in the gene coding 
for soluble, cytoplasmic enzyme Cu,Zn superoxide dismutase (S0D1) (locus on 
chromosome 21q22.11) were associated with a subset (about 15%) of familial 
ALS patients (Rosen et al., 1993). This landmark discovery represented an 
important step forward in the ALS research, permitting the creation of new 
experimental models to study the ALS pathology. S0D1 is an abundant protein, 
representing up to 2% of the soluble proteins of the brain. SOD1 is a 153 amino 
acid, cytoplasmic homodimer that convert superoxide, which is produced 
primarily as a by-product of oxidative phosphorylation in mitochondria, to water 
and hydrogen peroxide (Figure 1.2). Catalysis by S0D1 is mediated in two 
asymmetric steps by an essential copper atom, which is alternately reduced and 
oxidized by superoxide. The zinc atom has a structural function.
To date, more than one hundred different mutations have been identified in 
S0D1 gene in familial cases. The different mutations are almost entirely located 
on the five exons and scattered throughout the primary structure of the protein. 
The bulk of them determine an amino acid substitution (missense mutations). 
The remaining are nonsense, insertion and deletion mutations but none 
completely eliminate protein synthesis.
Almost all the S0D1 mutations known are inherited as a dominant trait, 
with the only exception of S0D1^®°^ (Andersen et al., 1995). However, it is not
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clear yet how such a wide range of diverse mutations in S0D1, which is 
ubiquitously expressed in all the cells, can cause the selective motor neurone 
degeneration with no obvious clinical differences between the different mutant 
forms.
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Figure 1.2: S0D1 chemistry
Normal superoxide dismutase 1 (SOD1) chemistry: SOD1-mediated dismutation 
of superoxide in two asymmetric steps.
It was initially proposed that the toxicity of mutated S0D1 is associated 
with the loss of superoxide dismutase activity. However, most mutated S0D1 
forms appear to fully retain their enzymatic property. The creation of transgenic 
mice expressing S0D1 with some of the mutations found in the human patients, 
which develop a motor syndrome similar to human ALS, show that catalytic 
activity is unchanged or elevated (Gurney et al., 1994; Ripps et al., 1995a; 
Wong et al., 1995; Bruijn et al., 1997b). Furthermore, S0D1 knockout mice do 
not develop spontaneous motor neurone disease (Reaume et al., 1996). The
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conclusion is that S0D1 mutants acquire one or more toxic properties, 
irrespective of the amount of superoxide dismutase activity that each of them 
retains.
Loci for several other genetic motor neurone disorders have been 
identified (Table 1.2). These include one example of a syndrome with dominant 
inheritance and apparently complete penetrance (probability of a genetic trait 
being expressed in the phenotype), with very juvenile onset (in the late teens) 
and a very slow progression of distal limb atrophy and motor neurone loss that 
does not reduce lifespan (ALS4). The locus has been mapped to chromosome 
9q34, (Chance et al., 1998) and missense mutations (T3I, L389S, and R2136H) 
have been detected in the senataxin gene. This gene encodes a protein that 
has unknown function. It contains a DNA/RNA helicase domain with strong 
homology to human RENT1 and IGHMBP2, two genes encoding proteins 
known to have roles in RNA processing (Chen et al., 2004).
Two other ALS-like disorders associated with mutations, with recessive 
inheritance and juvenile onset, have been clearly described. Found in seven 
Tunisian families, one of them is characterized by initial atrophy and weakness 
of hands and feet, with later involvement of upper motor neurones, associated 
with spasticity of limbs, and long survival. The mutation locus has been 
localized at 15q15.22, but the affected gene has not yet been identified (Hentati 
et al., 1998). The second one is associated to a gene called ALS2 or alsin, 
originally mapped to chromosome 2q33, which has been found to encode a 184 
KDa protein derived from 34 exons that span 80 Kb (Yang et al., 2001). To 
date, two deletion mutations have been discovered on this gene. The disease
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related to ALS2 is distinguished by the predominance of spasticity of facial and 
limbs muscles. Sequence inspection of the gene reveals that the 650 amino 
acids of the amino-terminal of AL82 contain all of the sequence motifs that are 
characteristic of guanine exchange factors (GEFs). These proteins are involved 
into recycle of a specific small G protein from its GDP-bound state to its GTP- 
state. There is no information so far about which G protein is the partner for this 
putative GEF. The carboxy-terminal half of ALS2 contains two further domains, 
which are similar to those of the Rho G-protein family that modulates dynamic 
actin assembly. Like S0D1, ALS2 is probably widely expressed.
Recently, a genome screening study of ALS families lacking S0D1 
mutations allowed to identify a new putative locus on chromosome 16q12.1- 
q12.2. The region associated with disease was further refined in the major 
family that contributed to this result and was localized to D16S409-D16S3032, a 
14.74-cM genetic interval that corresponds to a physical distance of 6.6 Mb 
(Abalkhail et al., 2003).
A set of small in-frame deletions or insertions in the repetitive tail domain 
of the large neurofilament subunit NF-H has been identified in about 1% of 
1,300 sporadic ALS patients examined (Al-Chalabi et al., 1999). Search in this 
one domain alone has therefore found mutations in the overall patient 
population. They result about half as frequent as S0D1 mutations. Although the 
known neurofilament sequence variants are thought not to be capable by 
themselves of producing disease with high penetrance, it is likely that variants in 
neurofilaments are at least important risk factors for apparently sporadic 
disease.
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A number of other genetic alterations have been identified, which may 
confer a higher predisposition to development of ALS syndrome. They include 
mitochondrial DNA microdeletions encoding for cytochrome-C oxidase 
(Borthwick et al., 1999), RNA processing errors in the glutamate transporter 
EAAT2 (Lin et al., 1998), an abnormal copy number of the survival motor 
neurone (SMN) gene (Corcia et al., 2002) and gene deletions of the 
chromosome 5q13-linked neuronal apoptosis inhibitory protein (NAIP) gene 
(Jackson et al., 1996). An increased frequency of the cytochrome P450 
debrisoquine hydroxylase CYP2D6(B) allele, encoding a cytochrome P450 
monooxygenase involved in drug metabolism and associated with a "poor 
metabolizer" phenotype, has been also described (Siddons et al., 1996).
Category Inheritance
features
Chromosomal
location
Gene identified
ALS1 AD 21q22 S0D1
ALS2 AR 2q33-35 Alsin
ALS3 AD Unknown
ALS4 AD 9q34 senataxin
ALS5 AR 15q15.22
ALS6 AD 18q21
ALS/FT AD 9q21-22
AD: autosomal dominant; AR: autosomal recessive
Table 1.2: Familial ALS, known inheritance patterns
44
1.6 Epidemiology of amyotrophic lateral sclerosis
ALS is considered as a rare disease. However, its personal and 
socioeconomic impact is grater than its annual incidence (number of new 
identified patients per year). It has been calculated that considering a 
generation time of 20 years, one in 200 people have a family member affected 
by ALS. The epidemiology studies generally consider three distinct forms of the 
disease with different epidemiologic and pathologic characteristics: the two 
forms discussed above, sporadic ALS and familial ALS but also Western Pacific 
ALS, a form of the disease found particularly in this geographic area.
Sporadic ALS occurs in about 1-3 people per 100,000 population per year 
with a prevalence (number of surviving patients at any given time) of about 5-7 
per 100,000. Typically, it strikes adults between the ages of 55 and 75. It is 
predominantly men who are affected, with a male to female ratio of 1.4 to 2.5. 
However, bulbar onset has been reported to be more frequent in female, 
probably due to the effect of sexual hormones on bulbar motor neurones 
expressing androgen receptors (Matsuura et al., 1993). People of all races and 
ethnic backgrounds are affected by it. The average survival for sporadic ALS 
patients is approximately 3 years after the onset of the disease.
Although familial ALS is almost indistinguishable from the sporadic form in 
terms of clinical phenotype, some differences distinguish FALS from an 
epidemiological point of view. FALS represent worldwide 5% to 10% of all ALS 
cases. Inheritance is predominantly autosomal dominant with some recessive 
exceptions. The average onset of FALS cases is approximately 47 years, a
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decade earlier than the sporadic type. FALS occurs equally in males and 
females. In FALS, symptoms more frequently begin in the lower extremities 
compared to sporadic ALS. Once diagnosed, the familial form leads to death in 
1 or 2 years, although some individuals survive 5 years. Very aggressive cases 
with a survival of less than 1 year have been also reported.
The incidence of ALS disease in Western pacific islands such as Guam, 
Rota and Micronesia, in the Kii Peninsula of Japan and in west New Guinea is 
approximately 100-150 fold higher than the other world regions. Although the 
clinical features of the Western Pacific ALS are similar to the others, this form is 
considered a distinct disease because it is often associated to Parkinsonism 
dementia, with pathological alteration resembling Alzheimer's disease 
(neurofibrillary tangles). This disease is not considered further in this thesis.
1.7 Experimental models of amyotrophic lateral sclerosis
Hystopathological studies performed on post mortem tissue obtained from 
ALS patients at autopsy may give important information about the status of 
motor neurones and other cells involved in the pathology at the final stage of 
the disease. However, they provide a poor contribution to the comprehension of 
the pathogenic mechanisms. Thus, the study of experimental models of ALS is 
necessary to investigate the triggering events occurring earlier in the pathology.
Mice carrying naturally occurring autosomal recessive mutations on 
unidentified genes provide animal models with motor system impairment. PMN 
mice show a progressive motor neuronopathy characterised by paralysis of the
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limbs, neurogenic atrophy of muscles, axonal degeneration but with relative 
sparing of motor neurone cell body (Schmalbruch et al., 1991). The PMN locus 
has been identified on chromosome 13 but the gene involved is not known 
(Brunialti et al., 1995).
The wobbler mice represent another model of motor neurone disease 
(Mitsumoto and Bradley, 1982). They show a progressive forelimb weakness 
associated with proximal axonal degeneration and vacuolar changes within the 
anterior horn cells of the spinal cord with a little involvement of the brain. In this 
case, the gene responsible for this syndrome has been mapped on 
chromosome 11 but it has not been identified yet (Kaupmann et al., 1992).
Mice showing neuromuscular degeneration, with autosomal recessive 
mutation localized on the gene coding for the ATPase/DNA helicase have been 
described (Cook et al., 1995; Cox et al., 1998). Called nmd mice, they present 
rapidly progressive hindlimb weakness and motor neurone cell body 
degeneration.
Another spontaneous animal model of motor dysfunction is represented by 
mnd mice, considered in the past a model of ALS. These mice develop a late 
onset motor neurone degeneration characterized by progressive deterioration of 
motor function more severe in the lumbosacral than in the other regions, as well 
as variable pathology in the lower cranial nerves (Messer et al., 1987). 
However, the number of choline acetyltransferase (ChAT) immunopositive 
lumbar motor neurones are not different from normal mice (Mennini et al., 
2002). The mnd mice carry a spontaneous homozygous mutation in the coding 
region of the gene Cln8 belonging to the family of neuronal ceroid lipofuscinose-
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related genes (CLNs) (Ranta et al., 1999). Thus, the presence of abnormal 
autofluorescent cytoplasmic inclusions rich in lipofuscin found in neurones but 
also in many other somatic organs, makes these animals a useful model for 
human neuronal ceroid lipofuscinosis rather than for ALS (Bronson et al., 1993).
Recently, Ahmad-Annuar and colleagues have described another mutant 
mouse model of motor neurone disease, the legs-at-odd-angles (Loa) mutant. 
In these mice mutations in the cytoplasmic dynein heavy chain gene (Dnchcl) 
cause motor neurone degeneration. Mice exhibiting the Loa phenotype suffer 
progressive loss of locomotor function and homozygous animals have neuronal 
inclusion bodies that are positive for S0D1, CDK5, neurofilament and ubiquitin 
proteins (Ahmad-Annuar et al., 2003). As this phenotype reproduces some 
aspects of human motor neurone degeneration disorders, it is possible that 
dynein may be a causative gene or susceptibility factor in human motor neurone 
disease. However, to date, no association between familial motor neurone 
disease and the genotypes presented by Loa mice has been found.
All these mice strains offer several advantages in the study of early 
phenomena occurring in a motor neurone disorder, involving a progressive and 
naturally occurring impairment of motor system. However, many features are 
quite dissimilar from human ALS pathology. Moreover, it is possible that the 
genetic alterations affecting these mice (if known) and the associated 
biochemical defects (if known) do not contribute to the human disease. Thus 
these models are not particularly reliable for testing therapeutic intervention or 
uncovering disease mechanisms, althought the study of the pathology occurring
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in these mouse models may contribute to the discovery of still unknown risk 
factors for human ALS.
In 1993, Rosen et al. reported that missense mutations in the gene 
encoding Cu/Zn superoxide dismutase (S0D1) were associated with a fifth of 
familial cases of ALS (Rosen et al., 1993). This landmark discovery radically 
revolutionised the experimental approach for the study of ALS. In fact, for the 
first time it was possible to generate an animal model closely resembling the 
human disorder, using transgenic technology. This technique was used to insert 
in mouse genome the S0D1 gene carrying some of the mutation found in the 
FALS patients. Investigators have generated different lines of these transgenic 
mice overexpressing human S0D1 (hSODI) with G93A, G37R and G85R 
mutation (substitution) (Gurney et al., 1994; Wong et al., 1995; Bruijn et al., 
1997b) or mouse S0D1 (mSODI) with G86R mutation (substitution) (Ripps et 
al., 1995b). Rats expressing hSODI®®^^ have been also generated (Howland et 
al., 2002). All these animals develop a motor syndrome characterized by the 
selective motor neurone death. They show normal motor functions in the early 
phase of their life but then develop a progressive weakness, especially starting 
in the hind limbs, which eventually results in paralysis and death. The age of 
onset, the duration and several pathological features of this motor dysfunction 
show some differences in the different transgenic animals strains. However, all 
these transgenic mice and rats provide an excellent and suitable in vivo model 
resembling human ALS.
Mice expressing hSODI®®®  ^ develop a late onset but very aggressive (2 
weeks from the first symptoms to the death) pathology, even with a low
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expression of the transgene. Motor neurones and astrocytes present inclusions 
immunopositive for ubiquitin and S0D1 (Bruijn et a!., 1997b).
Transgenic mice expressing low level of mutant show a motor
disease restricted to lower motor neurones, whereas higher copy number 
causes more severe abnormalities and affects a variety of other neuronal 
populations. The most obvious cellular abnormality is the presence in axons 
and dendrites of membrane-bounded vacuoles, which appear to be derived 
from degenerating mitochondria (Wong et al., 1995).
Transgenic mice that express mutant SODI®®^^ develop motor system 
disease prevalently affecting motor neurones. Ultrastructural and microscopical 
analysis reveals that the earliest pathological feature in these mice is 
vacuolization of large neurones of the anterior horns of the spinal cord (Bendotti 
et al., 2001a). It has been hypothesised that these vacuoles originate from 
dilation of rough endoplasmic reticulum and from degenerating mitochondria. At 
the end stage, motor neuronal depletion is evident and hyaline, filamentous 
inclusions immunopositive for ubiquitin and neurofilaments are present in some 
of the surviving neurones (Gurney et al., 1994; Migheli et al., 1999).
It is noteworthy that transgenic mice overexpressing the wild type form of 
human S0D1 (hSODI'^) do not develop any motor symptoms or altered 
phenotype. However, some neurodegenerative changes consisting of swelling 
and vacuolization of mitochondria, axonal degeneration of some long fiber tracts 
and a moderate loss of spinal motor neurones at two years of age, have been 
reported (Jaarsma et al., 2000). Thus, hSODI'^ transgenic mice have 
demonstrated that mutations on SOD1 gene are necessary to induce an evident
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motor disease. Therefore, transgenic technology have directly clarified that 
S0D1 mutants cause pathology because of gain of function and not because of 
the loss of S0D1 catalytic properties. Moreover, expression of mutant forms of 
S0D1 restricted to astrocytes or neurones is not sufficient to cause 
motoneurone degeneration in transgenic mice (Gong et al., 2000; Pramatarova 
et al., 2001; Lino et al., 2002). These reports suggest that simultaneous 
alterations in both neuronal and astroglial cells are necessary to induce the 
pathology in ALS mice.
More recently, the transgenic technology has also permitted the creation of 
transgenic rats expressing the G93A mutant of S0D1. Motor neurone disease 
in these animals depends on high levels of mutant S0D1 expression. Disease 
onset in SODI®®^^ rats is quite early and disease progression is very rapid (11 
days to reach the end stage). Pathological abnormalities include vacuoles 
initially in the lumbar spinal cord and subsequently in more cervical areas, with 
inclusion bodies that stained for S0D1, Hsp70, neurofilaments and ubiquitin. 
Vacuolization and gliosis are evident before clinical onset and before motor 
neurone death in the spinal cord and brainstem (Howland et al., 2002).
Despite the existence of reliable in vivo models of motor neurone 
degeneration associated with human ALS, in vitro approaches are also very 
useful since they offer an easier manipulation and study of a simpler system. 
For example, gene transfection or pharmacological study of biochemical 
pathways in isolated cell populations may be extremely useful in elucidating 
intracellular mechanisms underling the disease and the exact timing of 
biochemical events, in a way that is not always realisable in vivo. Neuronal and
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glial primary cultures, motor neurone like-cell line and organotypic slices 
therefore provide important tools to obtain information, which combined with 
data from in vivo studies, will hopefully help to find new therapeutic strategies 
for treatment of ALS.
1.8 Pathogenetic hypotheses in amyotrophic lateral 
sclerosis
To date, the mechanism(s) underling the motor neurone death in ALS still 
remains unknown, even in FALS where single gene mutations have been 
identified. The crucial point, which much research is focused on, is to clarify why 
and how the disease selectively affects motor neurones. In addition, the 
degeneration of motor neurones occurs in a progressive way, starting from 
adulthood. This suggests the existence of one or more triggering phenomenon 
that apparently strikes the motor system in a particular life period. Studies 
performed on human ALS autopsy samples or on transgenic mice expressing 
ALS linked S0D1 mutations during the presymptomatic stage and the whole 
course of the disease, have suggested the involvement of various processes as 
triggering (primary) or secondary events in ALS pathology. Thus, most 
researchers consider ALS as a multifactorial disease where many different 
alterations contribute to death of motor neurones. They include oxidative 
damage, mitochondrial dysfunction, alteration of cytoskeletal structure, 
formation of aggregates and excitotoxicity.
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1.8.1 Oxidative damage
The role of oxidative stress as primary or secondary event in the 
pathogenesis of ALS still remains controversial. Increase of oxidative damage 
markers such as protein carbonyl adducts, lipid peroxidation and DNA damage, 
have been reported in human patients affected by both sporadic and inherited 
forms of ALS (Beal et al., 1997; Ferrante et al., 1997b; Liu et al., 1999) and in a 
transgenic mouse model of the disease (Ferrante et al., 1997a; Andrus et al., 
1998; Liu et al., 1998). However, in other studies, no significant differences in 
markers of oxidative damage associated with the expression of SOD1 mutants 
were found (Shaw et al., 1995a; Bruijn et al., 1997a). Evidence of increased 
oxidative insult has been provided more consistently in sporadic ALS patients 
(Shaw et al., 1995a; Ferrante et al., 1997b; Pedersen et al., 1998).
Since no changes in the development of the mutated S0D1 mediated 
disease have been found in transgenic mice following either removal or 
elevation of wild type S0D1 (Bruijn et al., 1998), this suggests no direct 
involvement of the activity of S0D1 in oxidative damage generation.
Concerning the familial forms of ALS and S0D1 mutant transgenic mice, it 
has been hypothesized that a possible source of oxidative insult may be 
represented by the gain of toxic function of mutated SOD1 (Cleveland and 
Rothstein, 2001). Yim and co-workers showed that mutations of S0D1 protein 
can decrease its Km for hydrogen peroxide (Yim et al., 1996; Yim et al., 1997). 
The use of hydrogen peroxide as a substrate by the reduced S0D1-Cu^ form 
might produce the extraordinarily reactive hydroxyl radical (OH ) leading to a
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cascade of peroxidation (Wiedau-Pazos et al., 1996). On the other hand, other 
evidence does not support this hypothesis. Singh and colleagues demonstrated 
that a significant fraction of 5,5'-dimethyl-1-pyrrolline N-oxide (DMPO)/OH 
formed during the reaction of S0D1 and familial ALS S0D1 mutants with 
hydrogen peroxide (H2O2) is derived from the incorporation of oxygen from 
water due to oxidation of DMPO to DMPO/OH, presumably via DMPO radical 
cation. However, no differences were detected between wild type and mutant 
form of S0D1, (Singh et al., 1998).
Beckman and collaborators proposed that an altered folding of the enzyme 
caused by the mutations, might determine a grater access of abnormal 
substrates such as peroxinitrite ( ONOO) to the catalytic copper site. This could 
lead to aberrant tyrosine nitration and numerous toxic events (Beckman et al., 
1993).
Another hypothesis suggests that mutations may reduce the zinc bound 
allowing a rapid reduction of mutant S0D1 to the Cu^  ^ form by abundant 
intracellular reductants. The reduced S0D1 mutant would then run the normal 
catalytic step backwards, converting oxygen to superoxide. The superoxide so 
produced would react with nitric oxide producing peroxynitrite, which would 
promote intracellular damage, including protein nitration (Estevez et al., 1999).
The time course of accumulation of oxidative damage relative to disease 
onset and progression in ALS patients is not known. Even if oxidative damage 
is secondary and does not initiate toxic events, it is probable that oxidative 
stress contributes significantly to the neuronal death in ALS. Treatment with the 
antioxidant vitamin E (alpha-tocopherol) slowed down the onset and
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progression of paralysis in transgenic mice expressing S0D1 carrying G93A 
mutation (Gurney et al., 1996). However, a clinical trial carried out on ALS 
patients with the same drug did not ameliorate survival or motor function 
(Desnuelle et al., 2001).
1.8.2 Mitochondrial dysfunction
Swollen mitochondria were observed in the motor neurones of transgenic 
mouse lines carrying the G93A (Dal Canto and Gurney, 1995; Bendotti et al., 
2001a) or G37R (Wong et al., 1995) mutations at the early stage of the disease. 
They were also seen in the distal part of motor axons of phrenic and sciatic 
nerves in SODI®®^^ mice before the onset of the pathology (Bendotti et al., 
2001a). Decreases of complexes I and IV of the mitochondrial respiratory 
enzymes were reported in the spinal cord and brainstem homogenates of the 
same transgenic mouse line before clinical symptoms (Browne et al., 1998). 
Accumulation of SODI®®^  ^in swollen mitochondria of transgenic mice has been 
showed (Higgins et al., 2002) and there is recent evidence that shows that 
mutant S0D1 is selectively recruited by spinal cord mitochondria (Liu et al., 
2004). It has been reported that SODI®®^^ induces alterations of mitochondrial 
functions in transgenic mice and in NSC-34 motor neuron-like cells (Liu et al., 
2002; Mattiazzi et al., 2002). These data suggest that mitochondrial alteration 
may be an early pathogenetic event in ALS. Energetic metabolism failure or 
proapoptotic release of cytochrome-C may trigger intracellular cascades that 
lead to motor neurone death. These alterations may be the result of changes in
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mitochondrial permeability, induced by increased Ca^^ influx through 
glutamatergic receptors, and/or by intracellular increase of free radicals induced 
by mutant S0D1.
1.8.3 Cytoskeletal alterations
The idea that cytoskeleton abnormalities may play a role in ALS pathology 
arises from early reports of neurofilament accumulations in the cell bodies and 
proximal axons of motor neurones of both sporadic and familial ALS (Hirano et 
al., 1984a; Hirano et al., 1984b). Subsequently, aberrant assembly of 
neurofilaments in motor neurones has been established as a hallmark of the 
disease. Data showing that transgenes that encode mutant neurofilament 
subunits cause the selective degeneration and death of motor neurones in 
mice, lead to the hypothesis that damage to neurofilaments is directly involved 
in the pathogenesis of ALS (Cote et al., 1993; Xu et al., 1993). However, it has 
not yet been clarified whether neurofilament disorganisation represents a 
secondary product of pathological processes or whether it directly contributes to 
motor neurone death.
Several recent studies on transgenic mice have demonstrate that 
neurofilament content and organization strongly influence motor neurone 
disease induced by mutant S0D1 (Couillard-Despres et al., 1998; Williamson et 
al., 1998; Couillard-Despres et al., 2000; Kong and Xu, 2000). Eliminating 
neurofilaments by deletion of the NF-L subunit increases the survival of S0D1 
mutant mice. Enhancing the expression of the NF-L or NF-H subunits slows
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S0D1 mutant-mediated disease. In these studies transgenic mice showed 
increased amounts of neurofilament subunits in motor neurone cell bodies and 
reduced axonal neurofilament content. The protective effects of increased NF-H 
content in perikarya may be due to the ability of neurofilaments to “buffer” 
against a cascade of aberrant and harmful events in the cell body (Couillard- 
Despres et al., 1998). Since one of the earliest cellular abnormalities in motor 
neurones of mutant S0D1 mice is the reduction of slow axonal transport, the 
cosequent accumulation of neurofilaments in perikarya might represent a 
reactive process to counterbalance the toxicity of the S0D1 mutants 
(Williamson and Cleveland, 1999).
Al-Chalabi and colleagues have identified a set of small in-frame deletions 
or insertions in the repetitive tail domain of the NF-H neurofilament subunit in 
about 1% of sporadic ALS patients (Al-Chalabi et al., 1999). Although the 
known neurofilament variants cannot provoke by themselves motor neurone 
disease, the evidence strongly indicates that variants in neurofilaments may 
represent at least important risk factors for sporadic disease.
1.8.4 Protein aggregation and proteasome failure
Another hypothesis formulated about the pathogenesis of ALS concerns 
the propensity of S0D1 mutants to aggregate into cytoplasmic inclusion bodies. 
Aggregates intensely immunoreactive to S0D1 were detected in motor 
neurones and astrocytes of mice expressing mutant S0D1 as well as in human 
ALS cases linked to S0D1 (Bruijn et al., 1998). Johnston et al. showed that the
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aggregation of S0D1 into insoluble high molecular weight complexes is an early 
event occurring in mice (Johnston et al., 2000). These aggregates
develop before the onset of clinical symptoms. In mice they represent
the first pathological sign of disease, increasing in number during disease 
progression (Bruijn et al., 1997b). The S0D1 aggregates have been classified 
in two classes. The first is represented by aggregates detectable by 
conventional histological stains and are characterized by intense and localized 
S0D1 immunoreactivity throughout the inclusions or, less frequently, only at the 
periphery of them. The second type includes cell body deposits that are more 
diffusely distributed. Misfolded S0D1 aggregates cannot be dissociated, even 
with strong detergents and reducing agents. Their harmful effects could result 
from altered catalytic activity mediated by the misfolded aggregated mutants, 
the cosequestering of essential cellular proteins such as chaperones and/or 
overload of the ubiquitin proteaosome pathway, which degrades damaged 
proteins (Cleveland and Rothstein, 2001). Consistent with the latter hypothesis, 
the aggregates from transgenic mice and human ALS patients are markedly 
immunopositive for ubiquitin (Stieber et al., 2000; Watanabe et al., 2001; 
Bendotti et al., 2004; Kabashi et al., 2004). Since one of the roles of ubiquitin is 
to label and target misfolded and no more active proteins to the proteasome 
machinery, it has been hypothesized that proteasome activity could be inhibited 
by S0D1, leading to accumulation of aberrantly folded forms of SOD1 and other 
proteins (Cleveland and Rothstein, 2001). However, it is not yet clear whether 
these aggregates are central to disease pathogenesis, harmless by-products, or 
potentially beneficial through the sequestration of abnormal proteins.
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1.8.5 Inflammation
Neuroinflammatory changes are found in several neurodegenerative 
disorders such as Alzheimer’s and Parkinson’s disease (McGeer and McGeer, 
2003; McGeer and McGeer, 2004). An increasing body of evidence suggests 
the involvement of inflammatory processes also in ALS. Accumulation of 
reactive microglia and astrocytes have been documented in the spinal cord and 
motor cortex of ALS patients and animal models of the disease (Kawamata et 
al., 1992; Hall et al., 1998), representing an important cellular clue about the 
existence of neuroinflammation processes occurring in motor neurone diseases. 
Elevated levels of cyclooxygenase 2 (COX-2), a highly inducible enzyme related 
to inflammation, reported in the spinal cord of human patients and transgenic 
ALS mice confirm these findings (Aimer et al., 2001; Yasojima et al., 2001). 
Upregulation of proinflammatory factors before the development of motor 
neurone impairment in the SODI®®^^ transgenic mice as well as the increasing 
of immune activation as disease progresses suggests that immune- 
inflammatory mechanisms could also contribute to the triggering of the disease 
(Alexianu et al., 2001). In particular, TNFa mRNA is increased in the spinal cord 
of SODI®®^  ^ mice at early stage of the pathology (Elliott, 2001). The level of 
TNFa has also been shown to be increased in the blood of human ALS cases 
(Poloni et al., 2000). In addition, interleukin-6 is also upregulated in the spinal 
cord of SODI®®^  ^ mice (Hensley et al., 2003) as well as in the cerebrospinal 
fluid of ALS patients (Sekizawa et al., 1998). Several inflammatory cytokines
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can regulate and be regulated by the mitogen activated protein kinase p38 
(p38MAPK) (Adams et al., 2001; Barone et al., 2001a). Recently, this MAP 
kinase has been suggested to be implicated in ALS pathology. Motor neurones 
in culture have shown a specific sensitivity to death pathways involving the 
p38MAPK cascade (Raoul et al., 2002). Treatment with minocycline, a second- 
generation tetracycline that, among other effects, seems to inhibit the activation 
of p38MAPK, delays the onset of motor neurone degeneration and increases 
the life span of SODI®^^*  ^mice, diminishing the p38MAPK activation in reactive 
microglia (Kriz et al., 2002). Since activation of p38MAPK has been related to 
excitotoxic events and expression of AM PA receptors (Giardina and Bead, 
2002; Rivera-Cervantes et al., 2004), it is possible that inflammatory processes 
and glutamate metabolism alteration may be linked in ALS pathology. This 
hypothesis will be discussed in more detail in chapter 7.
1.8.6 Excitotoxicity
Glutamate-induced excitotoxicity is considered another major mechanism 
that may contribute to the aetiology of ALS. An over-stimulation of neuronal 
glutamate receptors can cause neurone death via increases in cytosolic free 
calcium and activation of death cascades such as those involving mytogen 
activated protein kinase pathways. This phenomenon may be exacerbated by 
regulation of glutamatergic receptor activity or subunit composition, which can 
render them more permeable to Ca^  ^and Zx^^. Glutamate transporters play an 
important role in preventing an aberrant activation of these receptors removing
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glutamate from synaptic cleft. Thus, changes in the equilibrium of this system 
may result in harmful events to motor neurones in ALS.
Excitotoxicity and the valuation of its potential role in ALS pathology has 
been the target of the experiments performed in this thesis. Thus, in the next 
section, I will review this topic in more detail.
1.9 Glutamatergic neurotransmission in the motor system 
and evidence concerning the role of excitotoxicity in 
amyotrophic lateral sclerosis
1.9.1 Glutamate neurotransmission
Glutamate is the most abundant and important excitatory neurotransmitter 
of the mammalian central nervous system. One fifth of the total glutamate, 
which is predominantly involved in metabolic processes of the cells, is stored in 
synaptic nerve terminals to be used as chemical mediator of nerve impulses by 
the glutamatergic pathways in the CNS. These are represented by numerous 
local circuits in different nervous system areas such as cortex, hippocampus, 
cerebellum, spinal cord and many others. Glutamate is also the principal 
excitatory neurotransmitter utilized by corticopontine, corticothalamic, 
corticobulbar and corticospinal tracts. Glutamatergic inputs to motor neurones 
principally derive from the descending corticospinal pathways and from spinal 
cord excitatory interneurones (Heath and Shaw, 2002).
During the normal glutamatergic neurotransmission, glutamate is released 
from presynaptic terminals in a calcium-dependent manner in response to
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depolarization of the membrane. Glutamate crosses the synaptic cleft to bind 
and activate postsynaptic receptors. Glutamate receptors are classified in two 
groups: ionotropic receptors, formed by ion channels and metabotropic 
receptors, linked to G-proteins.
The glutamatergic signal is rapidly termined by the action of glutamate 
transporters that are mainly located on surrounding astrocytes. Glutamate 
transporters remove glutamate from the synaptic cleft. Within the astrocytes, 
glutamate is converted in glutamine by glutamine synthetase or metabolized to 
a-ketoglutarate. Glutamine is then exported from astrocytes and taken up by 
nerve terminals by SAT 1 and SAT2 transporters, where it is used as precursor 
of the neurotransmitter glutamate by the action of phosphate-activated 
glutaminase, completing the recycling process (Laake et al., 1995).
1.9.2 Excitotoxic process
Excitotoxicity, which was first described by OIney in the 1970s (OIney et 
al., 1975), involves the activation of glutamate receptors in the central nervous 
system. High concentrations of glutamate, or neurotoxins acting at the same 
receptors, cause cell death through excessive receptor activation. Increased 
amount of glutamate in the synaptic cleft can arise from impaired glutamate 
uptake or from augmented release of glutamate from the nerve terminals. 
Molecular properties and localization of the different glutamate receptor 
subtypes can also influence the glutamate-mediated neurone degeneration. 
Moreover, the activation of intracellular pathways downstream the receptor
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overstimulation or the subsequent activation of other ion channels may 
contribute to the death process. The molecular mechanisms involved in 
glutamate-mediated neuronal death are however not yet completely elucidated 
but several pathways have been shown to contribute to the toxic effects such as 
activation of Ca^^-dependent enzymatic pathways, increased generation of 
intracellular free radicals through the aberrant activation of arachidonic acid 
cascade, xanthine oxidase and nitric oxide synthase, and the competitive 
interference with cystine uptake which lead to glutathione depletion (Heath and 
Shaw, 2002).
It is well established that one of the key mechanisms underlying the 
neuronal injury during the excitotoxic event involves the disregulation of calcium 
homeostasis. Under normal conditions, calcium levels control numerous 
intracellular processes. For this reason, neurones have a complex homeostatic 
machinery for calcium including calcium binding proteins (e.g parvalbumin and 
calbindin), mechanisms for sequestration within cellular compartments 
(endoplasmic reticulum and mitochondria) and membrane transporters that 
maintain the calcium intracellular concentration below 0.1 pmol/l (Heath and 
Shaw, 2002; Arundine and Tymianski, 2003). During the excitotoxic process, a 
first entry of sodium and chloride ions as a result of depolarization, is followed 
by an influx of calcium into the neurone through the ion channel of NMDA and 
GluR2-lacking AM PA receptors and also through voltage gated calcium 
channels and sodium-calcium exchange proteins. NMDA receptors have long 
been considered to be important in the generation of excitotoxic damage but it 
is now clear that excitotoxicity can result from activation of AM PA receptors,
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particularly during chronic exposure to glutamate. AMPA receptors that not 
include GluR2 subunits in their molecular structure result highly permeable to 
calcium. In fact, GluR2 has a functional dominance in controlling the calcium 
influx due to a positively charged arginine located in the pore channel of the 
receptor that prevent calcium from entering. As a result, it is probable that 
neurones that express calcium-permeable AMPA receptors (do not express 
GluR2) are more susceptible to glutamate toxicity.
Upon excessive glutamate stimulation, the calcium concentration inside 
the cell raises to a critical level, because of the massive Ca^^ influx through 
over-activated glutamate receptors and/or calcium release form intracellular 
compartments. This causes the generation of free radicals, the transcriptional 
activation of specific cell death cascades and the activation of a variety of 
calcium-dependent enzymes such as lipases, phospholipases, endonucleases, 
protein kinase C, nitric oxide synthase and many others, which in turn lead to 
cell degeneration and death (Arundine and Tymianski, 2003).
1.9.3 Excitotoxic hypothesis and ALS
Excitotoxic damage has been associated to a wide range of neurological 
disorders. Excessive activation of glutamate receptors is believed to contribute 
to neuronal death after several insults including ischemia, trauma and epileptic 
seizure. Excitotoxicity might be also involved in the aetiology of chronic 
neurodegenerative pathologies such as Alzheimer's disease, Huntington's 
chorea and AIDS encephalopathy. Some disorders affecting the motor system
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have been linked to glutamate-mediate neuronal death, suggesting a possible 
role of altered glutamatergic neurotransmission also in motor neurone diseases. 
The ingestion of food contaminated with domoic acid, a tricarboxylic acid similar 
to the glutamate receptor agonist kainic acid, causes various neurological 
symptoms. Among these, pure motor or sensorimotor neuropathy has been 
reported (Teitelbaum et al., 1990). Lathyrism, a chronic disease that affects 
predominantly cortical upper motor neurones, occurs as a result of the ingestion 
of p-Af-oxalylamino-L-alanine (BOAA), a glutamate analogue (Ludolph et al., 
1987; Ludolph and Spencer, 1996).
The excitotoxic hypothesis proposed for ALS arises from several studies 
indicating a disgregulated glutamate metabolism in ALS cases. Levels of 
glutamate was found significantly elevated in the plasma (Plaitakis and 
Caroscio, 1987) and in the cerebrospinal fluid (CSF) (Rothstein et al., 1990) of 
ALS patients. However, other studies did not confirm these results (Perry et al., 
1990; Camu et al., 1993; Shaw et al., 1995b). Interestingly, extracts from 
plasma and CSF of ALS patients resulted toxic to cultured neurones (Roisen et 
al., 1982; Couratier et al., 1993; Cid et al., 2003) and this toxicity was abolished 
by AMPA receptor antagonists (Couratier et al., 1993; Couratier et al., 1994). 
However, a similar study could not reproduce a similar effect on motor neurones 
in culture (Iwasaki et al., 1995). Glutamate content was found to be reduced in 
several brain regions and in the spinal cord of the ALS patients (Perry et al., 
1987). Furthermore, riluzole, which is the only drug officially approved for the 
treatment of ALS, is proposed to reduce damage to motor neurones by 
inhibiting the release of glutamate (Doble, 1996).
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Taken together, these observations suggest that glutamate system may 
be disturbed at least in a subset of ALS patients, because of an aberrant 
metabolism or a failure in glutamate uptake capability, leading to raised 
extracellular levels of glutamate and reduced levels within CNS tissue. 
Moreover the fact that AMPA receptor antagonists can block the neurotoxic 
effect of CSF and plasma on neurones and delay the disease progress in ALS 
mice (Canton et al., 2001; Van Damme et al., 2003), suggests a possible role 
played by of these receptors. The AMPA receptor and glutamate transporter 
involvement in ALS will be widely discussed in chapter 3 and chapter 6 
respectively.
1.10 The therapy for amyotrophic lateral sclerosis
To date, no cure has been found yet for ALS. However, in early 1996 the 
Food and Drug Administration (FDA) approved the first and the only official drug 
treatment for the disease: riluzole (Miller et al., 1996). Riluzole is believed to 
reduce damage to motor neurones by inhibiting the release of glutamic acid, 
considered an important detrimental factor involved in ALS pathology. This 
effect may be partly due to inactivation of voltage-dependent sodium channels 
on glutamatergic nerve terminals, as well as activation of a G-protein-dependent 
signal transduction process. Riluzole also blocks some of the postsynaptic 
effects of glutamate by non competitive blockade of N-methyl-D-aspartate 
(NMDA) receptors (Doble, 1996). Clinical trials with ALS patients showed that 
riluzole prolongs survival by several months, particularly in those patients with
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difficulty in swallowing. The drug also extends the time before a patient needs 
ventilation support, prolonging the period spent within a less severe stage of 
illness (Riviere et al., 1998). Riluzole does not reverse the damage already 
done to motor neurones but may reduce further neuronal loss, as suggested by 
a study that used proton density magnetic resonance spectroscopy (Kaira et al., 
1998).
This first disease-specific therapy offers the hope that new medications or 
combinations of drugs may one day slow the progression of ALS. Thus, plenty 
of clinical trials have been organized and are still running to test on human 
patients drugs that have shown effects on neuronal survival in experimental 
models, in the attempt to slow the progressive deterioration of motor function in 
people affected by ALS.
It has been hypothesized that neurotrophic factors may have a positive 
impact on neuronal toxicity and slow the progression of the disease. In 
particular, IGF-1 is a neurotrophic factor essential for normal development of 
the nervous system and shows protection of motor neurones in animal models 
and cell culture systems. Some clinical trials using recombinant human IGF-1 
have been carried out. However, only one of two clinical studies performed in 
North America showed improvement of mortality rate and functional decline (Lai 
et al., 1997), whereas an European protocol failed to find any benefit on ALS 
progression (Borasio et al., 1998). In another study. Brain Derived Neurotrophic 
Factor (BDNF) was administered as a subcutaneous preparation. Although the 
results showed that BDNF had no significant benefit in ALS, it was well 
tolerated and few side effects were observed. Thus, two further trials of BDNF
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were performed. A second 12 month trial where higher doses of BDNF were 
administered under the skin was initiated in North America. At the same time a 
third intrathecal BDNF study was commenced in Europe and North America. In 
this trial BDNF was administered directly into the cerebrospinal fluid to allow the 
drug to reach higher concentrations in the central nervous system, overcoming 
the blood brain barrier. Both the sub-cutaneous and intrathecal BDNF studies 
were halted as no improvements in survival were found (Clinical Trial Summary, 
Motor Neurone Disease Association Web site).
It has been reported that creatine improves the function of mitochondria 
and that has a neuroprotective effect in laboratory animals and in ALS 
transgenic mice in particular (Klivenyi et al., 1999). Thus, several clinical studies 
testing the effect of treatment with creatine on ALS patients were recently 
carried out. Creatine has not demonstrated benefit for people with ALS (Shefner 
et al, 14*^  International Symposium on ALS/MND meeting Milan, Italy, 2003).
Enrolment for phase III trial to test the promising tetracycline antibiotic 
minocycline has been recently opened. Minocycline has been shown to protect 
neurones and reduce cell death prolonging survival in animal models of stroke, 
trauma, Huntington's disease, Parkinson's disease (Yrjanheikki et al., 1998; 
Yrjanheikki et al., 1999; Chen et al., 2000; Wu et al., 2002) and in two different 
transgenic models of ALS (Kriz et al., 2002; Zhu et al., 2002b). The 
mechanisms of action of this drug is not fully understood but evidence suggests 
that it can inhibit the activity of caspase-1, caspase-3, inducible form of nitric 
oxide synthetase (iNOS), microglia activation, p38 mitogen activated protein
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kinase (p38MAPK) as well as the release of cytochrome-C by mitochondria 
(Tikka et al., 2001; Zhu et al., 2002b).
Several other drugs have been tested in numerous clinical trials but 
unfortunately no one showed so far significant improvements of motor function 
impairment and life expectation. Novel areas of therapy are under investigation 
in animal models, including the vascular endothelial growth factor (VEGF), 
whose lack induces motor neurone degeneration (Oosthuyse et al., 2001), 
leukemia inhibitory factor (LIF), whose administration prolongs survival in 
SODI®®^^ transgenic mice (Azari et al., 2001) and the use of stem cells (Silani 
et al., 2002).
Nevertheless, despite the large number of clinical trials testing many 
different drugs and the massive effort produced to investigate the cellular 
mechanisms involved in the selective motor neurone degeneration, to date ALS 
still remains orphan of an effective therapy.
1.11 Overall aim of the thesis
The aim of this thesis is to carry out a study that may allow to understand 
further the mechanisms that trigger or contribute to the development of ALS 
pathology. In particular, I have investigated the excitotoxic hypothesis, focusing 
on the possibility of development of novel therapeutic strategies.
Specific aims of this thesis have been:
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to investigate whether there are early changes in subunit composition of 
glutamatergic AMPA receptor in the motor neurones of transgenic
ALS mice, which might explain an increased susceptibility of these cells to 
glutamate excitotoxicity.
to evaluate the effect of chronic treatment with a new AMPA receptor 
antagonist on symptom development and survival in S0D1®®^  ^transgenic ALS 
mice, to determine whether AMPA receptor activation contributes to disease 
progression.
to investigate whether zinc ions may be involved in excitotoxicity to motor 
neurones and whether motor neurones may be more vulnerable to zinc toxicity 
than other neurones because of a different expression of a specific zinc 
transporter.
to evaluate whether there are deficits in expression of glial glutamate 
transporters in S0D1®^^^ transgenic ALS mice and to determine whether 
can regulate glutamate transporter expression and function in 
primary astrocyte cultures.
to investigate the activation of p38MAPK pathway in S0D1®®^^ transgenic 
ALS mice to clarify whether its activation may be involved in ALS pathology and 
in regulation of AMPA receptor activity in particular.
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CHAPTER 2
METHODS
(General procedures)
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2.1 Animals
Procedures involving animals and their care were conducted in according 
to the institutional guidelines that are in compliance with national (D.L. no. 116, 
G.U. suppl. 40, Feb. 18, 1992, Circolare No.8, G.U., 14 luglio 1994) and 
international laws and policies (EEC Council Directive 86/609, OJ L 358, 1 
DEC. 12, 1987; NIH Guide for the Care and use of Laboratory Animals, U.S. 
National Research Council, 1996). The animals were housed under standard 
conditions (22 ± 1°C, 60% relative humidity, 12 hour light/dark schedule), 3-4 
per cage, with free access to food (Altromin, MT, Rieper) and water.
At the Mario Negri Institute we have developed a colony of transgenic mice 
originally obtained from Jackson Laboratories (B6SJL-TgNSOD-1-G93A-1Gur) 
expressing about 20 copies of mutant human S0D1 with a Gly 93 Ala 
substitution (SODI®®^^) or wild type human S0D1 (SODI'^) on a C57BL/6 mice 
strain. Mice expressing S0D1°^^^ (Figure 2.1) develop the first signs of 
muscular dysfunction around two months of age, with an impairment of the 
evoked response tested electromiographically (EMG). Thereafter, tremors 
appear in the hind limb, associated with a progressive reduction in the 
extension reflex when the mice are raised by the tail. At four months of age, the 
mice show a progressive muscular weakness starting from the hind limb, 
revealed by the increasing difficulty to stay on a rotating bar and by a reduction 
in stride length on an inclined ramp. At this stage, more than 50% of motor 
neurones of the lumbar spinal cord are lost and one month later these mice die.
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Figure 2.1: Graphic representation of the behaviourai and neuropathological 
progression of the disease occurring in transgenic mice.
Mitochondrial vacuolisation and the swelling of motor neurones are among 
the earliest events and are accompanied by a decreased function of the 
mitochondria. Later, but still at the asymptomatic stage, the mice
show signs of cytoskeletal disorganization in the motor neurones, with the 
accumulation of phosphorylated neurofilaments. The accumulation of detergent- 
insoluble proteins and ubiquitinated intracellular inclusions are particularly 
evident at advanced stages of the disease. Reactive gliosis, which involves 
hypertrophy and the activation of astrocytes and the proliferation and activation 
of microglia, is detectable with the degeneration of motor neurones and 
becomes prominent when the cell loss is remarkable. Hypertrophic astrocytes 
and reactive microglia are usually located around degenerating motor neurones.
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For the present study female mice have been killed at 8, 14 and 19 weeks of 
age corresponding respectively to a presymptomatic, early symptomatic and 
advanced stage of the progression of the motor dysfunction. Age-matched non 
transgenic littermates or transgenic mice expressing wild type human S0D1 
have been used as controls.
2.2 Primary astrocyte cultures
Primary cortical astrocyte cultures were prepared from 15-16 day old 
Swiss mouse embryos (NIH, Harlan, U.K.). Cortices were dissected away from 
brain and mechanically dissociated using a fire-polished glass Pasteur pipette in 
Phosphate Buffered Saline (PBS) Ca^  ^ and Mg^  ^ free, supplemented with 
glucose (33 mM). Cells were plated into 24-well or 6-well Nunc multiwell plates 
that had been previously coated overnight with 1.5 pg/ml poly-L-ornithine 
(Gibco-BRL Life Technologies, Gathiesburg, MD, USA) and then sequentially 
washed in water and PBS before coating with culture medium supplemented 
with 10% heat inactivated foetal bovine serum (FBS, Gibco-BRL Life 
Technologies) for 2 hours. Following removal of the final coating solution, cells 
were seeded (500,000/ml) in a medium composed of a mixture of Dulbecco’s 
modified Eagle’s medium and F-12 nutrient (1:1 vol/vol) (Gibco-BRL Life 
Technologies) supplemented with 33 mM glucose, 2 mM glutamine, 6.5 mM 
sodium bicarbonate, 5 mM HEPES buffer (pH 7.4), 100 pg/ml streptomycin, 60 
|xg/ml penicillin, 10% FBS (all from Gibco-BRL Life Technologies). Cells were 
cultured at 37°C in a humidified atmosphere of 95% air and 5% COg. Medium
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was replaced after 6, 10 and 13 days in vitro (DIV) and cultures were also 
washed twice with PBS/glucose at 10 and 13 DIV to remove neuronal cells. 
Cells were used for transfection after 15-16 DIV when the astrocytes were 
confluent and neither neurones nor oligodendrocytes could be found in the 
cultures.
2.3 In situ hybridization
Mice were killed by decapitation and brain and spinal cord rapidly 
removeved. Tissue were immediately frozen in 2-methylbutane at -45°C and 
coserved at -80° until the experiments. Frozen lumbar spinal cords and brains 
of transgenic and non transgenic mice were cut on a cryostat at -20°G and 
sections (14 pm) mounted on poly-L-lysine coated microscope slides. Sections 
were then fixed in 4% para-formaldehyde for 15 minutes followed by two 10 
minutes incubations in PBS, acetylated (0.1 M triethanolamine and 0.25% 
acetic anhydride in 0.9% NaCI), dehydrated through a graded series of ethanol, 
delipidated for 5 minutes in chloroform, air dried and stored frozen at -80°C. At 
the day of the experiment the slides were brought to room temperature and 
hybridized with ^^S-labelled RNA probes obtained by in vitro transcription 
(Bendotti et al., 1990). The reaction mixture for the in vitro transcription 
contained: 1 pg of DNA, IX  transcription buffer, 10 mM dithiothreitol (DTT), 15 
U of human placental RNase inhibitor, 0.5 mM ATP, 0.5 mM GTP, 0.5 mM OTP, 
10 pM DTP (all the reagent were purchased from Promega, Madison, Wl, USA) 
and 2.5 pM ^^S-UTP (1,000 Ci/mmol; Amersham Biosciences, Little Chalfont,
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Buckinghamshire, UK). After a 1 hour incubation at 37°C, the templates were 
digested with 1 U of DNase I - RNase free (Promega) for 15 minutes at 37 °C. 
The templates were hydrolysed in mild alkalin buffer (80 mM NaHCOa and 120 
mM Na2HC0 3 ) at 60°C to obtain fragments of 150-200 base pairs in lenght. The 
mixtures were neutralized and the ^^S-labelled riboprobes were purified by G-50 
Sephadex Quick Spin Colomns (Roche, Basel, Switzerland). Probes were 
diluted to 1.5 X 10"* cpm/pl with hybridization buffer containing 50% formamide, 
2X sodium saline citrate buffer (SSC), 10 mM Tris/HCI pH 7.5, IX  DenhaiTs 
solution, dextran sulfate 10%, 0.2% SDS, 100 mM DTT, 500 pg/ml double­
strand Salmon Sperm DNA (Roche). Sections were incubated overnight at 55°C 
in sealed humidified chambers using Parafilm coverslips. After hybridization, 
coverslips were removed and sections were incubated in IX  SSC for 10 
minutes at room temperature. Sections were then washed for 30 minutes at 
37°C in 20 pg/pl of RNase A in RNase buffer (0.5 M NaCI, 1 mM EDTA and 10 
mM Tris/HCI, pH 8.0) followed by 30 minutes at 37°C in RNase buffer alone. 
Sections were then washed in IX  SSC for 30 minutes at room temperature, 
0.5X SSC for 30 minutes at 65°C and 0.5X SSC for 10 minutes at room 
temperature before dehydrating through a graded series of ethanol. The slides 
were exposed to Beta-max film (Amersham Biosciences) for 7 days, dipped in 
photographic emulsion (Ilford K5 diluted 1:1 with 0.1% Tween 20) and exposed 
for 15 days at 4°C. Sections were then developed, counterstained with cresyl 
violet and examined by light and dark field microscope before the quantitative 
analysis of the grain density. The specificity of the in situ hybridisation for the 
different trasncripts was verified by the absence of the signal using sense
76
radiolabelled probes. Densitometric analysis of autoradiographic films was done 
using a computer-assisted image analysis system (AIS 3.0, Imaging Research 
Inc., St. Catherines, Ont. Canada). Grain density in single motor neurones was 
quantitatively evaluated using a computerized microscope image analyzer 
(IBAS 2, PC 386, Zeiss-Kontron, München, Germany) according to the 
procedure by Masseroli and coworkers (Masseroli et al., 1993). Cresyl violet 
stained cells were used to define the circular frame outlining the cell and the 
grain density over a single cell was expressed as number of grains/pm^ cell 
area. Motor neurones from at least two sections from each animal was 
determined and the mean values of these measures were used for statystical 
analysis by analysis of variance (ANOVA Two-Way) followed by Tu key's test. 
All the statistical analyses were done using the Graph Pad Prism 2.0a for Power 
Macintosh (GraphPad Software Inc., San Diego, CA, USA), designed by Dr. 
Harvey J. Motulsky (1994-1995).
2.4 Immunohistochemistry
Mice were anaesthetised with Equithesin (1% phenobarbitol / 4% (vol / vol) 
chloral hydrate, 30 pi /10 g, ip.) and transcardiaily perfused with 20 ml saline 
followed by 50 ml of sodium phosphate buffered 4% paraformaldehyde solution. 
Spinal cords were removed, post fixed in fixative for two hours, transferred to 
20% sucrose solution in PBS overnight, then in 30% sucrose solution until they 
sank. Finally spinal cords were frozen in 2-methylbutane at -45°C and 
conserved at -80° until the experiments. Fixed and frozen lumbar spinal cords of
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transgenic and non transgenic mice were cut on a cryostat at -20°C to obtain 
coronal sections of 30 pm at the L2-L4 levels. Free-floating sections were first 
treated with H2O2 1% in PBS 0.01 M for 10 minutes. Then they were incubated 
in 10% normal goat serum (NGS), 0.1% Triton X-100 in PBS 0.01 M, for 1 hour 
and kept overnight at 4°C in the primary antibody solution. The following day, 
after three washing in PBS 0.01 M, sections were incubated with biotinylated 
secondary antibody (1:200, Vectastain kit. Vector Laboratories, Burlingame, CA, 
US) for 1 hour, washed and incubated in avidine-biotin-peroxidase solution 
(Vectastain kit. Vector Laboratories). Immunostaining was revealed by the 
reaction with 3'-3-diaminobenzidine tetrahydrocholride (10 mg/20 ml in TBS + 6 
pi H2O2 30%). Subsequently, sections were washed, dried and mounted on 
poly-L-lysine coated slides, dehydrated through graded alcohols, fixed in 
xylene, verslipped using DPX mountant (BDH, Poole, UK) and analyzed using 
light microscope. Controls sections were incubated without the primary antibody 
or using the primary antisera preadsorbed with the respective antigen to test the 
signal specificity.
2.5 Western blot
Mice were killed by decapitation and the spinal cord and brain were rapidly 
removed, frozen in 2-methylbutane at -45°C and stored at -80°C until the 
experiment. Frozen spinal cords and brain of transgenic and non transgenic 
mice were sonicated in boiling lysis buffer (20 mM Tris/HCI, pH 7.5, 10% SDS) 
and centrifugated at 13000 rpm for 3 minutes at 4°C. Protein concentrations
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from supernatant were determined using a BCA Protein Assay Reagent Kit 
(Pierce, Rockford,IL,USA). Samples were then boiled for 3 minutes in loading 
buffer (100 mM Tris/HCI, pH 7.5, 15% p-mercaptoethanol, 4% SDS; 15% 
glycerol, 5 mM EGTA, 5 mM EDTA, 0,2% bromophenol blue) and run on 
polyacrylamide-SDS gel and transferred to nitrocellulose membrane (Scheicher 
and Schuell, Keene, NH, USA) Membranes were incubated in blocking buffer 
made of TBST (20 mM Tris/HCI, 150 mM NaCI, 0,1% Tween-20) with 5% 
skimmed milk for 2 hours at room temperature, followed by incubation overnight 
at 4°C with primary antibody diluted in TBST with 5% bovineserum albumin. 
The blots were then washed three times in TBST and incubated with secondary 
antibody in TBST with 5% skimmed dry milk, for 1 hour at room temperature. 
Blots were then developed by the ECL technique (Amersham Biosciences) 
according to the manufacturer's instructions. Densitometric analysis of 
autoradiographic bands was done using a computer-assisted image analysis 
system (AIS 3.0, Imaging Research Inc.). Statistical analysis was performed 
using One-Way ANOVA followed by Bonferroni's post-hoc test (GraphPad 
Prism 2.0a for Power Macintosh, GraphPad Software Inc.).
2.6 Material
Unless otherwise stated, the reagents used for the experiments were 
obtained from Sigma-Aldrich (Poole, U.K.).
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CHAPTER 3
Study of the expression of glutamate AMPA 
receptor subunits in the spinal cord of 
SOD1®®^  ^transgenic mice
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3.1 Introduction
3.1.1 Glutamate receptors
The excitatory amino acid receptors can be classified as ionotropic 
receptors, where receptor activation is directly coupled to a membrane ion 
channel, and metabotropic receptors, where receptor activation is coupled to an 
intracellular biochemical cascade that indirectly leads to opening or closing of 
membrane ion channels.
3.1.1.1. Ionotropic receptors
The ionotropic glutamate receptors are multimeric structures formed by 
four or five subunits and are subdivided into three groups according to 
pharmacologic and structural similarities: NMDA (N-methyl-D-aspartate), AMPA 
(alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and Kainate 
receptors. All ionotropic glutamate receptor subunits share a common basic 
structure. Like other ligand gated ion channels, such as the GABAa receptor, 
the ionotropic glutamate receptor subunits possess four hydrophobic regions 
(transmembrane domains) within the central portion of the sequence. However, 
in contrast to other receptor subunits, the second transmembrane domain forms 
a re-entrant loop that forms the pore region of the ion channel and that gives 
these receptors an extracellular N-terminus and intracellular C-terminus. The
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extracellular N-terminus, together with a loop between transmembrane domains 
III and IV, forms the ligand binding domain (Standley and Baudry, 2000)
3.1.1.1.a NMDA receptors
The NMDA receptor has been extensively studied and it is known that 
these receptors have a high Ca^  ^permeability. They are blocked by Mg^  ^ in a 
voltage-dependent manner, have a requirement for glycine as a coagonist, and 
modulatory sites for polyamines, reducing agents, Zn^^ and protons (Heath and 
Shaw, 2002). Molecular biological techniques have revealed that the NMDA 
receptor channel complex comprises two subunits: NR1 and NR2. There are 
eight splice variants of NR1 (Zukin and Bennett, 1995) and it is thought that 
NR1 is a component of all native NMDA receptors. Although NR1 subunits can 
be assembled into homomeric NR1 channels, there are four NR2 subunit types 
(NR2A-NR2D), which when coexpressed with NR1 are thought to form native 
NMDA receptor channel complexes. The different NR2 subunits confer different 
physiological and pharmacological properties to the receptors (Meguro et al., 
1992): for example, NR1-NR2C channels are more sensitive to Mg^^ blockade 
and display the highest affinity sites for glycine binding compared to other 
heteromeric channels, whereas the NR1-NR2A channel differs from the others 
in its response to reducing agents. The NR1 subunit is ubiquitous throughout 
the CNS, whereas there are regional differences in distribution of NR2 subunits. 
NMDAR3 has been recently identified as third NMDA receptor subunit but little 
is known about its physiological role (Das et al., 1998).
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3.1.1.1.b AMPA receptors
AMPA receptors mediate fast synaptic transmission in the CNS. These 
receptors were originally classified on the basis of their activation by the agonist 
quisqualate but not NMDA. The use of quisqualate as an agonist for these 
receptors has now been abandoned in favour of the more selective agonist a- 
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and these 
receptors are thus referred to either as non-NMDA ionotropic receptors or 
AMPA/kainate receptors. AMPA receptors are also potently activated by 
kainate. Molecular biological techniques have so far revealed the existence of 
four glutamate receptor subunits (GluR1-GluR4), products from separate genes, 
that are AMPA receptor subunits. Each of these subunits can form homomeric 
and heteromeric channel assemblies with other subunits. The AMPA receptors 
exist in vivo as pentameric architecture, generating a number of different 
arrangements, which can vary between neuronal subtypes and even individual 
neurones. AMPA receptor composition is not rigid but it can change being 
dynamically influenced by the environmental conditions (Luscher et al., 2000; 
Zhou et al., 2001; Lee et al., 2004).
The GluR2 subunit is particularly important in determining the calcium 
permeability of the assembled AMPA receptor. In fact, without GluR2, AMPA 
receptors have a non linear current voltage relationship and are relatively Ca^^ 
permeable. However, heteromeric AMPA receptors containing GluR2 have 
linear current voltage properties and low permeability to Ca^ "^ . GluR2 therefore
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has a dominant effect to reduce Ca^^ permeability. In most CNS neurones 
AMPA/kainate responses show little Ca^  ^permeability and this is in accordance 
with the widespread expression of GluR2 throughout the CNS. The calcium 
impermeability of the GluR2 subunit is due to post-transcriptional editing of its 
mRNA, which results in a change of a single amino acid in the second 
transmembrane region from glutamine (Q) to arginine (R) (Michaelis, 1998; 
Dingledine et al., 1999). This is the so called Q/R editing site. GluR2(Q) is 
calcium permeable (Figure 3.1 B) whilst GluR2(R) is not (Figure 3.1 A). Almost 
all the GluR2 protein expressed in the CNS is in the GluR2(R) form, generating 
calcium impermeable AMPA receptors. This, along with the interactions with 
other intracellular proteins, makes GluR2 perhaps the most important AMPA 
receptor subunit in the context of neurodegeneration.
Each of the AMPA receptor subunits can exist in two isoforms due to 
alternative splicing of a gene region encoding about 30 amino acids near the 
fourth transmembrane domain. These isoforms are known as flip and flop 
forms. The flip isoform of the protein is mainly represented in prenatal and early 
postnatal neurones. A postnatal developmental change determines the 
augmented expression of the flop forms of the AMPA receptor subunits. The 
flop isoform shows more rapid glutamate-induced desensitization than the flip 
isoform. Thus, it is probable that the flip/flop alternative splicing control 
desensitization and recovery of the AMPA receptors (Myers et al., 1998).
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Figure 3.1: GluR2 subunit editing regulates AMPA receptor permeability to 
calcium
From Pellegrini-Giampietro E. et al, TINS, 1997
3.1.1 .1.C Kainate receptors
Kainate receptors constitute a separate group from the NMDA and AMPA 
receptors, although they share many of the same structural characteristics. 
They are built from multimeric assemblies of GluR5-7 and KA-1/2 subunits. Like 
the other ionotropic glutamate receptors, they possess an extracellular N- 
terminus that represents the ligand binding domain and a re-entrant loop that 
forms the pore region of the channel. They also undergo both splice and RNA 
editing, giving rise to a large number of possible receptors with different
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pharmacological and functional properties. The agonist kainate is not selective 
for kainate receptors, also acting as a non desensitizing agonist of AMPA 
receptors (Heath and Shaw, 2002).
3.1.1.2. Metabotropic receptors
To date, at least eight metabotropic glutamate receptors (mGluR1-8) are 
known (Michaelis, 1998). These are G-protein coupled receptors that have been 
subdivided into three groups. Group I comprises mGluRI and mGluRS and 
these receptors appear to be coupled to postsynaptic inositol phosphate 
metabolism. Group II includes mGluR2 and mGluRS, and Group III comprises 
mGluR4, mGluR6, mGluR7 and mGluR8. Groups II and III can couple to an 
inhibitory cAMP cascade in many expression systems, but may also couple to 
other transduction mechanisms under physiological conditions. The Group II 
and III receptors have been suggested to mediate presynaptic actions of 
glutamate in several brain areas, although this does not preclude the possibility 
that these receptors may also mediate postsynaptic effects in some locations. 
Similarly, there is evidence that Group I receptors may be found in presynaptic 
locations in some cases (Heath and Shaw, 2002).
3.1.2 Glutamate receptors and ALS
Glutamate can cause neuronal death through the activation of both NMDA 
and AMPA receptors by excitotoxic calcium-dependent mechanism. However,
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NMDA stimulation seems to be more related to acute glutamatergic insults, 
whereas AMPA receptors are mainly involved in slow neuronal degeneration, 
phenomenon occurring in chronic diseases such as ALS (Weiss and Choi, 
1991).
It is quite well established that motor neurones are more susceptible than 
other spinal neurones to toxicity mediated by AMPA receptors. In 1993, 
Rothstein and collaborators reported that the inhibition of glutamate transport 
and the consequent increase of synaptic glutamate concentration in organotypic 
spinal cord slices, produced slow degeneration of motor neurones and that 
motor neurone toxicity were selectively prevented by AMPA but not by NMDA 
glutamate receptor antagonists (Rothstein et al., 1993). Excitotoxic agonists 
selective for AMPA receptors applied directly onto the lumbar spinal cord, 
preferentially affect motor neurones (Ikonomidou et al., 1996). In spinal mixed 
cultures, brief exposure to AMPA/kainate agonists induces the selective loss of 
motor neurones in a calcium-dependent manner (Carriedo et al., 1995; Carriedo 
et al., 1996). These results has been confirmed by many other studies 
performed in different in vitro systems (Bar-Peled et al., 1999; Carriedo et al., 
2000; Saroff et al., 2000; Van Den Bosch et al., 2000; Vandenberghe et al., 
2000a).
It has been hypothesized that this selective vulnerability of motor neurone 
to AMPA activation, in respect to other spinal neurones, might result from 
differences in AMPA receptor subunit expression. For example, the presence of 
AMPA receptors lacking GluR2 or lacking edited GluR2 would confer an 
increased Ga^  ^ permeability, which in turn can lead to deleterious enhanced
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levels of intracellular calcium and cell death as described in section 1.9.2. A 
large body of evidence reports the presence of calcium-permeable AMPA 
receptors on motor neurones. Carriedo and colleagues showed that cultured 
motor neurones, selectively killed by kainate in a Ca^^-dependent manner, were 
capable of taking up cobalt after kainate stimulation, Co^  ^ labelling being a 
selective marker for neurones possessing Ca^^-permeable AMPA receptors 
(Carriedo et al., 1995; Carriedo et al., 1996). These experiments were the first 
clue about the possibility that possession of these receptor channels may be 
one of the factors that predispose motor neurones to degeneration in diseases 
such as ALS, where glutamatergic neurotransmission may be altered in same 
way. Subsequently, many other works on rodent motor neurone cultures 
reinforced these findings (Launey et al., 1998; Terro et al., 1998; Bar-Peled et 
al., 1999; Greig et al., 2000; Van Den Bosch et al., 2000).
Support for such an hypothesis was strengthened by several reports 
showing that human motor neurones do not express or have very low 
expression of GluR2 mRNA (Williams et al., 1997; Heath et al., 2002; Kawahara 
et al., 2003) or GluR2 protein (Shaw et al., 1999). This suggests that lack or low 
expression of GluR2 subunit may be the cause of the existence of Ca^^- 
permeble AMPA receptors on motor neurones, making them more prone to 
excitotoxicity. GluR2 expression has been widely examined also in animal 
models. Apart from one paper reporting the absence of GluR2 on motor 
neurones in dissociated rat spinal cord cultures (Bar-Peled et al., 1999), several 
studies have clearly demonstrated the abundant presence of this subunit in 
cultured motor neuronal cells of rodents (Greig et al., 2000; Van Den Bosch et
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al., 2000; Vandenberghe et al., 2000b; Lasio et al., 2001). Moreover, GluR2 
seems to be entirely edited at the Q/R site (Vandenberghe et al., 2000a). 
However, despite the high expression of edited GluR2, this subunit may be 
excluded from a subset of AMPA receptors, generating AMPA receptors 
permeable to calcium, as demonstrated by the Co^  ^ labelling (Carriedo et al., 
1995; Carriedo et al., 1996; Launey et al., 1998; Terro et al., 1998; Bar-Peled et 
al., 1999; Greig et al., 2000; Van Den Bosch et al., 2000), by the action of Joro 
spider toxin, a selective blocker of Ca^^-permeable AMPA receptors that 
prevents AMPA evocated current in motor neurones (Greig et al., 2000) and by 
motor neurone death occurring after kainate exposure (Van Den Bosch et al., 
2000). Thus, it is plausible that GluR2-containing and GluR2-lacking AMPA 
receptors can coexist in single motor neurones.
Nevertheless, it has been reported that there are not significant differences 
between motor neurones and dorsal horn neurones in terms of GluR2 
abundance and whole cell relative Ca^  ^ permeability (Vandenberghe et al., 
2000a), in spite of a lower Co^  ^ uptake in the dorsal horn neurones 
(Albuquerque et al., 1999; Bar-Peled et al., 1999). This would mean that, in 
physiological conditions, the presence of calcium-permeable AMPA receptors 
might not be enough to explain selective vulnerability of motor neurones. 
However, AMPA receptor current density is threefold higher in motor neurones 
than in dorsal horn neurones, suggesting a higher density of functional AMPA 
receptors in motor neurone surface (Vandenberghe et al., 2000b).
Other factors may render motor neurones more responsive to AMPA- 
mediated increase of Ca^  ^ influx in comparison to other cell types. It has been
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reported that immunoreactivity for Ca^^ buffering protein calretinin was negative 
in cultured rat motor neurones (Terro et al., 1998). Other two proteins involved 
in calcium sequestration, parvalbumin and calbindin, were not found in human 
spinal motor neurones (Ince et al., 1993). Moreover, motor neurone death 
induced by increased intracellular calcium upon AMPA receptor stimulation is 
attenuated by overexpression of parvalbumin in transgenic mice (Van Den 
Bosch et al., 2002b). Therefore, low cytosolic calcium buffering capacity may 
also contribute to render motor neurones particularly exposed to glutamatergic 
insults.
Another hypothesis proposed regards the mitochondrial susceptibility 
demonstrated by motor neurones. It has been shown that AMPA or kainate 
exposure selectively triggers mitochondria Ca^  ^overloading in these cells with 
only a little effect on cortical GABAergic neurones, which also express calcium- 
permeable AMPA receptors (Carriedo et al., 2000). The accumulation of 
calcium in mitochondria causes mitochondrial membrane depolarization and 
consequent reactive oxygen species (ROS) generation. Mitochondria 
impairment has been well documented in animal models of ALS (Dal Canto and 
Gurney, 1995; Wong et al., 1995; Bendotti et al., 2001a; Higgins et al., 2002), 
suggesting that excitotoxic insults mediated by AMPA receptors might be 
harmful to motor neurones through damaging the mitochondrial system. Altered 
mitochondria have been observed in motor neurone dendrites of ALS mice a 
long time before the massive loss of motor neurones (Bendotti et al., 2001a). 
Interestingly, it has been shown that the majority of GluR2-lacking and
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consequently Ca^^-permeable AMPA receptors present on motor neurones are 
localized on dendrites (Launey et al., 1998; Vandenberghe et al., 2001).
All the above observations regarding composition, distribution and working 
properties of AMPA receptors are relative to normal motor neurones. They 
suggest that motor neurones are predisposed to be injured by excitotoxic 
damage because of the presence of a subset of calcium-permeable AMPA 
receptors and their peculiar cellular characteristics, which render them more 
sensitive to abnormal calcium influx.
It is also conceivable that molecular and functional features of AMPA 
channels may be altered in certain disease states, representing a triggering or 
enhancing event for the pathology. It has been described that GluR2 mRNA is 
downregulated in susceptible neurones of animal models after transient 
forebrain ischemia or kainite-induced epilepsy (Pellegrini-Giampietro et al.,
1997). Traumatic spinal cord injury determines a persistent reduction of GluR2 
protein and mRNA in motor neurones near the injury site (Grossman et al.,
1999) and decrease of GluR3 and GluR4 expression in white matter astrocytes 
(Park et al., 2003). These data demonstrate the dynamic nature of AMPA 
receptor composition that could lead to the induction of calcium-permeable 
receptors as a component of the pathological process. This hypothesis has 
been also investigated in ALS. Several papers have reported the decreased 
transcription of GluR2 mRNA in ventral spinal cord of ALS cases, compared to 
normal control (Virgo et al., 1996; Takuma et al., 1999). In particular, significant 
downregulation of the flop form of GluR2 has been observed, suggesting the 
formation of slowly desensitizing AMPA receptors (Tomiyama et al., 2002).
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However, Kawahara and coworkers have recently showed unchanged level of 
GluR2 mRNA in single motor neurones of ALS patient examined by quantitative 
RT-PCR (Kawahara et al., 2003), even if the editing efficiency was incomplete 
in 44% of cases (Kawahara et al., 2004). Therefore, the role of this subunit in 
ALS pathology remains controversial.
The study of in vitro or animal models of the disease has not clarified this 
issue. Expression of S0D1 mutants enhances AMPA-mediate toxicity in 
cultured motor neurones, associated with increased intracellular calcium levels 
and mitochondrial dysfunction (Roy et al., 1998; Kruman et al., 1999; Spalloni et 
al., 2004). However, GluR2-immunoreactivity did not appear to be altered in 
spinal cord of mice overexpressing G86R mutant murine S0D1 (Morrison et al.,
1998). Recently, unchanged levels of AMPA receptor subunit mRNAs have 
been also reported in cultured motor neurones expressing S0D1 with G93A 
mutation, although elevated expression flip forms was found (Spalloni et al., 
2004). In general, none of these studies have determined whether there are 
changes in AMPA receptors at presymptomatic stages of ALS.
Support for an involvement of AMPA receptors in ALS pathology comes 
from two studies showing that treatment with AMPA antagonist drugs 
ameliorates symptoms and survival of transgenic ALS mice (Canton et al., 
2001; Van Damme et al., 2003).
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3.2 Hypothesis and aim
The hypothesis tested in this part of the thesis is that the expression of 
G93A mutant of human S0D1 in transgenic mice may result in changes of 
AMPA receptor subunit expression in motor neurones, making them prone to be 
preferentially injured by glutamatergic insults.
Thus, the aim of this section is to evaluate protein and mRNA expression 
of AMPA receptor subunits in the lumbar spinal cord of mice during
the progression of disease, in order to clarify whether early alterations may be 
involved in pathology.
3.3 Methods
3.3.1 In situ hybridisation for glutamate AMPA receptor subunit mRNAs 
in mice
In situ hybridisation was performed as described in section 2.4. Lumbar 
spinal cords (L2-L4 levels) of SODI®®^ ,^ SODI'^ and non transgenic mice used 
as control at 8, 14 and 19 weeks of age (4 to 6 mice each group), were used.
^^S-labelled RNA probes complementary to the flop variant of GluRI, 
GluR2, GluR3 and GluR4 mRNAs were prepared through in vitro transcription 
of cDNA fragments. GluRI, GluR2 and GluR3 (inserts were 2992, 3505 and 
3083 base pairs in length respectively) were cloned between the EcoRI site (5’) 
and the Xhol site (3') of the polylinker region of pBluescript SK (-) plasmid. 
Antisense transcripts were obtained using T7 RNA polymerase enzyme and
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sense transcripts were obtained using T3 RNA polymerase enzyme. GluR4 
insert was 2971 base pairs in length and was cloned between the EcoRI site 
(5’) and the BamHI site (3’) of the polylinker region of the same plasmid. 
Antisense transcript was obtained using T3 RNA polymerase enzyme and 
sense transcript was obtained using T7 RNA polymerase enzyme. The 
plasmids were kindly provided by Dr Pellegrini Giampietro, Département of 
Preclinical and Clinical Pharmacology Mario Aiazzi Mancini, Universita' di 
Firenze, Firenze, Italy.
3.3.2 Immunohistochemical analysis of glutamate AMPA receptor 
subunits in S0D1°^^^ mice
Immunohistochemical analysis was performed as described in section 2.5. 
Fixed and frozen lumbar spinal cords of SODI®®^^ mice at 8, 14 and 19 weeks 
of age, SODI'^ mice and non transgenic mice at 8 weeks of age used as 
control (3-4 mice each group, 3 indipendent experiments performed with 
different animals) were used. The primary antibodies used were: monoclonal 
anti-GluR2 (1:200, Chemicon International, Harrow, UK) or monoclonal anti- 
GluR3 (1:100, Chemicon International) or monoclonal anti-GluR4 (1:500, 
Chemicon International), diluted in PBS 0.01 M additioned with 4% NGS and 
0.1% Triton X-100. Biotinylated anti-mouse secondary antibody was used.
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3.3.3 Western blot analysis of glutamate AMPA receptor subunits in 
S0D1°“ * mice
Western blot analysis was performed as described in section 2.6. Frozen 
spinal cords of mice at 8 and 19 weeks of age and non transgenic
mice at 8 weeks of age used as control (3 mice each group) were used. Eighty 
pg protein/lane of each sample were run on precast polyacrylamide-SDS 
gradient gel (4%-15%) (Bio-Rad laboratorie, Hercules, CA, USA). The primary 
antibodies used were: monoclonal mouse anti-GluR2 (1:500, Chemicon 
International) or monoclonal mouse anti-GluR3 (1:500, Chemicon International) 
or monoclonal mouse anti-actin (1:2000, Chemicon International). Anti-mouse 
IgG conjugated to horseradish peroxidase (1:2000, Sigma, Poole, UK) was 
used as secondary antibody. Blots were developed using ECL plus Western 
Blotting Detection System (Amersham Biosciences) according to the 
manufacturer's instructions
3.4 Results
3.4.1 Analysis of AMPA receptor subunit mRNAs in the spinal cord of
So d i °93a
The mRNA expression of AMPA glutamate receptor subunits GluRI, 
GluR2, GluR3 and GluR4 (flop variants) was investigated in the lumbar spinal 
cord of ALS transgenic mice expressing G93A mutant of human SOD1 enzyme.
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The lumbar tract of the cord was chosen because the hindlegs of these mice 
are affected erlier and more severely compared to the forelegs. In fact, only the 
50% of the motor neurones are spared in this spinal cord area. The analysis 
was performed by in situ hybridisation technique.
3.4.1.1 Expression of AMPA receptor subunit mRNAs in the spinal cord of 
control mice
Apart from GluRI, the other three AMPA subunits GluR2, GluR3 and 
GluR4 show a quite high level of mRNA expression in the spinal cord grey 
matter of C57BL/6 mice, used as control in this study (Figure 3.2).
GluRI mRNA presents a very faint signal distributed along the whole
spinal cord sections (Figure 3.2 A), with very low expression in the motor
neurones (Figure 3.2 a), as already reported in rats by Greig et al. (Greig et al.,
2000).
On the contrary, GluR2 mRNA is highly expressed in the substantia 
gelatinosa and in the other laminae of the dorsal horn of the spinal cord, with a 
prominent signal found in Laminae I and II (Figure 3.2 B). Labelling is also
present in many other cells of the grey matter, in particular in the motor
neurones of the ventral horn (Figure 3.2 b).
Low levels of mRNA has been detected for GluR3 in the substantia 
gelatinosa (Figure 3.2 C), whereas a quite high signal for this subunit is
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observed in the ventral horn motor neurones, even if it seems to be less intense 
in comparison to GluR2 (Figure 3.2 c).
GluR4 mRNA does not result expressed at significant levels in dorsal horn 
of the spinal cord but an elevated silver grain density is observable in the 
intermediate and ventral laminae (Figure 3.2 D). In the laminae IX, the 
accumulation of black grain on the motor neurones is particularly evident 
(Figure 3.2 d).
3.4.1.2 Expression of AMPA receptor subunit mRNAs in the spinal cord of
mice
A quantitative analysis of mRNA expression of AMPA receptor subunits 
was carried out in the ventral and dorsal horn of spinal cord and in particular in 
the motor neurones of mice at different stages of the disease:
presymptomatic (8 weeks of age), early symptomatic (14 weeks of age) and 
end stage (19 weeks of age). Given its almost undetectable expression 
revealed in the spinal cord of control mice, the GluRI subunit mRNA was not 
considered in this analysis. Non transgenic mice and mice overexpressing wild 
type human S0D1 (SODI'^) were used as controls.
a) GiuR2:
The widespread distribution of GluR2 mRNA observed in the whole grey 
matter of lumbar spinal cord of control mice does not change in SGDI^®^^ 
transgenic mice. Quantitative analysis of autoradiographic opical density of
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Figure 3.2: mRNAs distribution of AMPA receptor subunits in mouse spinal co ^
Representative hemisections of lumbar spinal cord. GluRI mRNA presents a very 
low expression in the whole spinal cord (A) with very low expression in the motor 
neurones (a). GluR2 mRNA is highly expressed in the dorsal horn (Laminae I and II) 
(B). Labelling is also present in many other cells of the grey matter, in particular in the 
motor neurones of the ventral horn (b). Low levels of GluR3 mRNA are observed in 
substantia gelatinosa (C) whereas a quite high signal is revealed in the ventral horn 
motor neurones (c). GluR4 mRNA is not expressed at significant levels in dorsal horn 
(D) but an elevated silver grain density is observable on the motor neurones in tne 
laminae IX (d). Scale bar: (A-D)=100 pm; (a-d)=30 pm.
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dorsal (laminae I, II, III and IV) (Figure 3.3) and ventral (laminae VII, VIII, and 
IX) (Figure 3.4) regions of the spinal cord performed with image analysis, 
revealed no significant variation in the expression GluR2 RNA messenger in 
mice at all the disease stages examined, compared to age-matched 
controls. Since the nature of my study, I put my attention on variation of GluR2 
mRNA expression in the motor neurones. Using a computerized microscope 
image analyzer, the I BAS 2, Kontron/Zeiss, according to the procedure by 
Masseroli and co-workers (Masseroli et al., 1993), I quantitatively evaluated the 
silver grain density in single motor neurones of presymptomatic, symptomatic 
and end stage SODI®®^^ mice. Quantitative analysis of the grain density on 
these cells did not show significant variations in transgenic mice at all stages of 
the disease when compared with age-matched controls (Figure 3.5).
b) GluR3:
The general distribution of GluR3 mRNA in the whole spinal cord of 
SODI®®^^ mice does not show appreciable differences when compared to 
control mice. Also in this case, quantitative analysis of autoradiographic opical 
density did not show statistical differences in the general expression pattern of 
GluR3 mRNA in dorsal (Figure 3.6) and ventral (Figure 3.7) horn of SOD1°®^^ 
mice compared to controls. However, quantitative analysis of autoradiographic 
grain density on motor neurones of transgenic mice revealed a trend to an 
increasing of mRNA at 8 weeks of age, which become significant at
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Figure 3.3: GluR2 mRNA expression in the dorsai horn ofSODI^ ^ '^  ^mouse spinai 
cord
Quantitative analysis of autoradiographic opical density revealed no significant 
variation in GluR2 mRNA expression in the spinal cord dorsal horn (laminae I, II, III and 
IV) of mice in respect to non transgenic mice (control) and SOD1'^ mice, at
all the ages considered (two sections from each animal). Each column is the mean ±  
S.E.M. (n = 4 to 6), data analysed by Two-Way ANOVA followed by Tukey's test.
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Figure 3.4: GluR2 mRNA expression in the ventral horn of mouse
spinal cord
Quantitative analysis of autoradiographic opical density revealed no significant 
variation in GluR2 mRNA expression in the spinal cord ventral horn (laminae VII, VIII, 
and IX) of mice in respect to non transgenic mice (control) and SODI'^ mice,
at all the ages considered (two sections from each animal). Each column is the mean ± 
S.E.M. (n = 4 to 6), data analysed by Two-Way ANOVA followed by Tukey's test.
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Figure 3.5: GluR2 mRNA expression in the ventral motor neurones of 
mouse spinal cord
Quantitative estimation of GluR2 mRNA expression in the motor neurones of 
mice was performed by evaluating the silver grain density in single motor 
neurones of presymptomatic (8 weeks of age), symptomatic (14 weeks of age) and end 
stage (19 weeks of age) mice (two sections from each animal). No significant variations 
was observed in transgenic mice at all stages of the disease when compared with age- 
matched controls (non transgenic mice). Each column is the mean ± S.E.M. (n = 4 to 
6), data analysed by Two-Way ANOVA followed by Tukey's test.
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Figure 3.6: GluR3 mRNA expression in the dorsal horn of mouse spinal
cord
Quantitative analysis of autoradiographic opical density revealed no significant 
variation in GluRS mRNA expression in the spinal cord dorsal horn (laminae I, II, III and 
IV) of mice in respect to non transgenic mice (control) and SODI'^ mice, at
all the ages considered (two sections from each animal). Each column is the mean ± 
S.E.M. (n = 4 to 6), data analysed by Two-Way ANOVA followed by Tukey's test.
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Figure 3.7: GluR3 mRNA expression in the ventral horn of mouse
spinal cord
Quantitative analysis of autoradiographic opical density revealed no significant 
variation in GluRS mRNA expression in the spinal cord ventral horn (laminae VII, VIII, 
and IX) of mice in respect to non transgenic mice (control) and SODI'^ mice,
at all the ages considered (two sections from each animal). Each column is the mean ±  
S.E.M. (n = 4to 6), data analysed by Two-Way ANOVA followed by Tukey's test.
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Figure 3.8: GluR3 mRNA expression in the ventral motor neurones of 
mouse spinal cord
Quantitative estimation of GluRS mRNA expression in the motor neurones of 
mice was performed by evaluating the silver grain density in single motor 
neurones of presymptomatic (8 weeks of age), symptomatic (14 weeks of age) and end 
stage (19 weeks of age) mice (two sections from each animal). Significant increased of 
GluRS mRNA expression was revealed in transgenic mice at 14 weeks of age when 
compared with age-matched controls (non transgenic mice). Each column is the mean 
± S.E.M. (n = 4 to 6), data analysed by Two-Way ANOVA followed by Tukey's test, * = 
p < 0.05.
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Figure 3.9: GluR4 mRNA expression in the dorsal horn of mouse spinal
cord
Quantitative analysis of autoradiographic opical density revealed no significant 
variation in GluR4 mRNA expression in the spinal cord dorsal horn (laminae I, II, III and 
IV) of mice in respect to non transgenic mice (control) and SODI'^ mice, at
all the ages considered (two sections from each animal). Each column is the mean ± 
S.E.M. (n = 4 to 6), data analysed by Two-Way ANOVA followed by Tukey's test.
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Figure 3.10: GluR4 mRNA expression in the ventral horn of mouse
spinal cord
Quantitative analysis of autoradiographic opical density revealed no significant 
variation in GluR4 mRNA expression in the spinal cord ventral horn (laminae VII, VIII, 
and IX) of mice in respect to non transgenic mice (control) and SODI'^ mice,
at all the ages considered (two sections from each animal). Each column is the mean ±  
S.E.M. (n = 4to 6), data analysed by Two-Way ANOVA followed by Tukey's test.
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Figure 3.11: GluR4 mRNA expression in the ventral motor neurones of SODI^^^^ 
mouse spinal cord
Quantitative estimation of GluR4 mRNA expression in the motor neurones of 
mice was performed by evaluating the silver grain density in single motor 
neurones of presymptomatic (8 weeks of age), symptomatic (14 weeks of age) and end 
stage (19 weeks of age) mice (two sections from each animal). No significant variations 
was observed in transgenic mice at all stages cosidered when compared with age- 
matched non transgenic mice (controls). Each column is the mean ± S.E.M. (n =4 to 6), 
data analysed by Two-Way ANOVA followed by Tukey's test.
108
14 weeks of age, compared with age-matched control mice. In transgenic mice 
at 19 weeks of age, mRNA in surviving motor neurones is not different from 
respective control (Figure 3.8).
c) GluR4
Also in S0D1®®^  ^mice, GluR4 mRNA is almost absent in the dorsal horn 
of lumbar spinal cord of control mice. No appreciable differences were found 
after autoradiographic optical density examination of dorsal (Figure 3.9) or 
ventral (Figure 3.10) horn. Similarly, quantitative analysis of grain density on 
motor neurones of SODI^®^^ mice did not show significant alteration of mRNA 
level, at all stages of the disease (Figure 3.11).
3.4.2 Study of AMPA receptor subunit protein expression in the spinal 
cord of SOD1°®^^ mice
The protein expression and distribution of glutamate AMPA receptor 
subunits GluR2, GluRS and GluR4 in the spinal cord of SODI®^^^ transgenic 
mice was examined using immuhistochemistry and Western blot techniques. 
Since the almost absent expression of GluR1 mRNA in the lumbar motor 
neurones of control mice, experiments to determine the protein expression of 
this subunit were not performed.
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3.4.2.1 Expression and distribution of AMPA receptor subunit proteins in the 
spinal cord of mice examined by immunohistochemical
analysis
Immunolabelling for AMPA receptor subunits was performed in the lumbar 
spinal cord of mice at different stages of the disease and compared
to non transgenic mice and mice overexpressing wild type human S0D1.
GluR2:
In control mice GluR2 immunoreactivity is localized throughout the whole 
grey matter. A dense staining is observed in the cells and neuropil of substantia 
gelatinosa and in motor neurones of ventral horn (Figure 3.12 A). In the motor 
neurones, immunostaining is distributed in the cytoplasm of the cell body and 
neurites, with an intense granular immunoreactivity in the perinuclear region 
(Figure 3.12 a).
In SODI®®^^ mice there are no substantial changes in GluR2 
immunostaining observed in dorsal horn, whereas a decrease of signal is 
observed in the ventral region, at all stages of the disease, associated with a 
progressive loss of motor neurones (Figure 3.12 B, C and D). In particular, in 
the SODI®®^^ mice at 8 and 14 weeks of age, we could observe a decrease of 
GluR2 immunostaining and a more homogeneous distribution of labelling in the 
cytoplasm, associated with changes in the morphology of motor neurones and 
loss of neurites particularly at 14 week of age (Figure 3.12 b and c). These 
modifications were strongly marked in some animals, less evident in others and
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were not seen in control mice or in mice overexpressing wild type form of 
human S0D1 (Figure 3.12 e)
GluR3:
Reflecting what is observed for the mRNA, GluRS immunoreactivity is less 
intense than the one revealed for GluR2 in the dorsal laminae. The 
immunostaining in ventral horn is mainly localized in the motor neurones, as 
well as in other smaller neurones of this region (Figure 3.13 A). Within the motor 
neurones the immunostaining is homogenously distributed in the cytoplasma of 
the cell body and neurites (Figure 3.13 a).
In the SODI®®^^ mice at 8 weeks of age there was a general increase of 
immunoreactivity in neurones of grey matter in ventral horn and intermediate 
area. An increased immunostaining is also revealed in the cytoplasm of several 
motor neurones in lamina IX (Figure 3.13)
GluR4
Immunoreactivity of GluR4 subunit protein is distributed in almost all the 
cells of grey matter of lumbar spinal cord of control mice (Figure 3.14 A). Unlike 
the immunohistochemistry reported for rat spinal cord (Tachibana et al., 1994), 
we observe a prominent staining of nuclei of the cells. In particular, the nuclei of 
motor neurones of ventral regions are very intensely and homogeneously 
labelled (Figure 3.14 a).
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The GluR4 immunoreactivity was also prominent in the nuclei of motor 
neurones of mice, with levels that do not apparently differ from
controls (not shown).
3.4.22 Quantitative analysis of AMPA receptor subunit proteins in the total 
spinal cord of mice examined by Westem blot technique
The total amount of AMPA subunit proteins expressed in the spinal cord of 
mice was tested by Western blotting. This was studied at 
presymptomatic (8 weeks of age) and final (19 weeks of age) stage of the 
disease. Since variation in distribution and expression observed in the 
immuhistochemical studies was detected only for GluR2 and GluRS, the 
Western blot analysis was performed for these two subunits only (Figure 3.15 
A).
Quantitative determination of band optical density did not reveal any significant 
change in the total amount of these subunits. However, a trend to decrease 
(about -20%) is observable for GluR2 in S0D1®®^  ^ mice at presymptomatic 
phase (Figure 3.15 B). This was not revealed for GLURS (Figure 3.15 C). At 19 
weeks of age, the band density for both GluR2 and GluRS appears decreased 
(about 30%) in respect to controls, although the decrease does not reach 
statistical significance.
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Figure 3.12: GluR2 immunoreactivity in lumbar spinal cord ofSODI^^^^ mice
In control (non transgenic) mice at 8 weeks of age, a widespread GluR2 
immunoreactivity is localized throughout the whole grey matter with a marked staining 
in the dorsal laminae and in motor neurones of ventral horn (A). In the motor neurones, 
immunostaining is distributed in the cytoplasm of the cell body and neurites (a). No 
significant changes in GluR2 immunostaining are observed in the dorsal horn of 
mice (B,C,D). On the contrary, decreased labelling is revealed in the ventral 
region, at all stages of the disease, associated with a progressive loss of motor 
neurones. In particular, in the mice a 8 and 14 weeks of age, we could
observe a decrease of GluR2 immunostaining associated with changes in the 
morphology of motor neurones with a loss of neurites (b,c,d). No evident changes in 
GluR2 immunoreactivity are observed in SODI'^ mice (E-e). Scale bars: (A-E = 200 
jum); (a-e= 50 pm).
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Figure 3.13: GluR3 immunoreactivity in lumbar spinal cord of SODI^^^^ mice
The Immunostaining in ventral horn of non transgenic mice at 8 weeks of age 
(control) is mainly localized in the motor neurones, as well as in other smaller neurones 
of this region (A). Within the motor neurones the immunostaining is homogenously 
distributed in the cytoplasma of the cell body and neurites (a). In the mice at
8 weeks of age there was a general increase of immunoreactivity in neurones of grey 
matter in ventral horn and intermediate area (B). An increased immunostaining is also 
revealed in the cytoplasm of several motor neurones in lamina IX (b). No evident 
changes in GluRS immunoreactivity are observed in SODI'^ mice (E,e). Scale bars: (A- 
E = 200 pm); (a-,e = 20 pm).
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&Figure 3.14: GluR4 Immunoreactivity in lumbar spinai cord ofSODI^^^^ mice
Immunoreactivity of GluR4 subunit protein is distributed in almost all the cells of 
grey matter of lumbar spinal cord of control mice (A). A prominent staining of nuclei of 
the cells is observed. In particular, the nuclei of motor neurones of ventral regions are 
very intensely and homogeneously labelled (a). The GluR4 immunoreactivity in 
mice does not apparently differ from non transgenic controls (not shown). 
Scale bars: (A = 200 pm); (a = 20 pm).
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Figure 3.15: Western biot analysis of the expression of AMPA receptor subunits 
GiuR2 and GluR3 in the spinal cord ofSODI^^^^ mice
(A) No evident differences in GluR2 and GluRS band intensity was oserved in 
mice at presymptomatic (8 weeks of age) and final stage of the disease (19 
weeks of age), when compared to controls (non transgenic mice at 8 weeks of age). 
(B-C) Results show quantitative evaluation of GluR2 (B) and GluRS (C) protein levels 
expressed as ratio between their band intensity and actin band intensity from the same 
blot. Each column shows the mean ± S.E.M. (n = S). Data analysed by One-Way 
ANOVA followed by Bonferroni's multiple comparison test.
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3.5 Discussion
In this part of the project, I investigated the expression of AMPA receptor 
subunits in the spinal cord of a murine model of ALS, the SOD transgenic 
mouse. In fact, alterations of AMPA receptor composition may result in aberrant 
glutamate firing of motor neurones and increased calcium entry to cause 
selective death of these cells. Therefore, this kind of evaluation may give further 
important clues about the possible role of excitotoxicity in ALS.
The main result coming out from this study regards the decreased 
expression of GluR2 subunit in the motor neurones of S0D1®^^^ mice at 
presymptomatic stage of the disease, compared to non transgenic and S0D1'^ 
mice. This data represents the first evidence of altered glutamate receptor 
expression in this mouse model of ALS.
The decline of this subunit is only seen at the level of protein expression, 
without involving the mRNA production, as demonstrated by the in situ 
hybridisation study. In fact, quantitative evaluation of these experiments showed 
no significant changes in mRNA expression either in dorsal or ventral horn of 
the spinal cord, with no changes in motor neurones. On the contrary, the 
immunostaining for GluR2 appeared diminished in the cell bodies of many large 
motor neurones of transgenic mice at presymptomatic stage of the pathology. 
This phenomen was not observed in neurones of dorsal laminae. Although the 
immunohistochemical analysis does not provide a reliable quantitative 
evaluation of the results, the decrease of immunolabelling was observed in the 
motor neurones of a high percentage of the mice examined. Moreover, this data
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was in part supported by immunoblotting that showed a trend to decrease of the 
band density for GluR2 at presymptomatic stage of the disease. However, 
quantitative analysis did not reveal significant changes, probably due to 
unchanged high levels of GluR2 in the dorsal horn.
Another interesting result emerging from this study is the apparent general 
increase of GluRS protein expression observed by immunohistochemistry in the 
spinal cord, and in particular in motor neurones, of mice at the same
phase of the disease, even if the difference were less marked than the one 
observed for GluR2 subunit. In this case the quantitative estimation of mRNA in 
motor neurones showed a trend to increase at 8  weeks of age, which became 
significant at 14 weeks of age, confirming the general GluRS tendency to 
increase.
The other subunits, GluR1 and GluR4 were not examined in as much 
detail since GluR1 mRNA was not found on motor neurones of control mice and 
GluR4 protein showed an unusual distribution.
It is known that the presence of the Q/R edited form of GluR2 in the 
molecular structure of AMPA receptors determines the calcium impermeability 
of their channel. As outlined in the introduction to this chapter, changes in 
GluR2 levels in the motor neurones can results in increased calcium 
permeability of AMPA receptors and might lead to or derive from pathological 
condition in ALS, determining or contributing to motor neurone degeneration.
Whether the expression of GluR2 in the motor neurones of ALS patients is 
altered or not still remains uncertain. Confirming our results obtained in 
SODl®^^^ mice, Kawahara and collaborators have recently demonstrate
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unchanged level of GluR2 mRNA in single motor neurones of human ALS 
(Kawahara et al., 2003). However, GluR2 transcripts in the motor neurones of 
44% of ALS cases examinated were incompletely edited (Kawahara et al., 
2004). Spalloni and colleagues have recently reported unchanged levels of 
GluR2 subunit mRNA in cultured mouse motor neurones expressing S0D1®^^^ 
in respect to control (Spalloni et al., 2004), giving further confirmation of the lack 
of mRNA transcription involvement. In contrast to these negative findings, one 
study showed a decrease of GluR2 messenger RNA in total ventral grey matter 
of ALS patient spinal cord, evaluated by PCR technique (Takuma et al., 1999). 
Diminished mRNA levels for this AMPA subunit in whole human spinal cord 
homogenates was also described by Virgo and colleagues (Virgo et al., 1996). 
In all these reports, the protein level of GluR2 was not evaluated. Expression 
studies in human tissue are necessarily carried out on postmortem samples, 
which derive in most instances from end stage cases of the disease, when a 
large number of motor neurones are degenerated. Therefore, the reduction of 
GluR2 mRNA level observed in the whole spinal cord may reflect the massive 
loss of these cells. Thus, whether alteration of AMPA subunit expression can 
occur in early phase of human pathology is difficult to establish. Moreover, there 
are no studies about the protein expression of GluR2 in human patients. 
Transgenic mouse models of ALS such as the one used in this study provide 
therefore a good tool to clarify these aspects.
The results obtained in this study indicate that post transcriptional events 
can lead to decrease of GluR2 protein expression in the lumbar motor neurones 
of SODI®^^^ mice in respect to normal animals, even without decrement of its
121
mRNA. It suggests that pathological condition induced by the expression of 
ALS-linked mutant form of S0D1 may affect the translation or the biological 
stability of GluR2 protein.
Since this effect was already observed in mice at 8  weeks of age, when 
the symptoms are not yet evident, it can be assumed that this phenomenon 
may be a causative event of the disease that could help to trigger the pathology 
in these mice. Supporting this hypothesis, it has been showed that calcium 
entry into the motor neurones through the Ca^^-permeable AMPA receptors 
induces a selective damage to mitochondria into these cells (Carriedo et al., 
2000). A very early pathological marker observed in S0D1°^^^ mice is the 
vacuolisation of mitochondria in motor neurones (Bendotti et al., 2001a). 
Therefore, altered glutamatergic stimulation due to GluR2 deficiency might be 
the cause of this precocious mitochondria failure, indicating the excitotoxicity as 
a possible early event in S0D1®^^^ mice pathology. Support for such a theory 
comes from studies carried out on mixed spinal cord cultures derived from the 
same transgenic mice. The authors showed an increased vulnerability of motor 
neurones expressing S0D1®®^  ^ mutant to AMPA mediated glutamate toxicity 
(Spalloni et al., 2004) associated with enhanced reactive oxygen speciesi 
production, sustained elevations of intracellular calcium levels, and 
mitochondrial dysfunction (Kruman et al., 1999). On the other hand, it has 
recently been shown that mitochondrial dysfunction induced by complex I and 
complex II inhibitors predisposes cultured motor neurones to excitotoxicity 
mediated by glutamate ionotropic receptor (Kanki et al., 2004). It suggests that 
glutamate receptor alteration could also be secondary to early mitochondrial
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failure determined by other factors such as the accumulation of mutated S0D1 
onto mitochondria surface of motor neurones (Liu et al., 2004).
GluR2 immunoreactivity has been investigated in another transgenic 
model of ALS, the mice, which carry mutated murine gene as
transgene. Unlike the present study, Morrison and colleagues did not find 
apparent changes in GluR2 immunostaining in spinal cord of these mice at both 
presymptomatic and symptomatic stage of the pathology (Morrison et al., 1998). 
However, the SODI^®®^ mice develop an extremely aggressive disease and 
only few days pass between the onset of symptoms and total immobility and 
death (Ripps et al., 1995a). This rapid development of the pathology, so 
different from the disease progression occurring in ALS patients and in 
SODI®®^  ^ mice used in our study, render this model quite dissimilar from the 
chronic course of the human illness. Consequently, the acute motor dysfunction 
displayed by these mice can be ascribed to different processes, which could not 
involve the glutamatergic system.
Reduction of GluR2 subunits has been also observed in other pathological 
conditions. It has been shown that GluR2 mRNA is down regulated in 
susceptible neurones of animal models after transient forebrain ischemia or 
kainate-induced epilepsy (Pellegrini-Giampietro et al., 1992; Pollard et al., 1993; 
Friedman et al., 1994; Pellegrini-Giampietro et al., 1994). Another study 
demonstrated that traumatic spinal cord injury determines a long-lasting 
decrease of GluR2 mRNA and protein in motor neurones near the injury site 
(Grossman et al., 1999). Contrary to what observed in our model, in these 
cases the authors reported the decrement of GluR2 messenger RNA but the
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paradigms used are represented by acute condition of neurological injury, 
whereas the ALS-like pathology displayed by mice is a chronic
disease. Therefore, the mechanisms underlying the reduction of GluR2 
expression can be different. On the other hand, these data confirm that AMPA 
receptor architecture can undergo dynamic modification when stressed by 
harmful circumstances.
The mechanisms underlying the decreased expression of GluR2 observed 
in our experiments and in particular how the expression of the mutant 
can affect the GluR2 availability in the motor neurones remain to be elucidated.
It has been demonstrated that excessive glutamate stimulation of cultured 
hyppocampal neurones induces AMPA receptor internalization mediated by 
dynamin-dependent endocytotic process (Carroll et al., 1999; Lissin et al., 
1999). Zhou and collaborators found that the glutamate-induced internalization 
of AMPA receptors is caused by calcium influx, which in turn determines 
depolymerization of actin filaments (Zhou et al., 2001). The role of actin 
filaments in AMPA receptor anchoring to postsynaptic membrane surface 
suggests that disorganization of cytoskeletal structure can directly be involved 
in decreased expression of GluR2 in ALS. Neurofilament accumulations in the 
cell bodies and proximal axons of motor neurones have been documented in 
both sporadic and familial ALS (Hirano et al., 1984a; Hirano et al., 1984b). 
Several studies carried out on transgenic mice have shown that neurofilament 
content and organization strongly influence motor neurone disease induced by 
mutant S0D1 (Couillard-Despres et al., 1998; Williamson et al., 1998; Couillard-
124
Despres et al., 2000; Kong and Xu, 2000). However, direct involvement of actin 
in ALS pathology has never been reported, although it cannot be excluded.
Another possible mechanism involved in GluR2 protein downregulation 
relates to the p38MAPK pathway. Recently, it has been reported that inhibition 
of p38MAPK cascade can reverse the decrease of GluR2 expression observed 
in cortical neurones of neonatal rats after treatment with glutamate (Rivera- 
Cervantes et al., 2004). Zhu and colleagues have reported that AMPA receptor 
subunits with short intracellular tails such as GluR2 are continuously added to 
and removed from synapses during normal neuronal activity. In particular, they 
showed that removal of GluR2 require activation of Rap, a member of the Ras 
superfamily of small GTPases, and the activation of p38MAPK pathway (Zhu et 
al., 2002a). Since over activation of p38MAPK has been hypothesized to be 
involved in ALS pathology (Khz et al., 2002; Raoul et al., 2002; Van Den Bosch 
et al., 2002a; Bendotti et al., 2004), it is possible that decrease of GluR2 protein 
in motor neurones of ALS S0D1°^^^ mice can be due to early activation of this 
pathway with consequent internalisation and degradation. This aspect will be 
discussed more in detail in chapter 7.
Our results have shown an increased level of GluR3 mRNA in the spinal 
motor neurones of S0 D1 ®^ ^^  mice, which resulted significant at symptomatic 
stage of the disease. Moreover, immunohistochemistry also showed an 
overexpression of GluR3 protein in motor neurones already at presymptomatic 
phase of the pathology. This was not confirmed, however, by Western blotting, 
probably due to underestimation of the result deriving from the use of protein 
extract of whole spinal cord. These data are in line with the results reported in
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two recent studies. It has been shown that cultured spinal motor neurones 
derived from the same strand of transgenic ALS mice express higher levels of 
GluR3 mRNA in respect to controls, associated with unchanged levels of GluR2 
mRNA (Spalloni et al., 2004). An Australian group claimed they found increased 
amount of GluR3 protein in the spinal cord of mice analysed by
proteomic approach, despite the fact that they did not show the results 
(Rembach et al., 2004). In the same work, Rembach and collaborators treated 
mice with antisense peptide nucleic acid directed against GluR3, 
obtaining a significant extension of survival and improvement of symptoms. 
However, they could not show any downregulation of GluR3 protein in the 
spinal cord of transgenic mice.
Since GluR3 is a Ca^^-permeable AMPA receptor subunit, it is assumable 
that decrease of GluR2 subunit level, associated with overexpression of GluR3 
may result in increased number of AMPA receptors that permit the entrance of 
calcium during glutamatergic firing, contributing to motor neurone degeneration 
in ALS mice. However, given the lack of GluR2 mRNA involvement
and the significant elevation of GluR3 mRNA in motor neurones when the 
symptoms are already evident, a possible scenario is that the expression of 
S0 D1 ®®^  ^ mutant first determines early post transcriptional modifications of 
GluR2 protein, leading to its excessive degradation; motor neurones, in the 
attempt of replacing GluR2, activate the transcription not of GluR2 but of 
another AMPA subunit, GluR3. This causes the assembling of a high number of 
calcium-permeable AMPA receptors, which lead in turn to excitotoxicity and 
motor neurone death. Although rather speculative, this hypothesis deserves
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further investigation that allow to examine the simultaneous expression of the 
receptor subtypes in the same motor neurone.
Analysis of mRNA expression, carried out by in situ hybridisation, revealed 
low levels of GluR1 mRNA in the whole spinal cord and in particular in the 
motor neurones of control mice. This result is according with previous studies 
reporting low expression of this subunit in the motor neurones of rats 
(Furuyama et al., 1993; Grossman et al., 1999; Greig et al., 2000) but in 
contrast with other works showing relatively high levels of mRNA GluRI in the 
same animals (Van Den Bosch et al., 1999) and in humans (Williams et al., 
1997). However, there are not published studies regarding GluRI mRNA 
expression in mouse motor neurones. Thus, this represents the first report 
showing low levels of this subunit in mice.
Messenger RNA of GluR4 subunit resulted moderately expressed in the 
motor neurone of control mice and no significant differences of expression were 
detected in SODI^®^^ transgenic mice. Surprisingly, immunohistochemical 
analysis of GluR4 protein distribution revealed a prominent nuclear staining of 
the cells. In particular, the nuclei of motor neurones of ventral regions were 
intensely and homogeneously labelled. This is in contrast with previous study 
performed in rat spinal cord and showing a cytoplasmic localization of GluR4 
protein (Tachibana et al., 1994). The nuclear distribution found in mice does not 
seem to be due to low specificity of the antibody utilized. In fact, experiments 
carried out with the same antibody on rat brains showed cytoplasmic labelling of 
neurones similar to that reported in the literature, demonstrating its specificity.
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Thus, it is possible that this antibody recognise epitopes of nuclear proteins in 
C57 mice.
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CHAPTER 4
Study of the effect of the treatment with a 
glutamate AMPA receptor antagonist on 
SOD1®®^  ^transgenic mice
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4.1 Introduction
An altered subunit composition of glutamate AMPA receptors on motor 
neurones may result in their aberrant activation, which in turn can lead to 
excitotoxic events and motor neurone death in ALS. Because of this hypothesis, 
several competitive AMPA antagonist drugs were tested in animal models of 
motor neurone disease. The selective AMPA antagonist NBQX showed 
protective effects on MND mice, significantly improving the motor function 
scores, and on mice, prolonging their survival (Mennini et al., 1999;
Van Damme et al., 2003). The same effect on SODI^®^^ mice was obtained in 
a study with another AMPA antagonist RPR 119990, which also improved the 
grip muscle strength of these ALS mice (Canton et al., 2001). These promising 
results indicate that blockade of AMPA-mediated glutamatergic 
neurotransmission might represent a new therapeutic approach for the 
treatment of ALS. However, the use of competitive AMPA receptor antagonists 
in clinical therapy could cause problems because of the involvement of AMPA 
receptors in most physiological brain functions. Thus, the discovery of non­
competitive allosteric modulators of AMPA receptors, acting on a region 
different from the glutamate binding site, gives rise to new therapeutic agents 
with pharmacological properties different from the common AMPA antagonists. 
The first allosteric modulators of AMPA receptors were the 2,3- 
benzodiazepines, including non competitive GYKI 52466 and its more potent
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analogue GYKI 53655, which selectively inhibit AMPA receptors by interacting 
at a distinct site (Paternain et al., 1995; Bleakman et al., 1996).
The particular property of non competitive AMPA antagonists that is of 
potential clinical benefit, is that they are effective even in the presence of high 
levels of glutamate. Since it has been hypothesized that one of the factors 
contributing to excitotoxic firing on motor neurones might be the decreased 
expression and functioning of glial glutamate transporters (Rothstein et al., 
1992; Rothstein et al., 1995; Trotti et al., 1999), which leads in turn to high 
levels of glutamate in the synaptic cleft, the treatment with such kinds of drugs 
might be extremely useful in ALS therapy.
A benzodiazepine derivative, ZK 187638 (2,3-dimethyl-6-phenyl 12H- 
[1,3]dioxolo[4,5-h]imidazol[1,2-c][2,3] benzodiazepine), has been characterized 
as a non competitive AMPA receptor antagonist (Csuzdi et al., PCT Int.Appl. 
WO 97 28, 163; Chem. Abstr., 127, 205597n., 1997; Eiger et al., unpublished 
results). Preliminary studies showed that, compared to other AMPA antagonists, 
this compound demonstrated a good bioavailability in the central nervous 
system after oral administration. This represents an advantage for treatment of 
chronic diseases.
4.2 Hypothesis and aim
The hypothesis investigated in this chapter is that, since motor neurones in 
ALS are prone to excitotoxicity mediated by AMPA receptors because of their
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subunit composition, a non competitive AMPA antagonist will prevent motor 
neurone loss in mice.
The aim of this study is to test the effect a new non competitive AMPA 
receptor antagonist, ZK 187638, on motor functions and survival of SODI®®^^ 
mice.
4.3 Methods
4.3.1 Evaluation of ZK 187638 levels in plasma and CNS tissues
This part of the study was carried out in collaboration with the Drugs 
Metabolism Laboratory at Mario Negri Institute, Milano.
Blood samples from SODI^®^^ and non transgenic mice were collected in 
heparinized tubes and centrifuged to separate the plasma, which was stored at 
-20°C until analysis. Brains from the same animals were removed immediately 
after exsanguination, blotted with paper to absorb excess surface blood and 
stored at -20°C. Plasma were precipitated with acetonitrile (1:2) and the 
supernatant was taken directly for LC/MS/MS quantification, using calibration 
curves in a matrix and a related compound as internal standard. Separation was 
on an XTerra MS C l8  column (10 cm x 2.1 mm I D., 3.5 pm particle size; pre­
column 1 cm X 2.1 mm) at 25°C. The mobile phase was A: H2O + 0.1% acetic 
acid, B: acetonitrile + 0.1 acetic acid, flow rate 0.3 ml/min, gradient 75% A to 
5% A in 5 minutes. The retention time was 3.2 minutes for ZK 187638, 3.1 
minutes for the I S. Mass spectrometric detection was by TIS Pos MS.
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CNS tissue was homogenized (20 ml/g) in KH2PO4  0.01 M, pH 7.4, and 
0.5 ml containing approximately 25 mg of tissue was extracted as described for 
plasma. Separation was on a Discovery C l8  Column (15 cm x 4.6 mm I D., 5 
pm particle size) (Supelco, Bellefonte, USA), protected by a Lichrospher RP- 
select B 5-pm pre-column (Merck, Darmstadt, Germany), at room temperature. 
The mobile phase was 0.01 M KH2PO4 : CH3OH: CH3CN (39:58:3 v/v) adjusted 
to pH 5.0 with H3PO4 , at a flow rate of 1 ml/min. The retention times were 
approximately 10.6 minutes for ZK 187638 and 14.6 minutes for the I S.
4.3.2 Chronic treatment of 3001®®^  ^mice with ZK 187638
Transgenic SODI^®^^ mice received ZK 187638 orally, suspended in 10% 
Tween 80 (10 ml/Kg), and every other day starting from 11 weeks of age. At this 
age mice showed neurological symptoms of the disease such as tremors and 
reduced extension reflex of hind limbs when raised by the tail and 
neuropathological features like massive vacuolisation of motor neurones, as 
described in section 2.1 (Bendotti and Carri, 2004). One group of SODI®^^^ 
animals (n=23) received repeated doses of the drug at 70 mg/Kg. Another 
group of SODI®®^^ mice (n=24) was treated with a first dose of 100 mg/Kg and 
then with 140 mg/Kg. A third group of transgenic mice (n=19) received only the 
vehicle by the same schedule. Nine animals for each group were selected 
before the beginning of the treatment for the survival study. The other mice 
were scarified at 19 weeks of age for the histological analysis. Data for the 
motor behavioural and neurological tests were collected form the whole groups
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of animals. Three groups of non transgenic mice (n= 10) were also treated with 
the two doses of ZK 187638 and vehicle.
4.3.3 Motor behavioral and neurological tests performed during chronic 
treatment with ZK 187638
Quantitative assessment of the motor behavioral deficit was carried out by 
measuring the stride length and rotarod performance. Evaluation of survival was 
also performed. Body weight was recorded during treatment.
Stride length test:
To measure stride length, mice were trained to walking a 75 cm long ramp 
raised to a height of 13 cm at one end. A bright light was placed at the base of 
the ramp to provide an aversive stimulus. The mice's hind feet were painted 
with children's poster paints and the tracks left as they ran up the ramp were 
recorded on paper tape lining the floor of the ramp. Stride length was defined as 
the distance between successive right-to-right and left-to-left footprints.
Rotarod test:
SODI®^^^ mice were trained to remain on the rod and habituated to the 
handling involved for at least a week before testing. On the day of testing, mice 
were transferred to the rotarod room at least 15 minutes before the test. 
Strategies to overcome deficits (gripping the rod and rotating with it, falling and 
jumping back, etc.) were noted but not considered for the test. Performance
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was evaluated as the time (sec.) spent on the rotating rod ( 1 2  rpm) without 
falling off (RotaRod treadmill for mice, Ugo Basile, Comerio, VA, Italy). The test 
was stopped after 3 minutes. Mice that fell off before the third minute were 
tested three times, with at least 5 minutes between tests.
Survival:
SODI^®^^ mice were killed if they were unable to roll over when they were 
laid down on their side. This time was used for calculating the survival curves.
Statistics:
For each experimental group the median, mean, standard deviation and 
standard error were calculated. Deviation from Gaussian distribution was tested 
by the Kolmogorov-Smirnov test. All the data passed the normality test. Body 
weight, stride length and rotarod performance of SODI®®^^ mice were analysed 
by AN OVA for repeated measures (weeks) and the different groups 
(treatments), followed by post-hoc Dunnett's test to compare the effect of drug 
and vehicle at the individual weeks. The survival of SODI®^^^ mice treated with 
the drug or vehicle was analysed by the log-rank test. All the statistical analyses 
were done using the GraphPad Prism 2.0a for Power Macintosh (GraphPad 
Software Inc.).
4.3.4 Immunohistochemical analysis of ChAT positive motor neurones 
in mice treated with ZK 187638
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Immuhistochemical analysis was performed as decribed in section 2.5. 
Fixed and frozen lumbar spinal cords of mice treated with vehicle
(n=5), 70 mg/kg (n=5) or 140 mg/kg (n=6 ) of ZK 187638 and respective non 
transgenic mice groups (n=5 each) were use. Section were incubated with 
primary antibody (anti ChAT, 1:250, Chemicon International) in TBS + 3% NGS 
for 2 hours at room temperature and then overnight at 4°C.
Biotinylated anti-mouse secondary antibody (1:200, Vectastain kit. Vector 
Laboratories) was used. Slides were examined by light microscopy and the 
number of ChAT immunopositive neurones was determined in the lumbar spinal 
cord every ten sections (segments L2-L4) according to a previously reported 
procedure (Mennini et al., 2002). Five serial sections for each animal were 
processed for ChAT immunostaining, the number of ChAT immunopositive 
motor neurones was calculated for each hemisection, and the means of these 
determinations were used as individual data for statistical analysis. Differences 
in the number of motor neurones from the lumbar spinal cord of SODI®®^^ mice 
were analysed by AN OVA followed by Tukey's test (GraphPad Prism 2.0a for 
Power Macintosh, GraphPad Software Inc.).
4.3.5 In situ hybridisation for mRNA of glutamate AMPA receptor 
subunit GluR2 in mice treated with ZK 187638
In situ hybridisation to detect the mRNA of AMPA receptor subunit GluR2 
in spinal cord and brain of SODI®®^^ mice at 19 weeks of age treated with
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vehicle (n=5), 70 mg/Kg (n=5) or 140 mg/Kg (n=6 ) of ZK 187638 were 
performed as described in section 2.4 and 3.3.1.
4.4 Results
4.4.1 Pharmacokinetic and metabolic studies
Before starting the treatment of SODI®^^^ mice, pharmacokinetic and 
metabolic studies were performed in order to evaluate the bioavailability of the 
drug. Data about the brain-plasma distribution of ZK187638 were obtained after 
acute administration of this compound in SODI^®^^ mice. Single oral 
administration of 70 and 140 mg/Kg of ZK187638 produced plasma 
concentrations at 3 hours of 3.9 ± 0.4 pg/ml and 8.7 ± 0.6 pg/ml (mean ± 
S.E.M., n=7) respectively. A higher dose (210 mg/Kg) did not produce 
increased plasma concentration (9.7 ± 0.7 pg/ml, n=7). Similar results were 
achieved in brain tissue where the compound reached concentrations 2.6-3.9 
times higher than those observed in plasma, showing that the drug effectively 
reaches the central nervous system.
To evaluate drug concentration in plasma and brain after chronic 
administration, SODI®®^^ and non transgenic mice were treated every other day 
starting from 11 weeks of age and until the death of transgenic animals. Plasma 
concentrations of ZK 187638 in SODI^^^^ mice and in non transgenic controls 
on the last day of the repeated oral dosing schedule were essentially dose 
related. Drug concentration of 2.6 ± 0.6 (n=8 ) and 4.3 ±1.8 pg/ml (n=8 ) were
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found in mice and drug concentration of 1.6 ± 0.9 (n=7) and 2.6 ± 2.9
pg/ml (n=8 ) were found in non transgenic littermates after 70 and 140 mg/Kg, 
respectively. Brain concentrations (6.7 ±1.6 and 13.1 ± 9.8 in SODI®®^^ mice 
and 3.9 ± 0.9 and 7.5 ± 3.2 pg/g in non transgenic mice, after 70 and 140 
mg/Kg respectively) were about three times higher than plasma concentrations 
and there was a linear relationship between plasma and brain concentrations in 
both transgenic and non transgenic mice. ZK187638 brain concentrations were 
also similarly correlated with spinal cord concentrations.
At least two putative metabolite peaks were observed in the plasma 
chromatograms of SODI®®^^ and controls. These peaks were never found in 
drug free samples, suggesting they represent metabolites of ZK187638.
4.4.2 Treatment of mice and evaluation of behavioural
benefits
In order to mimic the therapeutical conditions used in the treatment of ALS 
patients, which receive the drugs after the diagnosis of the disease based on 
symptom and sign observation, chronic treatment of SODI®^^^ mice was 
started at first symptom indication represented by tremors and reduced 
adduction of the hind limbs when raised by the tail. This phase of the disease is 
displayed at 11 weeks of age. ZK 187638 was administrated orally, suspended 
in 10% Tween 80 (10 ml/Kg) and every other day. One group of SODI®®^^ 
animals (n=23) received repeated doses of the drug at 70 mg/Kg. Another
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group of mice (n=24) was treated with a first dose of 100 mg/Kg and
then with 140 mg/Kg. A third group of transgenic mice (n=19) received only the 
vehicle by the same protocol.
The motor function deficit of the animals of all the groups was 
quantitatively evaluated measuring stride length and rotarod performance. Body 
weight was also recorded during all the treatments. ZK 187638 70 and 140 
mg/Kg had no effect on the body weight, rotarod performance and gait of non 
transgenic mice (data not shown).
Impairment of motor functions, revealed by stride length and rotarod tests, 
in vehicle treated SODI®®^^ transgenic mice started at about 15 weeks of age 
and became rapidly worse until the mice died in a range of age between 2 0  and 
24 weeks. Oral administration of 70 and 140 mg/Kg of ZK 187638 slowed the 
reduction of stride length compared to vehicle treated mice. At 17 and 18 weeks 
of age the mean stride of mice treated with these doses was significantly longer 
than the vehicle group (Figure 4.1). ZK 187638 also significantly ameliorated 
the rotarod performance of SGDI*^®^  ^ mice. The time spent on the rotarod by 
transgenic mice treated with 70 and 140 mg/Kg of ZK 187638 was significantly 
longer than in vehicle treated mice. The highest dose showed a significantly 
improved performance, which was better than untreated mice even at 18 weeks 
of age (Figure 4.2). The improvement in gait and rotarod performance in treated 
mice persisted after this time point. However, since many vehicle treated mice 
died at this time and the group sizes become heavily unbalanced, graphic 
representation and statistical analysis of these data are omitted.
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Treatment with 70 and 140 mg/Kg of ZK 187638 also reduced the body 
weight loss of SODI^®^^ (Figure 4.3). Moreover, administration of both the 
doses of the drug extended the mean survival of treated animals. The life 
expectancy resulted prolonged by 11 and 17 days for 70 and 140 mg/Kg dose 
respectively, when compared to vehicle treated mice. However, the effect was 
significant only for the group treated with 140 mg/Kg (Figure 4.4).
4.4.3 Analysis of motor neurone survival in mice treated with
ZK 187638
To investigate whether ZK 187638 influenced motor neurone death, a 
group of SODI®^^^ mice treated with vehicle (n=5), 70 mg/Kg (n=5) or 140 
mg/Kg (n=6 ) of ZK 187638 and respective non transgenic mice groups (n=5 
each) were killed and perfused with fixative at 19 weeks of age. Sections from 
the lumbar spinal cord were examined by immunohistochemical technique 
(Figure 4.5). Quantitative analysis of choline acetyl transferase (ChAT) 
immunopositive motor neurones showed a significant reduction in the number of 
cells in SODI^®^^ mice treated with vehicle (59 ± 7%), compared to non 
transgenic littermates. ZK 187638 140 mg/Kg, but not 70 mg/Kg, slightly but 
significantly reduced the magnitude of motor neurone loss (48 ± 8 %) (p < 0.05, 
AN OVA with post-hoc Tukey's test). High magnification of the ChAT 
immunostained motor neurones from SODI®®^^ mice treated with vehicle 
showed marked changes in their morphology (loss of neuritic processes.
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Figure 4.1: Effect of the treatment with ZK 187638 70 and 140 mg/Kg on the stride 
length of SODI^^^^ mice
Oral administration of 70 and 140 mg/Kg of ZK 187638 significantly slowed the 
reduction of stride length occurring in SODI^^^^ mice when compared to vehicle 
treated transgenic mice. The curves were interrupted at 18 weeks of age since after 
this time point some died because of the disease, reducing the size of the groups. 
Data from vehicle (red diamonds, n=19), ZK 187638 70 mg/Kg (blue squares, n=23) 
and ZK 187638 140 mg/Kg (green triangles, n=24) mice are presented as mean ± 
S.E.M. Data were analyzed by ANOVA for repeated measures followed by post-hoc 
Dunnett’s test between treatments. *= p < 0.05 compared to vehicle treated group.
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Figure 4.2: Effect of the treatment with ZK 187638 70 and 140 mg/Kg on the 
rotarod performance of SODI^^^^ mice
Treatment with ZK 187638 70 and 140 mg/Kg significantly ameliorated the 
rotarod performance of SODI^^^^ mice. The highest dose showed a significant 
improving of performance that was better than untreated mice even at 18 weeks of 
age. The curves were interrupted at 18 weeks of age since some animals died of the 
disease after this age, rendering the animal groups unbalanced. Data from vehicle 
(red diamonds, n=19), ZK 187638 70 mg/Kg (blue squares, n=23) and ZK 187638 140 
mg/Kg (green triangles, n=24) mice are presented as mean ± S.E.M. Data were 
analyzed by ANOVA for repeated measures followed by post-hoc Dunnett’s test 
between treatments. * = p <0.05 compared to vehicle group.
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Figure 4.3: Effect of the treatment with ZK 187638 70 and 140 mg/Kg on body 
weithg of SODI^^^^ mice
Treatment with ZK 187638 70 and 140 mg/Kg reduced the body weight loss 
occurring in SODI^^^^ transgenic mice. The curves were interrupted at 18 weeks of 
age since some died because of the disease after this age, rendering the animal 
groups unbalanced. Data from vehicle (red diamonds, n=19), ZK 187638 70 mg/Kg 
(blue squares, n=23) and ZK 187638 140 mg/Kg (green triangles, n=24) mice are 
presented as mean ± S.E.M. Data were analyzed by ANOVA for repeated measures 
followed by post-hoc Dunnett’s test between treatments.
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Figure 4.4: Effect of the treatment with ZK 187638 70 and 140 mg/Kg on survival 
of SODI'^^^* mice
Administration of both ZK 187638 70 and 140 mg/Kg ameliorated the life 
expectancy of SODI^^^^ mice, extending the mean survival of treated animals in 
respect to vehicle treated mice. The life expectancy resulted prolonged by 11 and 17 
days for 70 and 140 mg/Kg dose respectively. However, the effect was significant only 
for the group treated with 140 mg/Kg. Data on survival were analysed by the log rank 
test (ZK 187638 70 mg/Kg p=0.15; ZK 187638 140 mg/Kg p=0.04, n=9 for each 
group).
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Figure 4.5: Effect of the treatment with ZK 187638 70 and 140 mg/Kg on ChAT 
positive motor neurone degeneration occurring in SODI^^^^ mice
A-C: Transverse semisections of lumbar (L2-L4) spinal cord showing ChAT 
immunopositive motor neurones in the ventral horn. Prominent loss of motor neurones 
is observed in mice at 19 weeks of age treated with vehicle (B) versus age
matched non transgenic littermates (A). The effect is less marked in 19 week old 
SODI^^^^ mice treated with ZK 187638 140 mg/Kg (0). a-c: High-magnification of the 
ChAT immunopositive motor neurones in the lamina XI of the ventral horn of spinal 
cord. There is marked vacuolization of the cytoplasm and apparent swelling of the 
motor neurones in SODI^^^^ mice (arrowheads) receiving vehicle (b), while in those 
treated with ZK 187638 140 mg/Kg (c) the surviving motor neurones show a better 
morphology, with intense immunostaining in the perikarya and neurites similar to the 
non trangenic mice (a) . Scale bar = (A-C) 200 pm; (a-c) 50 pm
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shrinkage or vacuolisation of the cell bodies). This effect was less prominent in 
the age matched mice treated with ZK 187638 140 mg/Kg.
4.4.4 mRNA expression of GluR2 AMPA receptor subunit in 
mice after treatment with ZK 187638
Since we found a decreased expression of GluR2 protein in the motor 
neurones of SODI^®^^ mice, we wished to investigate whether the treatment 
with ZK 187638, which has shown improvement of symptoms and survival of 
SODI®®^^ mice, has also determined changes in GluR2 expression. 
Unfortunately, we could not perform immunohistochemical analysis to 
determine GluR2 protein levels in the motor neurones, as perfused tissues of 
treated transgenic mice were not available. Thus, I just carried out the analysis 
of GluR2 mRNA by in situ hybridisation.
In order to determine whether the treatment with ZK 187638 can 
selectively change the GluR2 mRNA transcription in nervous system regions 
involved in the pathology, the study was performed on brain areas not affected 
by the neurodegeneration (hippocampus and prefrontal cortex) and in the spinal 
cord of SODI^®^^ and non transgenic mice at 19 weeks of age, treated with ZK 
187638 (70 and 140 mg/Kg) or vehicle. Quantitative analysis of
autoradiographic opical density of GluR2 mRNA radiolabelling in prefrontal 
cortex and CA1/CA2 area of hippocampus of SODI®®^^ mice treated with ZK 
187638 (70 and 140 mg/Kg), revealed no significant changes in GluR2 mRNA 
expression when compared to untreated transgenic mice (Figure 4.6) or non
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transgenic mice groups. The same analysis carried out on spinal cord showed 
unchanged level of GluR2 mRNA in dorsal regions (laminae I, II, III and IV) 
(Figure 4.7). However, examination of autoradiographic opical density of ventral 
horn (laminae VII, VIII, and IX) revealed significant increased expression GluR2 
RNA messenger in mice treated with ZK 187638 140 mg/Kg,
compared to SODI^®^^ mice treated with ZK 187638 70 mg/Kg or untreated 
transgenic animals (Figure 4.8). ZK 187638 70 mg/Kg did not show the same 
effect
4.5 Discussion
Preferential vulnerability of motor neurones to AMPA mediated glutamatergic 
stimulus has been well documented by numerous studies in vitro. Alteration of 
molecular structure of AMPA receptors occurring in certain pathological 
conditions might, therefore, exacerbate this sensitivity and produce excitotoxic 
damage to motor neurones. Early decrease of GluR2 protein levels in the motor 
neurones of SODI^®^^ ALS mice, observed in this study (see chapter 3), could 
result in augmented number of calcium permeable AMPA receptors, which can 
cause motor neurone degeneration via glutamate-mediated damage to these 
cells. These current observations suggest that AMPA receptor activation is 
directly involved in ALS pathology. In this part of the project, we successfully 
tested the effect of two different doses of a new 2,3 benzodiazepine, ZK 
187638, which displays non competitive AMPA antagonist properties, on the 
disease progression of SODI®^^^ transgenic mice. The treatment determined
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Figure 4.6: GluR2 mRNA expression in brain areas of mice treated with
ZK 187638
Quantitative analysis of autoradiographic opical density revealed no significant 
variation in GluR2 mRNA expression in prefrontal cortex and CA1/CA2 region of 
hippocampus of mice treated with ZK 187638 70 and 140 mg/Kg in respect
to non transgenic mice (control) and SODI^^^^ mice treated with vehicle (two sections 
from each animal). The mice used for the experiments were killed at 19 weeks of age. 
Each column is the mean ± S.E.M. (n =4 to 6); data analysed by Two-Way ANOVA 
followed by Tukey’s test.
149
(/)cQ)
- ?(Ü ■—
o c
ft
3
o
0.35' 
0.30- 
0.25' 
0.20- 
0.15- 
0.1 O' 
0.05' 
0.00'
m
■mg
control
■
I
S0D1 G93A
Vehicle 
ZK 70 mg/Kg 
ZK 140 mg/Kg
Figure 4.7: GluR2 mRNA expression in the dorsal horn of mouse spinal
cord after treatment with ZK 187638
Quantitative analysis of autoradiographic opical density revealed no significant 
variation in GluR2 mRNA expression in the spinal cord dorsal horn (laminae I, II, III and 
IV) of treated with ZK 187638 70 and 140 mg/Kg in respect to non
transgenic mice (control) and SODI^^^^ mice treated with vehicle (two sections from 
each animal). The mice used for the experiments were killed at 19 weeks of age. Each 
column is the mean ± S.E.M. (n =4 to 6); data analysed by Two-Way ANOVA followed 
by Tukey's test.
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Figure 4.8: GluR2 mRNA expression in the ventral horn of mouse
spinal cord after treatment with ZK 187638
Quantitative analysis of autoradiographic opical density revealed a significant 
increase of GluR2 mRNA levels in the spinal cord ventral horn (laminae VII, VIII, and 
IX) of treated with ZK 187638 140 mg/Kg in respect to SODI^^^^ mice
treated with vehicle or ZK 187638 70 mg/Kg (two sections from each animal). The mice 
used for the experiments were killed at 19 weeks of age. Each column is the mean ± 
S.E.M. (n =4 to 6); data analysed by Two-Way ANOVA followed by Tukey's test. *= p < 
0.05
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the improvement of symptoms, revealed by stride length measurement and 
recording of performances on rotarod, and the significant prolongation of the life 
span of ALS mice. The effect of 140 mg/Kg of ZK 187638 on the survival of 
SODI^®^^ mice (11.3% prolongation from birth) was comparable to that gained 
with other AMPA receptor antagonists used in two previous studies. Canton and 
collaborators showed that a new synthetised compound with AMPA antagonist 
characteristics, RPR 119990, was active in improving grip muscle strength and 
extending life duration of SODI®®^^ mice (Canton et al., 2001). Similar effects 
on SODI®®^  ^ mice were also obtained in another study using a potent and 
selective AMPA antagonist, NBQX (Van Damme et al., 2003). Moreover, NBQX 
treatment relieved motor symptoms also in a different mouse model of motor 
neurone disease, the MND mice (Mennini etal., 1999).
Taken together, all these results provide functional demonstration of the 
role played by AMPA receptors in the development of the disesase in mouse 
model of ALS. All these AMPA antagonists ameliorate symptoms and prolong 
survival of ALS mice. In our study, the administration of the highest dose of ZK 
187638 was also associated with a modest but significant reduction in the loss 
of ChAT immunoreactive motor neurones in the lumbar spinal cord, suggesting 
that the slowing of disease progression correlates with a neuroprotective effect. 
However, in none case, these drugs could completely stop the progression of 
the pathology. Similar effects are also obtained, in mice and ALS patients, by 
riluzole, a drug that inhibits the release of glutamate and represents the only 
pharmacological treatment currently approved for ALS. This suggests that
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blocking the glutamatergic system and in particular AMPA receptor activation is 
not sufficient to arrest the death processes that lead to motor neurone 
degeneration. ALS is considered a multifactorial disease, which involves the 
harmful activation of several cellular death pathways triggered by unknown 
initial events. Thus, it is possible that structural alterations of AMPA receptors 
and their consequent abnormal activation can represent either the early 
triggering factor of the pathology or one of the elements that successively 
contributes, among the others, to the final event represented by motor neurone 
death. Therefore, the ineffectiveness of AMPA antagonists in completely 
reverting the disease progression may be due a) to the tardy beginning of the 
treatment, which starts when AMPA receptors overactivation has already 
compromised motor neurone health and/or b) to the activation of others death 
processes, which act independently and that cannot be stopped by AMPA 
antagonists. Despite the efficacy of the treatment with AMPA antagonists could 
be higher if administered very early, to date, in human therapy, the 
administration of drugs can only start when the manifestation of symptoms allow 
clear diagnosis. This is the consequence of the lacking of early diagnostic 
markers, which would permit to begin the treatment when motor neurones are 
not yet compromised. Thus, it is important to find compounds that can show 
good effects even if administered after the beginning of symptoms. Interestingly, 
unlike the treatment with other AMPA antagonists reported in previous works 
(Canton et al., 2001 ; Van Damme et al., 2003), the administration of ZK 187638 
slowed the disease progression starting when SODI^®^^ mice already showed 
evident motor dysfunction such as tremors and reduced adduction of the hind
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limbs when raised by the tail, a condition more closely related to therapeutic 
intervention in symptomatic ALS patients. In spite of the lack of resolutive 
effects of this compound, improvement of symptomatology and survival 
represent a good result with a view to develop new therapeutic agents for the 
symptomatic treatment of patients with ALS. In regard to this aspect, ZK 187638 
has shown encouraging properties compared to the drugs used in other 
successful studies.
Despite RPR 119990 (Canton et al., 2001) and NBQX (Mennini et al., 
1999; Van Damme et al., 2003) were administered via subcutaneous and 
itraperitoneal injections, the bioavailability in nervous system of these 
compounds was very low. We showed that, unlike these drugs, ZK 187638 
offers a good in vivo availability in the brain after oral administration and a rapid 
distribution across the blood brain barrier. Oral administration and good 
bioavailability in nervous system would represent an advantage considering a 
future use in clinical therapy of chronic neurodegenerative diseases. Moreover, 
three month treatment with ZK 187638 was well tolerated by control mice.
Unlike the other AMPA antagonists tested in ALS mouse models, ZK 
187638 belongs to a compound class that acts as non competitive AMPA 
allosteric modulators on a region different from the glutamate binding site. 
These properties make ZK 187638 effective even in the presence of high levels 
of glutamate and minimize the side effects due to interaction with the numerous 
glutamatergic pathways of central nervous system. For the same reason, this 
kind of drug could replace molecules such riluzole, which acts aspecifically 
inhibiting glutamate release with general consequences. Therefore, all these
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characteristics render ZK 187638 extremely promising in consideration of future 
development of new therapeutic agents for the cure of ALS.
In this section of the study, we also wished to test whether blocking AMPA 
receptor activity could modify the expression of AMPA subunit GluR2, which 
was found decreased in motor neurones of presymptomatic mice
(see chapter 3). Unfortunately, we could not investigate the expression and 
localization of the protein because of technical reasons, as we did not have any 
more perfused tissue samples to analyse. Thus, we performed in situ 
hybridisation to test whether treatment with AMPA antagonist drug can 
influence the GluR2 mRNA transcription. We did not find changes in mRNA 
levels in brain areas not involved in the pathology, such as prefrontal cortex and 
hippocampus, and in dorsal horn of spinal cord. However, 140 mg/ml of ZK 
187638 caused significant increase of GluR2 mRNA in the ventral spinal cord of 
SODI®®^^ mice. The mechanisms involved in this upregulation have not been 
clarified and need further investigation. It can be speculated that, besides the 
property as AMPA receptor allosteric modulator, high doses of ZK 187638 may 
also displays effects on transcription of AMPA receptor subunits and in 
particular of GluR2. Upregulation of this subunit could reinforce the AMPA 
antagonist action and contribute to neuroprotection by reducing the number of 
calcium-permeable glutamate receptors. This hypothesis is supported by the 
fact that the treatment with the highest dose of ZK 187638 (140 mg/ml) also 
caused significant extension of survival and reduced motor neurone loss. 
However, the regulatory effect of ZK 187638 on GluR2 protein level and effects 
in motor neurones require further work.
155
CHAPTER 5
Study of the involvement of zinc transporter
ZnT-1 in ALS
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5.1 Introduction
5.1.1 Zinc ions and ALS
An increasing body of evidence indicates that the neuronal toxicity 
mediated by Ca^^-permeable AMPA receptors can be also ascribed to zinc 
influx through the ion channel. The divalent cation Zn^ "" is abundant in 
mammalian brain. It is not uniformly distributed, with the highest concentration 
in the grey and white matter of certain forebrain regions such as cortex, 
hippocampus and amygdala (Frederickson, 1989). Apart from its function as 
cofactor for many enzymes and transcription factors, zinc seems to play an 
important role in excitatory neurotransmission. It is localized in synaptic vesicles 
at glutamatergic nerve terminals and it is released at high concentration during 
excitatory synaptic activity (Assaf and Chung, 1984). The physiological 
relevance of this phenomenon is not yet clearly understood. 
Electrophysiological studies performed on cultured neurones have shown that 
zinc can decrease NMDA receptor activation and enhance AMPA receptor 
responses (Smart et al., 1994), modulating glutamatergic activity. Abnormal zinc 
release form glutamatergic presynaptic terminals may be toxic to postsynaptic 
neurones in several neurological disorders such as ischemia, seizures and 
trauma (Frederickson et al., 1989; Koh et al., 1996; Suh et al., 2000). 
Accumulation of Zn^^ in neurones that are selectively damaged in these 
conditions strongly supports this hypothesis (Tsuda et al., 1997). Zinc can enter 
in the neurones through both NMDA and Ca^^-permeable AMPA receptors and
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through extrasynaptic voltage sensitive calcium channels (Figure 5.1). However, 
it has been shown that AMPA receptors have a much higher permeability to 
zinc than NMDA receptors in cultured neurones (Sensi et al., 1999b), 
suggesting the preferential involvement of these receptors in Zn^^-mediated 
toxicity. The probable mechanism underling the harmful effect of zinc influx has 
been recently proposed. Sensi and colleagues reported that zinc entry through 
the calcium-permeable AMPA receptors produces reactive oxygen species 
(ROS) generation in cultured cortical neurones (Sensi et al., 1999b; Sensi et al., 
1999a). This phenomenon is directly related to mitochondrial zinc overloading 
and mitochondrial membrane depolarization (Sensi et al., 2000). Zinc effects on 
mitochondria require much lower intracellular concentrations than calcium and 
seem to last longer and to be less reversible. Thus, it is possible that zinc influx 
can mediate AMPA receptor dependent glutamate-mediated injury to motor 
neurones in ALS pathology, where mitochondrial dysfunction has been well 
documented. In fact, it has been shown that motor neurone somata and 
dendrites in mice are in contact with nerve terminals containing large vesicles 
rich in zinc ions (Jo et al., 2000) and that some of these terminals are 
glutamatergic terminals (Wang et al., 2001). Zn^  ^ might also induce neuronal 
injury through extra-mitochondrial pathways such as activation of PKC, which 
can result in ROS generation.
Indirect evidence supporting zinc involvement in the motor neurone death 
occurring in ALS comes from several studies performed on transgenic mice 
expressing mutant S0D1. The expression of metallothioneins, a low molecular 
weight protein family involved in maintaining intracellular concentration of
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metals such as zinc below toxic levels, is increased in spinal motor neurones 
and astrocytes of transgenic mice (Gong and Elliott, 2000; Nagano et
al., 2001). The same ALS mice, crossed with metallothionein knock out mice, 
displayed symptoms and died significantly earlier (Nagano et al., 2001). Another 
zinc binding protein, S100A6, has been found to be overexpressed in the same 
mice (Hoyaux et al., 2000). Moreover, it has been recently reported that chronic 
administration of zinc sulphate decreases survival of ALS mice (Groeneveld et 
al., 2003). However, whether zinc may play a toxic role in motor neurone death 
in ALS is not yet clearly understood.
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Figure 5.1: Role of Zn^ * in neurodegeneration
Adapted from Weiss J.H. etal, TIPS, 2000
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5.1.2 Possible involvement of zinc transporter ZnT-1 in motor neurone 
degeneration in ALS
Hydrophilic zinc ions cannot cross biological membranes by passive 
diffusion. Beside zinc entry via receptors and channels as described above, 
there are several specific transporters that mediate zinc uptake and release 
(Figure 5.1). ZnT-1 renders cells resistant to high level of intracellular zinc 
(Palmiter and Findley, 1995). ZnT-2, ZnT-3 and ZnT-4 are thought to sequester 
zinc in intracellular compartments. In particular, ZnT-3 has been shown to be 
involved in zinc accumulation into synaptic vesicles in glutamatergic terminals 
(Palmiter et al., 1996; Huang and Gitschier, 1997; Wenzel et al., 1997).
Among these transporters, ZnT-1 seems to be most implicated in neuronal 
protection. Localized on cellular membranes, ZnT-1 is a protein of about 500 
amino acids with six transmembrane regions. It has consensus site for N- 
glycosylation and phosphorylation by protein kinase C and tyrosine kinases 
(McMahon and Cousins, 1998a). Zinc transport process is sodium independent, 
does not require ATP and it has low affinity for other metals such as cadmium 
and copper (McMahon and Cousins, 1998a). In vitro and in vivo studies have 
shown that metal response element binding transcription factor (MTF-1) 
mediates the response to zinc of the ZnT-1 gene (Langmade et al., 2000). ZnT- 
1 is thought to be a zinc exporter. Thus, cells with low expression of this 
transporter are extremely sensitive to zinc influx (Palmiter and Findley, 1995).
The distribution of ZnT-1 in mouse brain has recently been elucidated, with 
the highest expression in cerebral cortex, cerebellum, hippocampus.
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hypothalamus and olfactory bulb (Sekler et al., 2002). The fact that ZnT-1 is 
almost undetectable in mouse brain at birth and that its expression and synaptic 
zinc increase significantly after the first postnatal week, suggests that ZnT-1 
may be important in protecting developing neurones against potential toxic zinc 
(Nitzan et al., 2002). However, to date, no data about the distribution and the 
possible protective function of ZnT-1 in the spinal cord and in particular in motor 
neurones have been reported. Thus, it is not known whether lack of zinc efflux 
mediated by this transporter may be involved in motor neurone death following 
potential harmful glutamatergic stimulus mediated by calcium and zinc 
permeable AMPA receptors.
5.2 Hypothesis and aim
Changes in the subunit composition and/or activity of AMPA glutamate 
receptors may alter their permeability to divalent ions and cause an 
accumulation of free zinc in the motor neurones of SODI®®^^ mice. The 
selectivity of death processes occurring in motor neurones may possibly relate 
to a lower capability of these cells to extrude excess zinc and this might be 
reflected by low levels of zinc transporter expression. Thus, the aim of this 
thesis section is to investigate whether mouse motor neurones express zinc 
transporter ZnT-1 and whether its expression level is lower in transgenic
g O D i° M A  m ic e .
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5.3 Methods
5.3.1 In situ hybridisation for zinc transporter ZnT-1 mRNA in SODI^^s* 
mice
In situ hybridization was carried out as described in section 2.4. Frozen 
lumbar spinal cords and brains of and non transgenic mice used as
control at 8, 14 and 19 weeks of age (3 to 4 mice each group), were analyzed. 
At the day of the experiment the slides were brought to room temperature and 
hybridized with ^^S-labelled RNA probes complementary to mRNA of ZnT-1 zinc 
transporter. Total RNA was extracted from mouse hippocampus using RNABee 
reagent (Biogenesis, Poole, UK) and reverse transcribed using M-MLV reverse 
transcriptase in the presence of 12.5 pg/ml oligo-dT, 1 mM dNTP, 5 mM MgCb 
and RNasin in IX  RT buffer (all from Promega). PCR was performed using 
oligonucleotide primers that were designed based on the sequences reported 
by Langmade and collaborators (Langmade et al., 2000), to amplify a specific 
region of ZnT-1 cDNA of 496 bp. The primers used had the following sequence 
(5'-3'): TGA CAA TCT GGA AGC GGA AGA CAAC (forward) and GGA AGC 
GGG GTC CTC ACA TTT TATG (reverse). PCR was carried out in the 
presence of 1.5 mM MgCb, 50 pM dNTP, 0.1 pM sense and antisense primers, 
1.25 U Taq DNA polymerase and 2.5 pi of RT product (cDNA), in IX  PCR buffer 
(all from Promega).
Then it was cloned into PCR2.1 plasmid (Invitrogen, Carlsbad, CA, USA). 
Riboprobe template was prepared by amplification of the plasmid (2 ng) in a
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volume of 500 pi with the following primers (5’-3’): ACC GAG CAA TTA A CC 
CTC ACT AAA GGG CCG CCA GTG TGC TGG AAT TCG (forward) and CGT 
TGT AAA ACG ACG GCC (reverse), that flanked the insert, and incorporated a 
T3 and T7 site into the template.
Antisense and sense riboprobes were synthesized by in vitro transcription 
from 1 pg of linear DNA templates using, respectively, T3 or T7 RNA 
polymerase enzymes (Promega) in a reaction mixture containing 1X 
transcription buffer, DTT 10 pM, RNase inhibitor 30 U (Roche), non labelled 
NTP 0,5 mM and UTP 10 pM (Promega) and ^^S-UTP 50 mCi (Amersham 
Bioscences). Probes were degraded to 150 base fragments by alkaline 
hydrolysis. The specificity of the in situ hybridisation was verified by the 
absence of the signal using sense radiolabelled probes and by the previous 
treatment of the sections with RNase.
5.3.2 Immunohistochemical analysis of zinc transporter ZnT-1 in 
S o d i ° “ a  m i c e
Immunohistochemical analysis was performed as described in section 2.5. 
Frozen spinal cords of three non transgenic mice and four SODI®^^^ mice for 
each age considered were used. Sections were incubated with primary antibody 
obtained from New Zealand White Rabbits immunized with ZnT-1 peptide, 
kindly provided by Dr Cousins, Food Science and Human Nutrition Department 
and Center for Nutritional Sciences, University of Florida, USA and Dr Perozzi, 
University of Rome, Italy (McMahon and Cousins, 1998b). Total IgG fraction
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prepared by affinity chromatography from the whole serum was used for the 
experiments. Incubation with primary antibody (1.6 pg/ml) was performed in 
0.1% Triton X-100 and 1% normal goat serum overnight at 4 °C under constant 
shaking. After three washes, spinal cord sections were incubated in biotinylated 
anti-rabbit antibody (1:200, Vector Laboratories) in PBS containing 1 % normal 
goat serum and 0.1% Triton X-100 for 60 minutes at room temperature. The 
secondary biotinylated antibody was revealed by TSA Kit amplification 
(Renaissance direct-NEL 705A, Dupont NEN, Bosto, MA, USA). Sections were 
incubated in TNB buffer (0.1M Tris/HCI, pH7.5, 0.15 M NaCI, 0.5% blocking 
reagent) for 90 minutes followed by incubation in streptavidin-HRP in TNB 
(1:50) for 30 minutes. After 3 washes with TNT buffer (0.1 M Tris/HCI, pH7.5, 
0.15 M NaCI, 0.05% Tween 20) the streptavidin-HRP was revealed with 
Tyramide conjugated to Cy5 (red, 1:50 dilution) in amplification diluent for 10 
minutes, then washed with TNT. Processed sections were mounted on slides 
and coverslipped with Fluorsave (Calbiochem, Notthingam, UK) and analysed 
by fluorescence microscope.
5.3.3 Western blot analysis of zinc transporter ZnT-1 in SODI^^^^ mice
Western blot analysis was carried out as described in section 2.6. Frozen 
brain of C57BL/6 mouse was used. Eighty pg protein/lane were run on precast 
polyacrylamide-SDS gradient gel (4%-15%) (Bio-Rad laboratorie, Hercules, CA, 
USA), and transferred to nitrocellulose membrane (Scheicher and Schuell). 
Antibody rose against ZnT-1 (see section 5.3.2), diluted (5 pg/ml) in TBST with
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5% bovine serum albumin was used as primary antibody. The blots were then 
washed three times in TBST and incubated with secondary antibodies: anti­
rabbit IgG conjugated to horseradish peroxidase (1:2000, Sigma) in TBST with 
5% skimmed milk, for 1 hour at room temperature. Blots were developed by the 
ECL technique using ECL plus Western Blotting Detection System (Amersham 
Biosciences) according to the manufacturer's instructions.
5.4 Results
5.4.1 Expression of ZnT-1 mRNA in the spinal cord of SOD1°®^^ mice
In order to verify whether spinal cord motor neurones, selectively affected 
by ALS-like pathology occurring in SGDI^®^^ mice, express zinc transporter 
ZnT-1, we performed in situ hybridisation to detect the presence of its 
messenger RNA. The experiment was carried out on tissue sections of spinal 
cord of non transgenic and SODI®®^^ transgenic mice at presymtomatic, 
symptomatic and final stage of the disease. Probes for sense sequence and 
tissue samples previously treated with Rnase were used to verify the specificity 
of labelling.
5.4.1.1 Distribution of Zn T-1 mRNA in mouse brain
Brain tissue was used as positive control since ZnT-1 protein distribution in 
mouse brain has been already published (Sekler et al., 2002). However, there
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are not data regarding mRNA expression in mouse central nervous system. 
Probe recognising ZnT-1 was obtained by RT-PCR using oligonucleotide 
primers which were designed based on published sequence of mouse ZnT-1 
(Langmade et al., 2000). Product of 496 bp was cloned in PCR 2.1 vector and 
use to generate a riboprobe template.
Confirming the results already reported by Sekler and collaborators about 
the ZnT-1 protein localization in mouse brain, autoradiographic films revealed 
high expression of ZnT-1 mRNA in frontal cerebral cortex, cerebellum and 
hippocampus (Figure 5.2 A). Previous treatment of the sections with RNase and 
the use of probes direct against sense sequence totally abolished the 
radiolabelling, demonstrating the specificity of the antisense probe for ZnT-1 
(Figure 5.2 B).
5.4.1.2 ZnT-1 mRNA expression in spinal motor neurones of SOD 1 mice
Analysis of silver grain distribution, obtained by dipping the radiolabelled 
slices in photographic emulsion, showed a very low expression of ZnT-1 mRNA 
in the whole spinal cord of control mice. In particular, large motor neurones 
exhibited a very faint signal as demonstrated by the comparison with labelling 
present in hippocampal neurones (Figure 5.3 A). The expression of ZnT-1 
mRNA did not considerably vary in the spinal motor neurones of in SODI^®^^ at 
all stages of the disease (Figure 5.3 B).
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Figure 5.2: ZnT~1 mRNA distribution in mouse brain
(A) In situ hybridisation experiments reveals high expression of ZnT-1 mRNA in 
frontal cerebral cortex, cerebellum and hippocampus, reflecting the protein distribution 
previously reported (Sekler et al., 2002). (B) Treatment of the sample with Rnase (b) 
and the use of probes direct against sense sequence (c) totally abolishes the 
radiolabelling, demonstrating the specificity of the antisense probe (a) for ZnT-1.
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5.4.2 Analysis of ZnT-1 protein distribution in the spinal cord of 
S0D1°®“  mice
In order to evaluate the expression of ZnT-1 protein in the spinal cord of 
SODI®®^^ mice, I performed immunofluorescence experiments using whole 
antiserum of New Zealand White Rabbits immunized with ZnT-1 peptide, kindly 
provided by Dr Cousins, University of Florida, USA and Dr Perozzi, University of 
Rome, Italy (McMahon and Cousins, 1998b). Total IgG fraction was obtained by 
affinity chromatography from the whole serum and this was used for the 
experiments. The immunolabelling of spinal cord sections of control mice 
showed a widespread signal in the whole grey matter of the spinal cord (Figure
5.4 A).
The staining was diffusely present in the ventral horn without specific 
labelling motor neurones. Dorsal horn was also intensely labeled. Despite 
several changes of different parameters in the protocol, the widespread nature 
of the signal remained unaltered and raised doubts about the specificity to ZnT- 
1 of the total IgG fraction used. In collaboration with the Protein Chemistry and 
Biochemistry Laboratory at Mario Negri Institute, we synthesized the peptide 
utilized to immunize the rabbits (McMahon and Cousins, 1998b) and we used it 
to preadsorb the IgG fraction before the incubation. This treatment did not lead 
to decrease of the labelling obtained by immunofluorescence in the spinal cord, 
suggesting the aspecificity of signal (Figure 5.4 B). Further confirmation was 
obtained by Western blot analysis of protein extract of mouse brain. 
Immunoblotting carried out with the same IgG fraction revealed bands at
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Figure 5.3: ZnT-1 mRNA levels In the motor neurones of mice
(A) Analysis of silver grain distribution reveals a very low expression of ZnT-1 
mRNA in the whole spinal cord of control mice and in particular in large motor neurons 
(arrows), as demonstrated by the comparison with labelling present in hyppocampal 
neurones. (B) The levels of ZnT-1 mRNA are not considerably changed in the spinal 
motor neurones of in SODI^^^  ^at all stages of the disease considered. Scale bar: 25 
pm.
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Figure 5.4: ZnT-1 immunoreactivity in the spinal cord ofSODI^^^^ mice
(A) Immunolabelling for ZnT-1 shows a widespread signal in the whole grey 
matter of the spinal cord. Both ventral and dorsal horns are diffusely stained, without 
specific labelling observed in the motor neurones. However, the nature of the signal 
raised doubts about the specificity to ZnT-1 of the total IgG fraction used. (B) 
Preadsorbation of the IgG fraction with the peptide utilized to immunize the rabbits 
(McMahon and Cousins, 1998b) does not abolish the signal suggesting the aspecificity 
of staining observed. Scale bar: 200 pm.
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— 60 KD
—  35KD
—  25 KD
Figure 5.5: Western blot analysis of ZnT-1 In mouse brain
Immunoblotting for ZnT-1 of C57BU6 mouse brain homogenate reveals a band at 
about 25 KD, a molecular weight much lower than the one (60KD) previously reported 
by Sekler et al (Sekler et al., 2002). No bands are observed at this molecular weight. 
This confirms the low specificity of the total IgG fraction used for these experiments.
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molecular weight (25 KD) different from those expected (60 KD) (Sekler et al., 
2002) (Figure 5.5).
Thus, distribution and eventual changes in the expression of ZnT-1 protein 
in the spinal motor neurones of control and SODI®^^^ mice could not been 
elucidated in this study.
5.5 Discussion
This part of the project was designed to investigate the possible role of 
zinc ions in the neuropathology of ALS. It has been demonstrated that zinc can 
enter into the neurones through Ca^^-permeable AMPA receptors and that high 
concentration of cytoplasmic zinc can severely affect mitochondria with 
consequent ROS production and neuronal injury (Sensi et al., 1999b; Sensi et 
al., 1999a, 2000; Sensi and Jeng, 2004). Motor neurone cell bodies and 
dendrites receive numerous glutamatergic nerve terminals containing large 
vesicles rich in zinc ions (Jo et al., 2000; Wang et al., 2001). Therefore, 
dysfunction of AMPA receptors due to altered subunit composition and/or their 
overactivation because of increased glutamate firing on motor neurones might 
result in abnormal zinc influx into these cells, which in turn could determine 
mitochondrial damage and motor neurone death. There is no direct 
demonstration that zinc contributes to motor neurone pathology, however there 
is indirect evidence: expression of metallothioneins and S100A6, two families of 
binding protein involved in cytoplasmatic zinc buffering, have been found to be 
overexpressed in spinal motor neurones of transgenic SODI^®^^ mice (Gong
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and Elliott, 2000; Hoyaux et al., 2000; Nagano et al., 2001). This could indicate 
that zinc homeostasis in motor neurones of ALS mice is altered enough to 
induce overproduction of zinc binding proteins.
For the part of the study presented here, the expression of ZnT-1 was 
considered to be a possible marker of zinc-mediated injury to the neurones. 
This transporter acts as zinc exporter, contributing to keep intracellular 
concentration of zinc below toxic levels. Tsuda and collaborators reported 
increased level of ZnT-1 mRNA in CA1 pyramidal neurones of gerbil 
hippocampus after transient ischemia. These neurones accumulated zinc after 
the ischemic event and died 7 days later (Tsuda et al., 1997). In the same 
study, the authors also showed that cultured hippocampal neurones exposed to 
zinc, overexpressed ZnT-1 mRNA. This work was the first evidence concerning 
the possible role played by ZnT-1 in defending neurones from zinc 
accumulation following a glutamatergic insult. In fact, the increased expression 
of ZnT-1 may represent the cellular attempt to defend itself against high toxic 
level of intracellular zinc by extruding Zn^^ through this transporter. Supporting 
this hypothesis, it has been demonstrated that PCI2 cell death induced by 
exposure to ZnCb was attenuated by overexpression of rat ZnT-1, associated 
with increased zinc efflux (Kim et al., 2000). Thus, overexpression of ZnT-1 in 
motor neurones of ALS models could represent the demonstration of zinc toxic 
accumulation in the cytoplasm and, indirectly, of overactivation of calcium- 
permeable AMPA receptors.
To date, ZnT-1 expression in the central nervous system has been very 
little investigated and the extent to which spinal motor neurones express ZnT-1
174
is not known. Seeker, Nitzan and collaborators showed ZnT-1 protein 
expression in brain areas examined by Western blotting and 
immunohistochemistry techniques (Nitzan et al., 2002; Sekler et al., 2002) but 
do not report whether or not motor neurones express high levels of this protein. 
In this study, immunohistochemistry was used using a total IgG fraction against 
ZnT-1 obtained from whole antiserum raised by Dr Cousins (McMahon and 
Cousins, 1998b). However, careful analysis suggested that the distribution 
pattern observed with this antibody in the spinal cord of mice was not specific. 
In fact, preadsorption of antibody with peptide used to produce it could not 
abolish the immunolabelling. Moreover, immunoblotting analysis showed bands 
at unexpected molecular weight. Therefore, further work is required to 
determine the expression of ZnT 1 protein in motor neurones and whether or not 
the levels of protein are altered during motor neurone disease pathology.
In order to determine the extent of ZnT-1 expression in spinal cord, in situ 
hybridisation experiments were carried out, which revealed very low expression 
of ZnT-1 mRNA in the spinal cord and in particular in the motor neurones of 
control mice. The near absence of ZnT-1 mRNA in mouse motor neurones 
suggests that motor neurones may be very sensitive to potential toxic influx of 
zinc, in respect to other neurones, since they may not be able to export it. Thus, 
the almost absent ZnT-1 mRNA expression could represent a selective risk 
factor for these cell population, rendering them more prone to be injured by 
glutamate-zinc injury mediated by AM PA receptor dysfunction.
On the other hand, on the basis of work carried out in hippocampus by 
Tsuda and coworkers (Tsuda et al., 1997), we may have expected an increase
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of ZnT-1 mRNA in motor neurones of symptomatic SODI®®^^ mice compared to 
controls, due to zinc influx-mediated enhancing of ZnT-1 transcription. This was 
not seen. The lack of change in ZnT-1 mRNA levels in motor neurones of 
transgenic mice may be seen as confirmation of the inability of these cells to 
conteract the excessive zinc entry. Furthermore, it is also plausible that, in 
chronic disease such as ALS, increased intracellular concentration of zinc in 
motor neurones, derived from abnormal functioning of AMPA receptors and low 
basal expression of zinc extruders, does not reach threshold values sufficient to 
induce ZnT-1 transcription, even though they result in toxicity for the cells. 
Therefore, a role of zinc ion in ALS pathology could not be excluded. Direct 
evidence is required to determine whether or not zinc is involved in motor 
neurone death. In our laboratory, work is in progress to investigate free zinc 
concentration in the motor neurones of SODI^®^^ mice using fluorescent probes 
specific to zinc ions.
In conclusion, ZnT-1 does not seem to play an active role in ALS-like 
pathology occurring in SODI^®^^ mice but its low expression might exacerbate 
vulnerability of motor neurones to altered glutamate stimulation mediated by 
AMPA receptors.
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CHAPTER 6
Study of the expression and function of 
giutamate transporters in the spinai cord of 
transgenic mice and in cultured 
astrocytes expressing the same mutant
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6.1 Introduction
6.1.1 Glutamate transport
An aberrant stimulation of glutamate AMPA receptors and consequent 
activation of death processes in motor neurones may be triggered by altered 
functionality of these receptors but also by increased glutamate concentration in 
the synaptic cleft. Motor neurones receive many glutamatergic inputs from 
descending fibres and from local interneurones and therefore require efficient 
removal of glutamate from synapses. Thus, disruption of synaptic glutamate 
“cleaning” machinery may result in abnormal firing on motor neurones and 
excitotoxic events.
The clearance of glutamate from extracellular environment is managed by 
transporter-mediated uptake. Glutamate transporters are expressed by many 
cell types in central nervous system, including oligodendrocytes, microglia, 
astrocytes and neurones (Rothstein et al., 1994). It can be sodium-independent 
and chloride-dependent but this uptake system represents only a small portion 
(5%) of the total glutamate removal. Five types of high-affinity Na^-dependent 
glutamate transporters, designated EAAT1 (known as G LAST in rodents), 
EAAT2 (named GLT1 in rodents), EAAT3 (EAAC1 in rodents), EAAT4 and 
EAAT5, have been cloned since 1992 (Kanai and Hediger, 1992; Pines et al., 
1992; Storck et al., 1992; Arriza et al., 1997). GLT-1 and G LAST are 
predominantly localized on astrocytes. GLT-1 is the most abundant glutamate 
transporter in the forebrain, with G LAST particularly expressed in the
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cerebellum. EAAC1 and EAAT4 are considered neuronal transporters, 
predominantly present on cell bodies and dendrites, with EAAT4 exclusively 
expressed in cerebellar Purkinje cells. However, no one of these two 
transporters has been so far detected within the synaptic cleft. EAAT5 has been 
found to be only expressed in retinal cells.
The majority of glutamate uptake is into astrocytes and is mediated by 
GLT-1 and G LAST, which are therefore considered the most important in 
removing glutamate from the synaptic cleft during normal neurotransmission 
(Rothstein et al., 1996; Danbolt, 2001). GLT-1 and G LAST have 65% of 
similarity in their amino acid sequences. The secondary structure has not been 
entirely clarified yet. The existence of either ten or eight transmembrane 
domains has been proposed. However, it is well established that a pore-loop 
structure is responsible for glutamate translocation. Two N-glycosylation sites 
have been discovered on extracellular domains. Uptake of glutamate occurs 
against concentration gradient (approximately 2 |iM of extracellular glutamate 
against 10 mM in the cytosol), coupling inward cotransport of 3 Na^ and 1 H  ^
and outward counter-transport of 1 K .^ GLT-1 and G LAST seem to have similar 
affinity for glutamate even though the data about their respective Km are 
controversial (Danbolt, 2001), probably because of studies performed on 
different in vitro systems. Energy is required via the action of Na^-K^ ATPase to 
maintain the Na^ gradient required for glutamate uptake and it has been 
estimated that more than one ATP molecule is utilized by transporters for each 
glutamate molecule transported, determining a very high consumption of energy 
(Anderson and Swanson, 2000). Glutamate uptake may be regulated by both
179
transporter expression on the cell surface and alteration of their activity. GLT-1 
and G LAST have consensus sites for intracellular phosphorylation carried out 
by protein kinase C (PKC) and cAMP-dependent protein kinase (PKA). Soluble 
factors released by neurones play a pivotal role in inducing GLT-1 expression in 
cultured astrocytes, whereas astrocyte-neurone contact seems to be 
determinant in glial G LAST expression (Gegelashvili et al., 1997). The activity of 
transporters may be regulated by post-translational modification such as 
phosphorylation, interaction with zinc and arachidonic acid, membrane 
translocation, sulfhydryl-based redox regulation and multimerization 
(Gegelashvili and Schousboe, 1997; Anderson and Swanson, 2000; Danbolt, 
2001).
6.1.2 Glutamate transporters and ALS
An alteration of the glutamate uptake capability in astrocytes has been 
suggested to be the possible cause of excitotoxic motor neurone death in ALS. 
Any decrease of glutamate uptake by astrocytes can lead to an increase of 
synaptic glutamate concentration, to overstimulation of glutamate receptors and 
consequently to excitotoxic insults to motor neurones. In ALS patients it has 
been shown that there is a marked decrease in the glutamate uptake in 
synaptosomes from spinal cord and motor cortex (Rothstein et al., 1992) and a 
massive loss of EAAT2 immunoreactivity in the same areas of the nervous 
system affected pathologically (Rothstein et al., 1995). Western blot analysis of 
the spinal cord total proteins of PALS mice carrying SGDI^®^^ mutant has also
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shown a decline of GLT-1 expression (Bruijn et al., 1997b). Since GLT-1 
decrease is only evident at the final stage of the disease, it is possible that the 
downregulation of GLT-1 transporter protein is not a primary cause of ALS but a 
consequence of motor neurone death. However, a decrease of GLT-1 protein 
expression before disease onset, when motor neurones are still present, has 
been found in a transgenic rat model of ALS carrying the SODI^®^^ mutation 
(Howland et al., 2002). Moreover, alterations in the functioning of GLT-1 may 
also occur even without a clear decrease of the protein levels. A decrease of 
glutamate uptake activity has been found in synaptosomes from spinal cord of 
transgenic mice expressing the SODI®^^^ mutation only at the end stage of the 
disease (Canton et al., 1998) but since experiments carried out on 
synaptosomes may reflect neuronal uptake, the role of glial transporters needs 
more investigation.
The effect of S0D1 mutations on glutamate transporters may be mediated 
via oxidative processes. It has been reported that hydrogen peroxide (H2O2), 
reactive oxygen species (ROS) and peroxynitrite (ONOO-) can inhibit glutamate 
uptake through their oxidant action on cysteine sulphidryl groups of all 
glutamate transporters (Volterra et al., 1994a; Volterra et al., 1994b; Trotti et al., 
1996). Trotti and collaborators have demonstrated that GLT-1-mediated 
glutamate uptake can be selectively affected by coexpression of S0D1 mutants 
in oocytes, upon administration of H2O2 . This effect is thought to involve 
reactive oxygen species such as hydroxyl radical, generated by mutated SOD1 
(A4V or II 1ST) from hydrogen peroxide (Trotti et al., 1999). However, the role of
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oxidative stress as primary event in the pathogenesis of ALS still remains 
controversial as discussed in the above section 1.8.1.
Thus, whether the expression of mutated human S0D1 can directly alter 
the mRNA or protein levels of glial glutamate transporters and inhibit glutamate 
uptake still needs to be investigated properly.
6.2 Hypothesis and aim
The hypothesis evaluated in this thesis section is that the expression of 
SODI®^^^ mutants may reduce the expression and/or the activity of the most 
important glial glutamate transporter GLT-1, in a way that is consistent with 
excitotoxic damage to motor neurones.
Thus, in this part of the study, I investigated the expression of glutamate 
transporter GLT-1 in the spinal cord of S0D1°^^^ mice and the effect of 
S0D1°^^^ mutant on the expression and activity of GLT-1 in isolated cultured 
astrocytes.
6.3 Methods
6.3.1 Immunohistochemical analysis for GLT-1 in mice
Immunohistochemical analysis was carried out as described in section 2.5. 
Frozen spinal cords of non transgenic and SODI^^^^ mice at 8, 14 and 19 
weeks of age were used
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The primary antibodies used were: antibody against GLT-1 (guinea pig 
polyclonal, 1:5000, Chemicon International) or glial fibrillary acidic protein 
(GFAP, 1:250 mouse monoclonal, Roche). The optical density of GLT-1 
immunostaining in the ventral and dorsal horn of lumbar spinal cord sections 
was measured relative to the medial dorsal white matter background of 
individual sections using an image analyser Imaging System KS300 (Zeiss- 
Kontron). Optical density was measured within a linear range as determined by 
increasing dilution of the primary antibody. Ventral horn included the laminae 
VII, VIII and IX, and dorsal horn included the laminae 1,11 and III of the grey 
matter at the L2-L4 level of spinal cord. The optical densities of two sections 
were quantified for each animal and the mean value of these determinations 
was used as individual data for statistical analysis by One-Way AN OVA 
followed by Tukey's test (GraphPad Prism 2.0a, GraphPad Software Inc.).
6.3.2 In situ hybridisation for GLT-1 mRNA in SODI®®^  ^mice
In situ hybridisation was performed as described in section2.4. Spinal cord 
sections of SODI^®^^ mice at different stages of disease progression (8,14 and 
19 weeks) and non transgenic mice used as controls were used. A rat GLT-1 
cDNA fragment was prepared by PCR using standard methods (Molloy et al.,
1998). A 327 bp fragment corresponding to bases 1310-1636 of the rat 
sequence (Pines et al., 1992) was amplified using specific primers (5’-3’): AGO 
CGT GGC AGO CATC TTC ATA GC (forward) and ATG TCT TCG TGC ATT 
CGG TGT TGG G (reverse). Then it was cloned into PCR2.1 (Invitrogen).
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Riboprobe template was prepared by amplification of the plasmid (2 ng) in a 
volume of 500 pi with the following primers (5-3’): ACC GAG CAA TTA A CC 
CTC ACT AAA GGG CCG CCA GTG TGC TGG AAT TCG (forward) and CGT 
TGT AAA ACG ACG GCC (reverse), that flanked the insert, and incorporated a 
T3 and T7 site into the template.
Antisense and sense RNA probes were synthesized by in vitro 
transcription from 1 pg of linear DNA templates using, respectively, T7 or T3 
RNA polymerase enzymes (Promega) in a reaction mixture containing 1X 
transcription buffer, DTT 10 pM, RNase inhibitor 30 U (Roche), non labelled 
NTP 0.5 mM and UTP 10 pM (Promega) and ^®S-UTP 50 mCi (Amersham 
Bioscences).
6.3.3 Cell transfection of primary astrocytes with human SOD1 gene
Wild type human S0D1 (hSODI'^) or human S0D1 carrying G93A 
mutation (hSODI®®^^) cDNAs were obtained by RT-PCR from total RNA of 
transgenic mice expressing hSGDI^®^^ or hSODI^ using the following primers 
(5’-3’): GCC GGA TCC TGC AGT CCT CGG AAC CAG GA (forward) and AAG 
GAA AGA AGC GGC CGC AGG ATA ACA GAT GAG TTA AGG G (reverse), 
which introduce a BamHI and a Notl restriction site, respectively. Full-length 
cDNAs were cloned into the BamHI and Notl sites of the mammalian expression 
vector pcDNA3 (Invitrogen). The sequence of the resultant clones was 
confirmed by DNA sequencing (Molecular Biology Unit, King’s College London). 
Primary cortical astrocyte cultures were transfected after 15-16 DIV using
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LipofectAMINE 2000 Reagent (Invitrogen), following the manufacturer’s 
protocol. The transfection was performed in a serum-free medium and without 
antibiotics for 6 hours. Then the medium with lipid-DNA complex were replaced 
with normal medium containing 10% FBS and incubated at 37°C in a humidified 
atmosphere of 95% air and 5% CO2 for 4 days before the experiments. Cultured 
astrocytes treated with lipofectamine only or transfected with the pcDNA3 vector 
only were used as negative controls. Transfection efficiency was tested by 
using the plasmid pWAY21, a mammalian vector containing a Green 
Fluorescent Protein (GFP) gene, kind gift of Dr Hughes (Lo et al., 1998).
6.3.4 Astrocyte viability and MTT assay
Astrocyte viability was investigated using the Trypan Blue dye exclusion 
assay. Four days after transfection, cells were washed twice with physiological 
buffer (140 mM NaCI, 5 mM KCI, 1 mM CaCL, 1.2 mM NaHP0 4 , 5 mM Glucose 
and 20 mM Hepes, pH 7.4) and then stained with 200 |il of 0.4% Trypan Blue 
(Sigma) for 1 minute, washed twice with PBS and then examined by phase 
contrast microscope Nikon Eclipse TS100 (Nikon U.K., Surrey, UK). The ability 
of mitochondrial succinate dehydrogenase to convert 3-(4,5-dimethylthiazol-2- 
yl)-2,5-diphenyl tétrazolium bromide (MTT) (Sigma) to the blue insoluble 
formazan salt was investigated. Four days after transfection, astrocytes in 
culture were washed twice with physiological buffer and incubated with MTT 
(0.5 mg/ml) dissolved in the same buffer for 1 h at 37°C. The medium was 
removed and the cells washed twice with PBS and the formazan produced by
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the cells was solubilized in 200 pi of dimethyl sulfoxide. Absorbance was 
measured at 505 nm using an automatic microplate reader Power Wave X340 
(Bio-Tek Instruments Inc., Winooski, Vermont, USA).
6.3.5 Western blot analysis for cultured astrocytes
Total cell proteins were extracted using a lysis buffer containing 50 mM 
Tris/HCI, pH 7.5, 150 mM NaCI, 1% SDS and 100 mM DTT, and diluted in 
loading buffer (100 mM Tris/HCI, pH 7.5, 15% p-mercaptoethanol, 4% SDS, 
15% glycerol, 5 mM EGTA, 5 mM EDTA, 0,2% bromophenol blu) without boiling 
(Trotti et al., 1998). Equal quantities of total protein (40-80 pg) were loaded into 
each well, and proteins were separated by electrophoresis on a 7.5% or 12% 
denaturing polyacrylamide-SDS gel. Following electroblotting, the membranes 
were blocked in TBS (20 mM Tris/HCI, 150 mM NaCI) containing 5% skimmed 
milk powder for 1 hour. Membranes were then incubated with primary 
antibodies diluted in TBS supplemented with 0.05% Tween-20 overnight. 
Antisera rose in rabbits against G LAST (Anti-A522, rabbit 68488, 0.1 pg/ml) and 
GLT-1 (Anti-B12, rabbit 26970, 0.06 pg/ml) were used, both kind gifts of Dr 
Danbolt, Oslo, Norway. For S0D1 a sheep antiserum that recognises the 
human and murine forms on Western blots (Anti-SODI, 1:2000, Upstate, Lake 
Placid, NY, USA) was used. As a control, rabbit-anti Glial Fibrillary Acidic 
Protein antibody (Anti-GFAP, 1:2000, DAKO, Ely, Cambridgeshire, UK) was 
used. The membranes were rinsed three times in TBS supplemented with 
0.05% Tween-20 and secondary antibodies were then applied (peroxidase-
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conjugated goat anti-rabbit IgG, 1:5000, Jackson ImmunoResearch, or rabbit 
anti-sheep IgG, 1:5000, Chemicon International) for 1 hour. After three washes 
the protein bands were detected using the ECL-Plus Western Blotting Detection 
System (Amersham Biosciences), and the membranes applied to Hyperfilms 
(Amersham Biosciences). Films were scanned and band densities obtained 
using Bio Image Intelligent Quantifier software (Ann Arbor). Statistical analysis 
was performed using One-Way AN OVA followed by Bonferroni's post-hoc test 
(Graph Pad Prism version 3.02, GraphPad Software Inc.)
6.3.6 RT-PCR for cultured astrocytes
Total RNA was extracted using RNABee reagent (Biogenesis) and reverse 
transcribed using M-MLV reverse transcriptase in the presence of 12.5 pg/ml 
oligo-dT, 1 mM dNTP, 5 mM MgCL and RNasin in IX  RT buffer (all from 
Promega). Oligonucleotide primers were designed to amplify specific regions of 
the genes encoding G LAST (653 bp, corresponding to bases 1162-815), GLT-1 
(326 bp, corresponding to bases 1310-1636) and p-actin (250 bp, 
corresponding to bases 1343-1652). The following primers were used (5-3'): 
GLAST, TCC TCA TTC ATG CCG TCA TCG TCC (forward) and TCT TGG TTT 
CGC TGT CTG GCA CG (reverse); GLT-1, AGC CGT GGC AGC CAT CTT 
CAT AGC (forward) and ATG TCT TCG TGC ATT CGG TGT TGG G (reverse); 
P-actin, ATC GTG GGC CGC CCT AGG CAC (forward) and TGG CCT TAG 
GGT TCA GAG GGG C (reverse). Semi-quantitative RT-PCR (Yip et al., 2001) 
was performed in the presence of 1.5 mM MgCL, 50 pM dNTP, 0.1 pM sense
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and antisense primers, 1.25 U Taq DNA polymerase and 2.5 pi of RT product 
(cDNA), in IX  PCR buffer (all from Promega). In order to verify that 
amplification of each gene was within the linear range, GLAST and GLT-1 were 
amplified for 21, 24, 27, 30 cycles and p-actin for 19, 22, 25 cycles. The semi- 
quantitative analysis was done using 27 cycles for glutamate transporters and 
22 cycles for actin (95 C for 30 seconds, 55 C for 45 seconds and 72 C for 1 
minute), followed by 10 minutes of final extension at 72 C. PCR products were 
subjected to agarose gel electrophoresis and visualised by UV illumination in 
the presence of ethidium bromide. Band intensity was evaluated using UVIsoft 
Image Acquisition and Analysis software (UVItec, Cambridge, UK). Statistical 
analysis was performed using One-Way AN OVA followed by Bonferroni's post- 
hoc test (Graph Pad Prism version 3.02, GraphPad Software Inc.).
6.3.7 ^H-D-aspartate and ^H-GABA uptake
Uptake experiments were performed in physiological buffer (140 mM NaCI, 
5 mM KCI, 1 mM CaCL, 1.2 mM NaHP0 4 , 5 mM Glucose and 20 mM Hepes, 
pH 7.4) on 15-16 DIV cultured astrocytes or 4 days after transfection. After 
washing twice with buffer, the experiment was started by adding buffer with 50 
nM ^H-D-Aspartate or 25 nM ^H-GABA (Amersham Biosciences) to the wells. 
The cells were incubated for 10 minutes at 37°C and the uptake was terminated 
by two washes with ice cold PBS, followed by immediate lysis of the cells with 
ice cold 0.1 M NaOH. Radioactivity was determined by liquid scintillation 
counting. When used, the glutamate uptake inhibitors L-fra/?s-2,4-pyrrolidine
188
dicarboxylate (2,4-PDC) (Tocris, Bristol, UK), dihydrokainic acid (DHK) (Tocris,) 
and L-serine 0-sulfate (L-SOS) (Sigma) were added 5 minutes before and were 
present during the uptake experiment. Statistical analysis was performed using 
One-Way AN OVA followed by Bonferroni's post-hoc test (Graph Pad Prism 
version 3.02, GraphPad Software Inc.).
6.3.8 Immunocytochemical analysis for cultured astrocytes
For immunocytochemistry studies, astrocytes (4 days after transfection) 
were fixed in PBS containing 4% paraformaldehyde for 1 hour at room 
temperature. Astrocytes were then permeabilized with 0.2% Triton X-100 made 
up in PBS containing 1% normal goat serum (blocking solution) for 1 hour and 
then incubated, with constant agitation, overnight with primary antibody (sheep 
anti-S0D1, 1:200, Upstate) or for 2 hours with mouse anti-oligodendrocyte 
Marker 04, (1:200, Chemicon International) in PBS, 0.2% Triton X-100, 1% 
rabbit serum. After three 10 minutes washes in PBS, astrocytes were incubated 
with rabbit anti-sheep IgG, (1:500, Chemicon International) or anti-mouse IgG, 
(1:200, Vector Laboratories) in PBS, 0.2% Triton X-100, 1% goat serum for 1 
hour and washed three times for 10 minutes with PBS. The signal was revealed 
by reaction with 3'-3-diaminobenzidine (DAB peroxidase substrate kit. Vector 
Laboratories) and analysed using light microscope Nikon Eclipse TS100 
(Nikon).
For double-staining immunofluorescence studies, astrocytes were cultured 
on glass coverslips that had been coated overnight with 1.5pg/ml poly L-
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ornithine and then with 2 pg/ml laminin for 2hours. Four days after transfection 
astrocytes were fixed in PBS containing 4% paraformaldehyde for 1 hour at 
room temperature. Astrocytes were then permeabilized with 0.2% Triton X-100 
made up in PBS containing 1% normal donkey serum (blocking solution) for 1 
hour and then incubated with the first primary antibody sheep anti-SODI (1:200, 
Upstate) in PBS, 0.2% Triton X-100, 1% donkey serum, overnight with constant 
agitation. After 3 x 1 0  minutes washes in PBS, astrocytes were incubated with 
rhodamine-conjugated donkey anti-sheep IgG, (1:100 dilution of stock Jackson 
Immuno Research) for 2 hours and washed 4 x 10 minutes with PBS. The 
procedure was repeated using the second primary antibody rabbit anti-GLT-1 
(Anti B12, rabbit 26970, 1.5 pg/ml) or anti-GLAST (Anti-A522, rabbit 68488, 2.5 
pg /ml). The GLAST and GLT-1 antibodies were kind gifts from Dr Danbolt, 
Oslo, Norway. Fluorescein-conjugated donkey anti-rabbit IgG secondary 
antibody at a dilution of (1:100, Jackson ImmunoResearch) was used. The 
fluorescence was visualized using the Zeiss AxioPlan 2 optical microscope 
(Carl Zeiss Microimaging, Inc., Thornwood, NY, USA). Statistical analysis was 
performed using One-Way AN OVA followed by Bonferroni's post-hoc test 
(Graph Pad Prism version 3.02, GraphPad Software Inc.)
6.3.9 DCDHF-DA assay for cultured astrocytes
DCDHF-DA assay was performed as previously described (Crossthwaite 
et al., 2002). Four days after transfection, cultured astrocytes were washed 
twice with physiological buffer (140 mM NaCI, 5 mM KCI, 1 mM CaCL, 1.2 mM
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NaHP0 4 , 5 mM Glucose and 20 mM Hepes, pH 7.4). 2',7'-
dichlorodihydrofluorescin diacetate (100 pM DCDHF-DA) (Molecular Probes, 
Eugene, OR, USA) in physiological buffer was placed on the astrocytes for 30 
minutes in 5% 002/95% air at 37°C. DCDHF-DA is hydrolysed inside the cells 
to form 2',7'-dichlorodihydrofluorescin which emits fluorescence when it is 
oxidized to 2',7'-dichlorofluorescein (DCF). Thus the fluorescence emitted by 
DCF directly reflects the overall oxidative status of a cell (Wang and Joseph,
1999). After the incubation, astrocyte cultures were washed three times with 
buffer. The relative fluorescence was monitored for 60 minutes using a 
SPECTRAmax® Gemini microplate spectrofluorometer (Molecular Devices, 
Wokingham, UK). The emission was recorded at 530 nm after exciting at 500 
nm. Each well was scanned in the instrument's well scan mode and the 
accumulated data from 21 independent points per-well were then transformed 
to an average signal, expressed in relative light units. All data were calculated 
and normalized with respect to the increase of fluorescence of untransfected 
controls. Statistical analysis was performed using One-Way AN OVA followed by 
Bonferroni's post-hoc test (Graph Pad Prism version 3.02, GraphPad Software 
Inc.).
6.3.10 Drug treatments for cultured astrocytes
When used, the glutathione peroxidase inhibitor L-S,R-buthionine 
sulfoximine (BSO) (Sigma) was added to the culture media at a final 
concentration of 500 pM 48 hours before the experiments. The catalase
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inhibitor, 3-amino-1,2,4-triazole (ATZ) (Sigma) was used at a concentration of 1 
mM and added to the culture medium 48 hours before the experiments. The 
antioxidant compound, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid 
(Trolox) (Fluka, Poole, UK) was used at a concentration of 200 pM and added 
to the culture medium 48 hours or 96 hours before the experiments. Statistical 
analysis was performed using One-Way AN OVA followed by Bonferroni's post- 
hoc test (Graph Pad Prism version 3.02, GraphPad Software Inc.).
6.4 Results
6.4.1 Study of GLT-1 expression in the spinal cord of SODI®®^  ^mice
In the first part of this study, we examined the expression of the main 
astroglial glutamate transporter GLT-1 in the spinal cord of SODI^®^^ mice.
6.4.1.1 Immunohistochemistry for GLT-1
In lumbar spinal cord of control mice, the GLT-1 immunoreactivity 
appeared widespread throughout the grey matter with the highest 
immunolabelling observed in the substantia gelatinosa of the dorsal horn. The 
white matter showed a filamentous pattern of strong immunostaining in the 
ventral and lateral regions of the spinal cord whereas a low signal appears in 
the dorsomedial region. Compared with non transgenic mice, a marked, 
decrease in the GLT-1 immunostaining in the ventral horn of the spinal cord
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was evident in the mice at symptomatic and final phases of the
disease, when motor impairments were present. However, there was no 
reduction in GLT-1 in presymptomatic animals at 8 weeks of age compared with 
age-matched non transgenic mice. No changes were revealed in the dorsal 
horn of SODI®^^^ mice at any of the ages tested (Figure 6.1). Immunostaining 
for GFAP, a selective marker of astroglial cell, revealed an increased labelling 
of ventral spinal cord, which gradually augmented during the course of the 
disease, reflecting the reactive astrocytosis occurring in these mice (Figure 6.2).
6.4.1.2 In situ hybridisation for GL T-1
Analysis of GLT-1 mRNA expression in the spinal cord of SODI®^^^ mice 
was performed by in situ hybridisation. The riboprobe for GLT-1 revealed 
widespread distribution of its mRNA throughout the grey matter of the spinal 
cord, consistent with the expression of this mRNA in astrocytes. Quantitative 
analysis of autoradiographic film showed no changes in the levels of GLT-1 
mRNA in either the ventral or dorsal regions of the spinal cord of S0D1°®^^ 
mice compared with non transgenic controls (Figure 6.3).
193
S0D1 G93A
CONTROL 8 weeks 14 weeks 19 weeks
Figure 6.1: Immunohistochemical analysis of GLT-1 expression in the spinal cord 
of SODl'^^^* mice
GLT-1 immunoreactivity in sections of the lumbar spinal cord of non transgenic 
(control) and mice. In non transgenic mice, GLT-1 immunostaining is mainly
distributed throughout the grey matter with the highest signal shown at the level of the 
substantia gelatinosa of dorsal horn. A gradual decrease of GLT-1 immunostaining in 
the ventral and intermediate region of the grey matter is evident in SODI^^^^ mice at 14 
and 19 weeks of age, whereas the dorsal horn maintains high immunostaining at all 
ages compared with non transgenic controls. Scale bar = 250 pm.
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Figure 6.2: GFAP immunoreactivity in the spinal cord of mice
(A-D) In non transgenic mice (control), GFAP immunostaining is scattered 
distributed in the grey matter with a filamentous pattern in the white matter. A gradual 
increase of the GFAP immunostaining in the whole section of the spinal cord appears 
in mice during the progression of the desease, with a prominent increase in
the grey matter of 14 and 19 week-old mice, (a-b) Fiigh magnification of the astrocytes 
from the ventral horn region shows in control mice a characteristic stellar shape with a 
tiny cell body surrounded by branched thin processes (arrows), whereas in SODI^^^^ 
mice the astrocytes appeared more intensely stained with hypertrophic cell bodies and 
processes, particulariy in 19 week old mice (arrowheads). Scale bar = (A-D) 250 pm, 
(a-d) 50 pm.
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Figure 6.3: GLT-1 mRNA expression in the spinal cord of SOD1^ ^^  ^mice
Quantitative analysis of autoradiographic opical density revealed no significant 
variation of GLT-1 mRNA levels in dorsal (laminae I, II, III and IV) and ventral (laminae 
VII, VIII, and IX) horn of SODI^^^^ mouse spinal cord in respect to non transgenic 
mice (control) at all the ages considered (two sections from each animal). Data are 
expressed as percentage relative to non transgenic controls. Each column is the mean 
± S.E.M. (n = 5 to 6), data analysed by Two-Way ANOVA followed by Tukey's test.
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6.4.2 Study of GLT-1 expression and activity in primary cultured 
astrocytes expressing SODI^^^^ mutant. Involvement of oxidative 
processes
In order to better understand the effect of mutant S0D1 on the expression 
and activity of GLT-1, we used isolated astrocytes in culture, transfected with 
human S0D1 carrying G93A mutation to evaluate the levels of GLT-1 and its 
functionality.
6.4.2.1 Cortical astrocyte cultures express glutamate transporter proteins and 
mRNAs and support high-affinity ^ H-D-aspartate uptake
Primary cortical astrocytes were grown in the presence of cortical 
neurones for 12-13 DIV as astrocyte-neurone co-cultures. Then, neuronal cells 
were removed by washing with PBS/glucose solution after 10 and 13 DIV and 
pure confluent astrocyte cultures were used at 15-16 DIV for the experiments. 
No oligodendrocytes were detected by immunocytochemistry (results not 
shown), and no neurones were found upon visual analysis using phase 
microscopy.
As previously reported (Gegelashvili et al., 1997; Swanson et al., 1997), 
RT-PCR showed that growing astrocytes in the presence of neuronal cells leads 
to increased levels of mRNAs encoding the glial glutamate transporters GLT-1 
and GLAST compared to astrocytes grown without neurones (Figure 6.4 A). 
Quantification of PCR bands (Figure 6.4 B) revealed that the expression was
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increased threefold for both the transporters and that relative proportion of 
GLAST and GLT-1 mRNAs was maintained.
Uptake of the glutamate transporter substrate ^H-D-aspartate into cultured 
astrocytes increases linearly until 15 minutes (results not shown). As a result, all 
the uptake experiments were carried out for 10 minutes. As shown in Figure 6.4 
C, high concentration of the glutamate uptake inhibitors L-fra/?s-2,4-pyrrolidine 
dicarboxylate (2,4-PDC), dihydrokainic acid (DHK) and L-serine 0-sulfate (L- 
SOS) (Bridges et al., 1999) block the majority of ^H-D-Aspartate uptake, 
demonstrating that uptake was mainly via high affinity glutamate transporters. 
Subtype-selective concentrations (Bridges et al., 1999) of DHK (0.2 mM), to 
selectively block GLT-1, and L-SOS (0.2 mM) to mainly block GLAST, each 
reduce ^H-D-aspartate uptake by about 50%, indicating a similar contribution of 
the two glial glutamate transporters to ^H-D-aspartate uptake in these astrocyte 
cultures.
6.4.2.2 Primary astrocyte cultures support high levels of hS0D1^^^^ or 
hS0D1'^ protein expression after transfection
Transfection was performed on confluent cultured astrocytes with human 
S0D1 carrying the FALS-linked G93A mutation (hSODI^®^^) or wild type 
human S0D1 (hSODI'^), both cloned in the expression vector pcDNA3. 
Immunocytochemistry revealed large numbers of astrocytes expressing high 
levels of S0D1 in transfected cultures compared to untransfected cultures 
(Figure 6.5 A-B). The transfected cells, intensely stained for S0D1, had the
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Figure 6.4: RT-PCR analysis of giial glutamate transporters GLAST and GLT-1 
mRNAs in cultured astrocytes
Total RNA extracted from cultured astrocytes grown as pure culture or as co­
culture with cortical neurons were used. RT-PCR for p-actin was carried out as control. 
(A) Bands of the predicted size of 653 bp for GLAST, 326 bp for GLT-1 and 250 bp for 
p-actin were identified. (B) The expression of both GLAST and GLT-1 mRNAs was 
increased about threefold in the presence of neurons. Values reported in graph are the 
ratio of band intensity of glutamate transporters and p-actin from the same samples (n 
= 3). (0) Effect of glutamate uptake inhibitors on ^H-D-aspartate uptake in cultured 
astrocytes. 2,4-PDC (0.2 mM), DHK (2 mM) and L-SOS (2 mM) blocked the majority of 
^H-D-aspartate uptake. Subtype selective concentrations of 0.2 mM DHK to block GLT- 
1 or 0.2 mM L-SOS to block GLAST reduced ^H-D-aspartate uptake by 52% and 58% 
respectively (n = 3).
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morphology of astrocytes (Figure 6.5 C). Analyses of GPP expression in 
cultures transfected with pWAY21 showed that transfection efficiencies were 
50% on average, but were somewhat variable (Figure 6.5 D). An antibody that 
recognizes both human and murine S0D1 as bands of different sizes on 
Western blots was used to further analyse hS0D1®^^^ or hS0D1'^ expression 
in transfected astrocytes. Transfected astrocyte cultures express high levels of 
human S0D1 (Figure 6.5 E) and the amount of total human S0D1 protein 
increases in a time dependent manner, reaching a slightly higher band intensity 
compared to murine S0D1 four days after transfection (Fig. 6.5 F). Although the 
anti-S0D1 antibody recognises murine S0D1 strongly on Western blots, under 
the conditions used here, it revealed very little labelling of untransfected 
astrocytes, suggesting that the antisera does not bind well to the epitopes of 
murine S0D1 that are exposed in this procedure (see Fig. 6.5 A).
6A.2.3 Expression of hS0D1^^^^ or hS0D1'^ in astrocytes downregulates 
GLT-1 protein expression without altering GLAST levels
Western blotting analysis was used to assess the regulation of protein levels of 
glial glutamate transporters after expression of hS0D1^®^^ or hS0D1'^. Using a 
buffer containing 1% SDS and 100 mM DTI to prevent transporters from 
oxidation during the protein extraction (Danbolt, 2001), the bulk of the GLT-1 
and GLAST proteins appeared as a monomeric band at the apparent molecular 
weights of 66 and 67 KDa respectively, as expected. A marked decrease of the 
expression of GLT-1 protein was found in cultured astrocytes expressing
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Figure 6.5: Immunoreactivity for S0D1 in transfected astrocyte
Immunocytochemistry for S0D1 performed on untransfected astrocytes (A) or 
astrocytes transfected with hSOD1 (B, C). An antibody which recognises both human 
and murine S0D1 was used. Because of the high level of human protein, transfected 
cells were distinguishable being much more intensely stained. No differences were 
found between hSOD1^^^^ or hS0D1^ transfected astrocytes staining. (D) Evaluation 
of transfection efficiency by Green Fluorescent Protein (GFP) expression detection. 
(E) Western blot analysis for S0D1 showed that total human S0D1 expression in 
transfected cultured astrocytes increased in a time dependent manner reaching a 
slightly higher levels than total endogenous murine S0D1 four days after transfection. 
No differences were found between hSOD1^^^^ orhSODI'^ transfected astrocytes. The 
same antibody, which recognises both human and murine SOD1 was used. (F) Data 
shows the ratio between levels of human and murine SOD1 protein. hSOD1^^^^ and 
hS0D1^ showed similar levels of expression (not shown). Scale bars (A, B, D) = 50 
jum; (0) = 10 pm.
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hS0D1®®^  ^ (Figure 6 . 6  A, p<0.001) compared to untransfected controls. 
Astrocytes transfected with hS0D1'^ also showed a similar downregulation of 
GLT-1 expression (p<0.01) although the decrease was slightly less than the 
reduction seen in astrocytes transfected with the mutant hSODI (Figure 6 . 6  A). 
The effect of the expression of both the forms of hSODI was specific for GLT-1 
since no changes were revealed in the expression of the other glial glutamate 
transporter analysed, GLAST (Figure 6 . 6  B). As an internal control, data were 
expressed relative to the intensity of the GFAP band obtained from the same 
blots (Figure 6 . 6  C, D).
In order to check that the GLT-1 downregulation was not due to the transfection 
procedure, we performed Western blot experiments on astrocytes either 
transfected with the pcDNA3 vector only or treated with the transfection reagent 
only. There was no reduction of GLT-1 protein level under either of these 
conditions (pcDNA3 results not shown).
It has been demonstrated that glutamate transporters form multimeric 
complexes under conditions of oxidative stress (Haugeto et al., 1996; Trotti et 
al., 1998). Since expression of mutated S0D1 has been suggested to induce 
oxidative damage (Yim et al., 1996; Beal et al., 1997; Ferrante et al., 1997b; 
Yim et al., 1997), we investigated whether the decrease of monomeric GLT-1 in 
astrocytes expressing either hSODI®®^^ or hSODI'^ was associated with 
increased formation of high molecular complexes. Figure 6.7 shows a whole 
blot probed with anti-GLT-1 antibody. In addition to intense 6 6  KDa monomeric 
bands, there are lighter bands at the apparent molecular weight of 180 KDa, 
representing a trimeric complex (Trotti et al., 1998). No bands corresponding to
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Figure 6.6: Western blot analysis for GLT-1 and GLAST glial glutamate 
transporters in transfected astrocytes
(A) Expression of either hSODI^^^^ or hSODI'^ caused a decrease of GLT-1 
levels in cultured astrocytes compared to untransfected controls with the decrease 
observed in astrocytes expressing wild type hSODI less intense than the reduction 
seen in astrocytes transfected with the mutant form. (B) No changes in GLAST 
expression were detected in transfected astrocytes. Transfection with the vector only 
(data not shown) or treated with the transfection reagent only (LF) did not cause any 
reduction of GLT-1 protein level. (0, D) Results show GLT-1 protein levels (0) or 
GLAST protein levels (D) divided by the band intensity of GFAP from the same blots 
and expressed as percentage relative to untransfected controls. Each column shows 
the mean ± S.E.M. (n = 6). *** = p < 0.001, ** = p <0.01 compared to untransfected 
control (One-Way ANOVA with Bonferroni’s multiple comparison test).
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a dimeric complex were found. Quantification of the band intensities (data not 
shown) revealed no significant differences in the levels of trimeric bands in 
astrocytes transfected with hS0D1°®^^ or hS0D1'^ compared to untransfected 
or lipofectamine treated control cultures. In addition to the band representing 
the trimeric complex a band of a higher molecular weight (>250 KDa) was 
observed but the identity of this band is not known.
6.4.2.4 Double labelling o f astrocytes reveals low GLT-1 protein levels in 
cells expressing high S0D1 levels
Cells were stained for S0D1 and GLT-1 or GLAST (Figure 6 .8 ). The cells 
expressing high levels of S0D1 protein are assumed to represent transfected 
cells. These highly stained cells occur in a similar proportion to the GFP 
positive cells as noted above (Figure 6.7 D). Visual analysis of these cultures 
strongly suggested that cells expressing high levels of hSODI®^^^ or hSODI'^ 
were relatively devoid of GLT-1 immunoreactivity compared to surrounding cells 
with low levels of S0D1 immunoreactivity (Figure 6 . 8  A-C). However the levels 
of GLAST protein in cells with high levels of S0D1 immunoreactivity were 
similar to, or in some cases higher than, the GLAST levels in untransfected cells 
(Figure 6 . 8  D-F). These results therefore confirm the findings from Western 
blots, that expression of hSODI®^^^ or hSODI'^ selectively causes 
downregulation of GLT-1 but not GLAST protein expression in astrocytes. 
Furthermore, the SOD1-mediated downregulation of GLT-1 appears to be 
mediated intracellularly since untransfected cells had normal levels of this
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protein compared to transfected cells. In no cases there were visible 
intracellular inclusions containing S0D1 immunoreactivity.
6.4.2.5 Expression o f hS0D1^^^^ o r hSOD1^ protein in astrocytes does not
alter GLT-1 or GLAST mRNA levels
To determine whether the reduction in GLT-1 protein was mediated by changes 
in steady-state levels of mRNA, we used semi-quantitative RT-PCR to analyse 
whether expression of hSODI^^^^ or hSODI'^ could alter the levels of GLT- 
land GLAST mRNAs. As shown in Figure 6.9 A, there were no changes in 
GLT-1 or GLAST mRNA levels in cultured astrocytes analysed four days after 
transfection, in comparison to untransfected controls. The data were expressed 
relative to the amount of p-actin mRNA from the same samples (Figure 6.9 B).
6.4.2.6 Expression o f hSODI^^^^ or hSO D I'^ in astrocytes downregulates
^H-D-aspartate uptake
We wished to test whether the decrease of monomeric form of GLT-1 is 
associated with downregulation of ^H-D-aspartate uptake in cultured astrocytes 
expressing hSODI^^^^ or hSODI'^. Transfection with either hSODI®®^^ or 
hSODI'^ caused a small (15%) but significant reduction of ^H-D-aspartate 
uptake activity compared to untransfected controls (Figure 6.10 A). In order to 
verify whether using a cationic lipid to transfect astrocytes could affect ^H-D- 
aspartate uptake by altering membrane properties, we also performed
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Figure 6.7: Western blot analysis for GLT-1 In transfected astrocytes
Using a buffer containing SDS 1% and 100 mM DTT, without boiling, to prevent 
oxidation during the sample preparation, the bulk of the GLT-1 proteins appeared as a 
monomeric GLT-1 (66 KDa) and loss of this monomer is evident in astrocytes 
expressing hSODI^^^^ or hSODI'^ compared to control and reagent only treated 
astrocytes (LF). Bands at the apparent molecular weight of 180 KDa, representing a 
GLT-1 trimeric complex, and bands at a much higher molecular weight (>250 KDa) 
were also present (arrows), but were not altered in astrocytes expressing hSODI^^^^ or 
hSODI'^ compared to controls (n = 6).
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Figure 6.8: Double staining immunofluorescence for S0D1 and for GLT-1 or 
GLAST in astrocytes transfected with hSODI^^^  ^or hSODI^
(A-C) Visual analysis showed that cells expressing high levels of S0D1 (red 
staining) were relatively devoid of GLT-1 (green staining) immunoreactivity compared 
to surrounding cells with low levels of SODl immunoreactivity. (D-F) The levels of 
GLAST (green staining) protein in cells with high levels of SODl (red staining) 
immunoreactivity were similar, or higher in same cases, to the GLAST levels in 
untransfected cells. hSODI^^^^ and hSODI^ showed similar results. In no cases 
intracellular inclusions containing SODl or GLT-1 immunoreactivity were observed.
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Figure 6.9: Semi-quantitative RT-PCR analysis for glial glutamate transporters 
GLAST and GLT-1 in transfected astrocytes
Total RNA used for experiments i/i/as extracted from untransfected astrocytes as 
control or from astrocytes transfected with hS0D1^^^^ or hS0D1^. RT-PCR for p-actin 
was performed as an internal control. (A) Bands of the predicted size of 653 bp for 
GLAST, 326 bp for GLT-1 and 250 bp for p-actin were identified. (B) The expression of 
GLAST mRNA and GLT-1 mRNA were not significantly changed in transfected 
astrocytes. Graph shows the ratio of transporter band intensity to p-actin band intensity 
from the same samples expressed as a percentage relative to untransfected control. 
Each column is the mean ± S.E.M. (n = 6), data analysed by One-Way ANOVA.
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experiments on astrocytes treated with transfection reagent only. The reagent 
caused no significant effect on the uptake (Figure 6.10 A).
In order to determine whether the loss of ^H-D-aspartate uptake was due 
to a downregulation of GLT-1, we examined the pharmacological characteristics 
of the uptake activity remaining after transfection of astrocytes with hSODI®®^ .^ 
In astrocyte cultures transfected with hSODI^®^^, the GLAST blocker L-SOS 
(0.2 mM) caused a highly significant inhibition of ^H-D-aspartate uptake (54.6 ±
1.7 %, n = 8 ), whereas L-SOS (0.2 mM) caused only a 34.6 ± 2.7 % (n =8 ) 
inhibition of ^H-D-aspartate uptake in control cultures. Since the ^H-D-aspartate 
uptake inhibition caused by this GLAST blocker is increased in cultures 
transfected with hSODI®^^^ in comparison to control (untransfected) cultures, 
this confirms that GLAST, but not GLT-1 predominates after transfection with 
hSODI^^^^
Furthermore, inhibition of transport processes was selective for glutamate 
transporters, which take up ^H-D-aspartate. The uptake of ^H-GABA was not 
significantly affected by the expression of hSODI®^^^ or hSODI'^ in astrocytes 
(Figure 6.10 B).
6.4.2.7 Expression of hS0D1^^^^ or hS0D1'^ in astrocytes does not cause 
astrocyte cell death, but reduces MTT conversion
Alterations in GLT-1 levels and glutamate transport activity could 
potentially result from cell death or damage. We therefore investigated whether 
expression of hSODI^®^^ or hSODI'^ could alter the viability of cultured
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astrocytes. Transfection with hS0D1®®^  ^ or hS0D1'^ does not produce any 
significant cell death in astrocyte cultures as indicated by trypan blue dye 
exclusion assay to test cell membrane permeability (data not shown). However, 
MTT assay showed that hS0D1®^^^ expression causes a small but significant 
(p<0.01) decrease of MTT conversion compared to control untransfected 
astrocytes (Figure 6.11). Interestingly, hSODI'^ expression also reduced 
significantly MTT conversion even if its effect tended to be smaller (p<0.05). 
The transfection reagent alone did not show any effect on cell viability or MTT 
turnover.
6.4.Z8 The effect of hSODl'^^^^ or hS0D1'^ on GLT-1 protein levels, ^H-D- 
aspartate uptake or MTT conversion does not involve oxidative 
processes
In order to investigate whether the effects of hSODI^®^^ or hSODI'^ on 
decrease of GLT-1 protein levels, ^H-D-aspartate uptake and MTT conversion 
were associated with increased oxidative stress in astrocytes, we measured 
intracellular reactive oxygen species production using the oxidation sensitive 
dye 2’,7-dichlorodihydrofluorescin diacetate (DCDHF-DA). After 30 minutes of 
incubation with DCF-DA 100 pM, the fluorescence emission was recorded for 1 
hour. Expression of hSODI^®^^ or hSODI'^ in astrocytes does not lead to 
detectable increase of intracellular reactive oxygen species (Figure 6.12). As a 
positive control, astrocytes were depleted of endogenous antioxidant stores by
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Figure 6.10: ^H-D-aspartate uptake in transfected astrocytes
(A) Overexpression of hSOD1^^^^ or hS0D1'^ caused a significant decrease of 
^H-D-aspartate in cultured astrocytes compared to untransfected control. Treatment 
with transfection reagent only (LF) did not alter ^H-D-aspartate uptake. (B) No 
significant change was observed on ^H-GABA uptake in transfected astrocytes 
expressing hSOD1^^^^ or hSODI'^. Values reported in graph represent uptake 
expressed as percentage relative to untransfected control. Data shows the mean ± 
S.E.M. (n =12 for D-aspartate uptake, n = 5 for G ABA uptake). *= p<0.05, compared to 
control (One-Way ANOVA with Bonferroni’s multiple comparison test).
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Figure 6.11: MTT assay in transfected astrocytes
Four days after transfection, cells expressing hSODl'^^^^ showed a small but 
significant decrease of complex II activity compared to control untransfected astrocytes 
or astrocytes treated with transfection reagent only (LF). hSODI'^ expression also 
reduced significantly MTT conversion even if its effect tended to be milder. No effect of 
transfection reagent was observed. Data were expressed as the percentage of 
formazan blue production relative to untransfected control, indicated as 100%. Each 
column is the mean ± S.E.M., n = 6 (**= p<0.01, *= p<0.05, compared to untransfected 
control, One-Way ANOVA with Bonferroni’s multiple comparison test).
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treatment for 48 hours with the catalase inhibitor ATZ (1 mM) and the 
glutathione peroxidase inhibitor BSO (500 pM).
We carried out additional experiments to determine whether the effect of 
hS0D1^®^^ or hS0D1'^ expression on GLT-1 protein levels or glutamate 
transporter activity was reversed by treatment with the antioxidant Trolox or 
enhanced by ATZ and BSO treatment. Downregulation of GLT-1 protein levels 
caused by hSODI®^^^ or hSODI'^ expression in astrocytes was not affected by 
treatment with Trolox 200 pM for 96 hours before the experiment (Figure 6.13). 
Treatment with Trolox 200 pM for 48 hours or with ATZ 1 mM and BSO 500 pM 
for 48 hours did not change the inhibitory effect of hSODI®^^^ or hSODI^ on 
^H-D-aspartate uptake in astrocytes (results not shown). The hSODI®^^^ or 
hSODI'^ induced decrease of MTT reduction was not attenuated by treatment 
with Trolox 200 pM for 48 hors before the experiment or enhanced by treatment 
with ATZ 1 mM and BSO 500 pM for 48 hours before the experiment (results 
not shown).
6.5 Discussion
In this part of the project we wished to investigate the role of GLT-1, the 
most important glial transporter involved in the glutamate uptake, in the 
pathology of ALS. In fact, alteration of glutamate transport may result in 
increased concentration of glutamate in the synaptic cleft leading to 
overstimulation of glutamate receptors on motor neurones and consequently to 
neuronal damage. Several evidences have indicated the diminished GLT-1
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Figure 6.12: DCDHF-DA assay in transfected astrocytes
DCDHF-DA assay was performed in order to determine whether expression of 
hS0D1^^^^ or hS0D1^ can induce reactive oxygen species production in transfected 
astrocytes. After incubation with DCDHF-DA, fluorescence emission was measured for 
60 minutes. Data are the relative fluorescence level at 60 minutes expressed as 
percentage of the values obtained from untransfected controls. Astrocytes treated 48 
hour with BSO (500 pM) and ATZ (1 mM) were used as positive control. Each column 
is the mean ± S.E.M. (n = 3). Data analysed by One-Way ANOVA.
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Figure 6.13: Western blot analysis for GLT-1 in transfected astrocytes after 
treatment with Trolox
The blot shows that the expression of either hS0D1^^^^ or hS0D1^ caused a 
decrease of GLT-1 compared to untransfected control. Blots were stripped and 
reprobed for GFAP to demonstrate equal loading of lanes (lower panel). 96-hour 
treatment with the antioxidant compound Trolox (200 pM) does not reverse GLT-1 
downregulation caused by hSODI^^^^ or hSODI^ (n = 3).
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expression as potential phenomenon occurring in the affected areas of central 
nervous system of ALS patients and animal models of the disease (Rothstein et 
al., 1995; Bruijn et al., 1997b; Howland et al., 2002). However, the role played 
by this transporter in the pathogenesis of motor neurone diseases remains 
rather unclear.
In the first section of this study, we analyzed the expression of GLT-1 in 
the spinal cord of SODI^®^^ mouse model of ALS. Our results revealed that 
levels of the GLT-1 protein but not of its mRNA, are significantly decreased in 
the spinal cord of SODI®^^^ mice at the advanced but not at the 
presymptomatic stage of the disease. These findings are in line with a previous 
study performed on transgenic mice expressing the same SODl mutant, which 
showed that synaptosomal glutamate uptake was significantly decreased only 
at 21 weeks of age corresponding to final phase of the pathology (Canton et al.,
1998). At 8  weeks of age, these transgenic mice do not show motor neurone 
loss or clinical symptoms although morphological alterations of motor neurones, 
such as vacuolization of cytoplasm and swelling of mitochondria, are present 
(Migheli et al., 1999; Bendotti et al., 2001a). Therefore, the present results 
suggest that the early stage of motor neurone damage in SODI®®^^ mice is not 
associated with changes in GLT-1 protein levels.
Our study demonstrates that the decrease of GLT-1 specifically occurs in 
the regions affected by the pathology since no significant changes in 
immunoreactivity were observed in the dorsal horn of the spinal cord where 
there is no neuronal degeneration. These data are in line with those obtained 
from post mortem tissues of patients with sporadic and familial ALS showing a
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selective decrease of GLT-1 in spinal cord and motor cortex but not in 
unaffected brain regions (Rothstein et al., 1995). More recently. Fray and 
collaborators, using quantitative immunohistochemistry for EAAT2, have shown 
a decreased expression in all regions of the lumbar spinal cords from motor 
neurone disease patients, but the highest reduction was observed in the ventral 
horn and intermediate grey matter, the most affected areas (Fray et al., 1998). 
As shown in ALS patients (Bristol and Rothstein, 1996), we have found no 
changes in the levels of mRNA of GLT-1 in the lumbar spinal cord of SODI^®^^ 
mice at any stage of the disease. Thus, these results suggest that the decrease 
of GLT-1 is due to a post-transcriptional regulation of this protein.
It has been demonstrated that glutamate transporters, and in particular 
GLT-1, are vulnerable to the oxidation resulting in an impaired glutamate uptake 
function (Volterra et al., 1994a; Trotti et al., 1998; Danbolt, 2001). In particular, it 
has been shown that the mutant SODl protein inactivates the GLT-1 in oocytes 
upon administration of H2O2 (Trotti et al., 1999). Thus, although our study 
demonstrates that the level of GLT-1 is unchanged in the lumbar spinal cord of 
young transgenic mice, we cannot exclude that the activity of this transporter is 
already compromised at this age. This may play a role in the initial process of 
motor neurone death by inducing an increase of extracellular glutamate 
concentration.
The changes in GLT-1 seem to be specifically associated with the 
pathology. In fact. Western blotting analysis on the total protein extract of spinal 
cord of SODI^®^^ mice, performed in collaboration with the Biochemical 
Neuropharmacology Group at the Wolfson Centre for Age Related Diseases,
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King's College, London, showed decresed expression of GLT-1 at the final 
stage of the disease, but unchanged levels of the another glial transporter, 
GLAST, during the progression of the disease (Bendotti et al., 2001b). This 
suggests a differential regulation of these two glial glutamate transporters under 
these pathological conditions. Since it has been reported that the expression of 
GLT-1 in astrocytes is under neuronal regulation (Gegelashvili et al., 1997; 
Swanson et al., 1997), it is plausible that the late decrease of GLT-1 observed 
in the transgenic FALS mice, as well as in the post mortem tissue of patients 
with ALS, can result from a loss of neuronal factors regulating the expression of 
this glial glutamate transporter in the affected regions, derived from motor 
neurone loss. The fact that GLAST was not changed suggests that these two 
glial transporters in the spinal cord may be regulated differently by neuronal 
factors. In order to further investigate a) whether the effects on GLT-1 
expression observed in transgenic mice are a direct consequence of mutated 
SODl expression or the effect of surrounding neuronal alterations and b) the 
possible effect of SODl mutant on the activity of the transporter, we used 
primary astrocytes transiently transfected with human wild type (hSODI'^) and 
G93A mutant (hSODI^®^^) superoxide dismutase.
The main result emerging from this part of the study is the clear decrease 
of GLT-1 protein expression also in cultured astrocytes in the presence of high 
levels of hSODI®®^ ,^ without changes of mRNA expression, confirming the 
results obtained in SODI®®^  ^ mice. Also in this experimental paradigm, the 
expression of hSODI^^^^ selectively affected GLT-1 since no significant 
changes were observed in GLAST protein expression. Reflecting the decline of
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GLT-1 protein level, ^H-D-aspartate uptake was also decreased, and the uptake 
component remaining had a greater proportion of GLAST activity than found in 
control cultures. Alteration of the glutamate uptake system was accompanied by 
decreased MTT conversion, without any sign of cell death. Furthermore, our 
results strongly suggest that these effects do not involve oxidative processes. 
Interestingly, the effect showed by hSODI^®^^ expression in cultured astrocytes 
was in part also observed after transfection with the wild type form of human 
SODl.
The key finding of this part of the study is that hSGDI^®^^ or hSODI'^ both 
cause downregulation of GLT-1 protein levels. This decrease was reflected as a 
functional loss of GLT-1 as the proportion of uptake activity due to GLAST 
activity (L-SOS sensitive component) was increased in cultures transfected with 
hSODI®®^ .^ Using Western blotting, a decreased expression of GLT-1 
monomeric protein was observed in astrocytes four days after transfection with 
hSODI®®^^ or hSODI^, and these observations were supported by 
immunocytochemical studies. Although the effect produced by hSODI®^^^ was 
greater, astrocytes expressing hSODI^ also showed a reduction of GLT-1 
expression. Since previous papers only focused on GLT-1 downregulation due 
to overexpression of mutant hSODI in transgenic animal models (Bruijn et al., 
1997b; Howland et al., 2002), this results are the first evidence suggesting that 
hSODI'^ can be as effective as hSODI®^^^ in mediating the downregulation of 
GLT-1. Despite the lack of severe motor pathology in mice overexpressing 
hSODI'^, it has been demonstrated that it can produce several potentially 
neurodegenerative alterations consisting of mitochondria swelling, axonal
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degeneration and mild motor dysfunction in old mice (Dal Canto and Gurney, 
1995; Jaarsma et al., 2000). Although gain-of-function mutations in SODl are 
necessary to induce clinical signs of motor neurone disease in ALS mice, the 
overexpression of human wild type protein can have some harmful properties, 
shared with SODI®®^ ,^ which are not enough to produce massive motor 
neurone death in mouse models but that become evident when expressed in a 
particular cell culture model like the one used here. However, the fact that 
hSODI®®^^ showed a slightly stronger effect suggests that the properties of 
SODl that produce downregulation of GLT-1 are enhanced in the mutant form 
of the enzyme.
Our results and evidence already reported (Bruijn et al., 1997b) show that 
GLT-1 protein expression declines only at the end stage of pathology in two 
different lines of FALS mice, carrying G93A or G85R mutations on SODl gene. 
As discussed above, the transgenic studies suggest that GLT-1 downregulation 
could be due to the death of motor neurones occurring at the final stage of 
disease. Neuronal factors are known to be crucial in regulating glutamate carrier 
expression and activity in astrocytes (Gegelashvili et al., 1997). These results in 
vitro therefore differ from the transgenic models sine they show a very rapid 
effect of hSODI in downregulating GLT-1 in mouse astrocytes, whereas the 
downregulation of GLT-1 in transgenic mice is slow. There is a similar 
overexpression of exogenous SODl in both mice and transfected cultured 
astrocytes; therefore the apparent difference in the timing of GLT-1 
downregulation may result from the lack of neurones in astrocyte cultures. We 
suggest that, in transgenic mice, despite the negative effect of mutated hSODI
223
on GLT-1 expression, GLT-1 levels could be maintained by the surrounding 
motor neurones. In this study, we grew astrocytes initially as co-culture but 
cultures of astrocytes without neurones were used for transfection, excluding 
any possible neuronal compensative regulation of hSODI effects on GLT-1.
Downregulation of GLT-1 expression after transfection with hSODI®^^^ or 
hSODI'^ was accompanied by small but significant decrease of ^H-D-aspartate 
uptake. The effects of hSODI appear to be selective for glutamate uptake since 
no decrease of GABA uptake was observed. Despite a large downregulation of 
GLT-1, the decrease of uptake was relatively small (15%). This can be 
explained by the fact that the contribution of GLT-1 to the glutamate uptake in 
our cultures was about 50% of the total and that GLT-1 protein was selectively 
lost. To test this hypothesis, we performed ^H-D-aspartate uptake experiments 
on transfected astrocytes in the presence of L-SOS to mainly block GLAST. In 
this set of experiments, the inhibitory effect of L-SOS on ^H-D-aspartate uptake 
in untransfected cells was about 35%, but the inhibitor effect of L-SOS in cells 
transfected with hSOD1G93A was about 55%, indicating a predominant 
contribution of GLAST (and decreased contribution of GLT-1) after transfection. 
Studies performed on synaptosomes showed decreased glutamate uptake in 
ALS patients (Rothstein et al., 1992) and in SODI^®^^ mice only at the final 
stage of the pathology (Canton et al., 1998). In both the cases, decline of Vmax 
without changes in Km was found. These data are consistent with 
downregulation of GLT-1 protein levels observed in human patients (Rothstein 
et al., 1995) and in the same transgenic mice strand as reported in our 
experiments. In human studies typical losses of 40-70% glutamate uptake
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activity are observed (Rothstein et al., 1992), but in our study we only find 
decreases of about 15% in D-aspartate uptake activity (reflecting a loss of about 
60% of GLT-1 protein levels). There are a number of major differences between 
these study systems. In the human studies, the glutamate uptake measured on 
synaptosomal preparation most likely reflects neuronal uptake, whereas this 
study reflects astroglial glutamate uptake only. Moreover, the changes reflect 
the severe pathology (including loss of nerve terminals and gliosis) occurring at 
the final stage of the disease, whereas the current results focuses on early 
changes after S0D1 expression.
As mentioned above, it can be hypothesized that glutamate uptake 
impairment can derive from action of oxidant species on the glutamate 
transporters that leads to their decreased activity. Trotti and colleagues have 
demonstrated that GLT-1 function can be selectively affected by co-expression 
of S0D1 mutants in oocytes, in the presence of oxidative insults (Trotti et al.,
1999). As we could not detect ROS production in transfected astrocytes and 
antioxidant treatment or depletion of endogenous antioxidant system did not 
change the decrease of ^H-D-aspartate uptake, we suggest that alteration on 
uptake system in astrocytes expressing hSODI is consequent to 
downregulation of GLT-1 protein expression rather than alteration in the level of 
GLT-1 activity. One possibility is that hSODI expression alters the degradation 
of GLT-1. The fact that no changes in GLT-1 mRNA levels were also found in 
vitro studies give further support to the hypothesis that the downregulation of 
the protein is due to post-transcriptional modifications. The effect of hSODI^^^^ 
or hSODI'^ appears to be selective for GLT-1 also in cultured astrocytes since
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we observed no downregulation of G LAST protein in these cultures, confirming 
the results obtained in mice.
The downregulation of GLT-1 protein by SODI®®^^ or hSODI'^ is most 
likely due firstly to overexpression of the exogenous proteins in astrocytes to 
produce effects via a variety of potential mechanisms. Formation of intracellular 
S0D1 aggregates has been proposed as a cause of ALS pathology (Cleveland 
and Rothstein, 2001). Cytoplasmic inclusions have been reported in motor 
neurones and astrocytes of ALS mice (Bruijn et al., 1997b) but GLT-1 
immunoreactivity was not revealed within the inclusions (Watanabe et al., 
2001). However, we could not observe intracellular inclusions containing S0D1 
or GLT-1 by immunocytochemistry in transfected astrocytes, suggesting that 
this is not the mechanism that links hSODI expression to GLT-1 
downregulation in these cultures. It could be assumed the most likely 
mechanism underlying hSODI downregulation of GLT-1 to be oxidative. It has 
been suggested that mutant forms of S0D1 can generate ROS through 
increased peroxidase activity (Yim et al., 1997) and that hSODI'^ transgenic 
mice show increased oxidative stress in cultured neurones, in muscle and brain 
tissue (Yim et al., 1996; Bar-Peled et al., 1999). Oxidative conditions may 
induce the formation of non functional GLT-1 homomultimers, reducing the 
availability of monomer required for the formation of active oligomeric structure, 
as revealed by immunoblotting (Haugeto et al., 1996). As well as in SODI®^^^ 
mice (Bendotti et al., 2001b), in our in vitro system. Western blot analysis 
showed high molecular weight bands, corresponding to trimeric GLT-1. In order 
to prevent transporters from oxidation during the sample preparation (Danbolt,
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2001), buffer containing SDS and DTT was used to extract proteins, and the 
samples were not heated. Thus, the high molecular weight bands observed in 
transfected astrocytes should derive from oxidative processes that occurred in 
living cells. An increase in trimeric or other high molecular weight complexes of 
GLT-1 could potentially explain the decrease of monomeric GLT-1 but no 
significant changes in the high molecular weight complexes were observed.
More direct exclusion of oxidative processes in regulating GLT-1 levels 
and function in this system came from experiments performed with DCDHF-DA 
as marker of intracellular ROS production, which revealed no detectable signs 
of oxidative stress in astrocyte cultures expressing either hSODI®^^^ or 
hSODI^. Furthermore the reduction in GLT-1 levels caused by expression of 
hSODI®^^^ or hSODI'^ was not ameliorated by Trolox treatment. This lack of 
involvement of oxidative stress is somewhat consistent with a recent study that 
reported that enhancing oxidative stress had no effects on glutamate 
transporter expression in cultured astrocytes (Miralles et al., 2001). Also 
indirectly supporting this concept are previous observations showing that 
astrocyte viability after exposure to oxidative injury was not potentiated by 
SODI'^ or SODI®®^  ^overexpression (Chen et al., 2001;Williams et al., 2001). 
In contrast, NSC-34 motor neuron-like cells showed significant increase of ROS 
production after infection with adenovirus containing hSODI®®^^ but not with 
hSODI'^ (Liu et al., 2002). Taken together, all these results suggest that 
hSODI^^^^ may induce oxidative damage in a cellular-specific way and 
astrocytes are resistant to its harmful oxidant properties.
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Interestingly, Vanoni and colleagues have recently reported that 
expression of downregulates GLT-1 protein levels, without the
involvement of oxidative processes, also in MDCK cells. Moreover, they have 
demonstrated that decrease of GLT-1 expression is consequence of increased 
internalisation and degradation of the transporter, mediated by cytosolic protein 
domain (Vanoni et al., 2004).
Our results also showed a decrease of MTT turnover associated with the 
expression of hSGDI^®^^ or hSODI'^. This alteration could reflect decreases in 
mitochondrial succinate dehydrogenase activity, and may directly relate to the 
pathological effects of hSODI expression, although this possibility was not 
tested in the present study. Accumulation of both the hSODI forms in swollen 
mitochondria of different lines of ALS mice has been reported (Higgins et al.,
2 0 0 2 ) and it has been reported that hSGDI^®^^ induces alterations of 
mitochondrial functions in transgenic mice and in NSC-34 motor neuron-like 
cells (Liu et al., 2002; Mattiazzi et al., 2002). In the same cell line, complex II 
activity was slightly decreased also by hSGDI'^ (Menzies et al., 2002). The 
SGD1 induced decrease in MTT conversion in cultured astrocytes was not 
changed by antioxidants or depletion of endogenous antioxidant system, 
indicating the lack of involvement of oxidative processes. It is possible that this 
effect is mediated by direct interaction of SGD1 with mitochondria (Liu et al., 
2004; Pasinelli et al., 2004). Further work is necessary to determine whether 
decreased mitochondrial metabolic activity is directly linked to decreases in 
GLT-1 levels.
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CHAPTER 7
Role of p38MAPK in the pathogenesis of 
ALS and its possible involvement in 
excitotoxic processes
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7.1 Introduction
7.1.1 p38MAPK, neuronal death and excitotoxicity
Excess of glutamate firing on neuronal cells, due to deficit in synaptic 
glutamate clearance or altered function of glutamate receptors, leads to cell 
death through Ca^^ cell overloading. This causes generation of free radicals and 
activation of a variety of calcium-dependent enzymes such as lipases, 
phospholipases, endonucleases, protein kinase C, nitric oxide synthase and 
many others, which in turn lead to neurone degeneration (Arundine and 
Tymianski, 2003). However, it is now well established that aberrant stimulation 
of glutamate receptors may induce neuronal death also through the activation of 
intracellular death cascades. One of these pathways involves the Mitogen 
Activated Protein Kinases (MAPKs).
MAPKs are a family of serine/threonine protein kinases that control several 
cellular functions in responses to proliferative or harmful stimuli. Members of the 
MAPK family include extracellular signal-regulated kinases (ERKs), c-Jun-N- 
terminal kinase or stress activated protein kinase (JNK/SAPK) and the p38 MAP 
kinase (p38MAPK). Particularly, p38MAPK is implicated in several functions 
relevant to ALS such as phosphorylation of cytoskeletal proteins, biosynthesis 
of inflammatory cytokines and production of nitric oxide (Mielke and Herdegen, 
2000; Ono and Han, 2000).
Activation of p38MAPK has been recently associated with neuronal 
degeneration in several neurological pathologies such as Alzheimer's disease
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and stroke (Takagi et al., 2000; Zhu et al., 2000; Barone et al., 2001b; Legos et 
al., 2001; Savage et al., 2002). Moreover, it has been shown that p38MAPK 
inhibitors can rescue primary cultured neurones from apoptosis induced by 
neurotrophic factor deprivation (Horstmann et al., 1998) and promote survival of 
transplanted dopamine neurones in Parkinsonian rats (Zawada et al., 2001).
A large body of evidence demonstrate that p38MAPK pathway is also 
implicated in neuronal death induced by excitotoxic insults. The neuronal 
damage occurring within the first minutes/hour after ischemia is essentially due 
to excitotoxic events and activation of p38MAPK has been documented in this 
phase (Takagi et al., 2000). Administration of p38MAPK inhibitors showed 
neuroprotective effects and reduction of infarct size in rats (Legos et al., 2001), 
suggesting the involvement of p38MAPK pathway in glutamate mediated 
neuronal damage. Intracortical injection of the glutamate analogue quinolinic 
acid in rats causes increased p38MAPK immunoreactivity in neurones and 
astrocytes surrounding the injection site, which precedes cell death (Ferrer et 
al., 2001). Support to this hypothesis also comes from in vitro studies. It has 
been shown that inhibition of p38MAPK confers protection to cultured neurones 
against excitotoxic exposure in different experimental paradigms (Kawasaki et 
al., 1997; Giardina and Bead, 2002; Legos et al., 2002; Chen et al., 2003).
Involvement of p38MAPK pathway in glutamate system regulation and 
activation is also suggested by recent works indicating the role played by this 
kinase in the control of glutamate receptor trafficking. Studies on long-term 
potentiation (LTP) and long-term depression (LTD) have revealed how AM PA 
receptor activity may be regulated through adding and removing different AM PA
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subunits at synaptic level (Huang et al., 2004). In particular, activation of Rap, a 
member of the Ras superfamily of small GTPases, results involved in removal 
of AM PA subunits with short cytoplasmic tails, such as GluR2 and GluR3, from 
the synapses, being this phenomenon mediated by p38MAPK (Zhu et al., 
2002a). Recently, it has been reported that inhibition of p38MAPK cascade can 
reverse the decrease of GluR2 mRNA observed in cortical neurones of neonatal 
rats after treatment with glutamate (Rivera-Cervantes et al., 2004).
7.1.2 pSBMARK and ALS
To date, the bulk of evidence about the implication of p38MAPK in ALS is 
based on studies on the effect of minocycline, a semi-synthetic tetracycline, 
which, among other effects, seems to inhibit p38MAPK pathway and to be 
protective to neurones. In fact, in vitro experiments performed on mixed spinal 
cord cultures have demonstrated that minocycline is neuroprotective against 
excitotoxicity by blocking microglia activation via p38MAPK inhibition (Tikka et 
al., 2001; Tikka et al., 2002). Moreover, it has been shown that the inhibitory 
effect of minocycline on p38MAPK cascade protects cerebellar granule 
neurones against NO induced cell death (Lin et al., 2001). Three independent 
studies carried out on two different lines of ALS mice showed beneficial effects 
of chronic treatment with minocycline on symptom onset, longevity and 
neuronal degeneration in these animals (Khz et al., 2002; Van Den Bosch et al., 
2002a; Zhu et al., 2002b). Furthermore, Raoul and collaborators have recently 
showed that FAS-induced death of motor neurones in culture requires activation
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of the p38MAPK cascade and that this death signalling is exacerbated in motor 
neurones expressing (Raoul et al., 2002).
7.2 Hypothesis and aim
The hypothesis tested in this section of the thesis is that p38MAPK is 
activated in motor neurones and contributes to ALS pathology. In particular, it is 
possible that activation of this pathway and its consequent harmful effect to the 
motor neurones may directly result from excitotoxic injury to these cells or other 
toxic stimuli. The aim of this part of the study is to evaluate the activation of 
p38MAPK pathway in the spinal cord of S0D1®^^^ mice and whether the 
inhibition of this pathway can ameliorate or arrest the course of the pathology.
7.3 Methods
7.3.1 Western blot analysis of p38MAPK
Spinal cords of S0D1^®^^ mice at 8  and 19 weeks of age and non 
transgenic mice used as control (3-5 mice each group) were homogenized in 
ice cold lysis buffer (20 mM Tris/HCI, pH 7.5, 10 mM EGTA, 500 mM p- 
glycerophosphate, 10 mM magnesium chloride, 2 mM DTT, 1 mM Na^VO^, 50
mM NaF, ImM PMSF, 1% Triton X-100, 10 mg/ml leupeptin, 10 mg/ml 
aprotinin) using a teflon-on-glass homogenizer and centrifuged at 13000 rpm for 
30 minutes at 4°C. Protein concentrations from supernatant were determined
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using a BCA Protein Assay Reagent Kit (Pierce). Lysates (50 jjg) from human 
monocytes treated for 3 minutes with N-Formylmethionine-Leucyl-Phenyl- 
alanine (f-MLP) 10'^ M were loaded as positive controls. Samples were then 
boiled for 3 minutes in loading buffer (100 mM Tris/HCI, pH 7.5, 15% p- 
mercaptoethanol, 4% SDS, 15% glycerol, 5 mM EGTA, 5 mM EDTA, 0,2% 
bromophenol blu) and 100 to 150 pg proteins/lane were run on 10% 
polyacrylamide-SDS gel and transferred to nitrocellulose membrane (Protran, 
Scheicher and Schuell). Membrane was incubated in blocking buffer, TBST with 
5% skimmed milk, for 2 hours at room temperature, followed by incubation 
overnight at 4°G with primary antibodies: rabbit anti-p38MAPK or rabbit anti- 
Phospho p38MAPK (P-p38MAPK) (both 1:1000, Calbiochem), in TBST with 5% 
bovineserum albumin, goat anti-AKT1 (1:2000, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) or with mouse anti-actin (1:2000, Chemicon 
International) in a buffer TBST with 5% skimmed milk. The blots were then 
washed in TBST and incubated with secondary antibodies: anti-rabbit, anti-goat 
or anti-mouse IgG conjugated to horseradish peroxidase (1:2000, Sigma) in 
TBST with 5% skimmed dry milk, for 1 hour at room temperature. Blots were 
developed by ECL technique using ECL Western Blotting Detection System 
(Amersham Biosciences) according to the manufacturer’s instructions. 
Densitometric analysis of autoradiographic bands was done using a computer 
assisted image analysis system (AIS 3.0, Imaging Research Inc.).
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7.3.2 RNA extraction and semiquantitatlve RT-PCR for p38MAPK
Total RNA was extracted from frozen spinal cord samples of non 
transgenic mice (controls) and mice at 1 0  and 19 weeks of age using
the acid guanidium-phenol-chloroform method as previously decribed (Bendotti 
et al., 2000). Two pg of total RNA was used for cDNA synthesis by MuLV 
reverse trascriptase (final concentration 2.5 U/pl), in the presence of oligo d(T) 
2.5 pM, dNTP mix 1 mM each component, Rnase inhibitor 1 U/pl, MgCb 5 mM 
in PCR Buffer II IX  (Gene Amp RNA PCR Kit, Perkin Elmer, CA, USA). The 
incubation was carried out for 30 minutes at 42°C, followed by 5 minutes at 
99°C and 5 minutes in ice. An aliquot (10 pi) of each cDNA synthetized in RT 
reaction was used for PCR amplification of cDNA encoding for p38MAPK and 
a-actin, in presence of AmpliTaq DNA Polymerase (final concentration 2.5 
U/IOOpI), MgCl2  (final concentration 2 mM), PCR Buffer II IX  (Gene Amp RNA 
PCR Kit, Perkin Elmer, CA, USA) and sense and antisense primers (final 
concentration 0.15 pM each). The sequences of primers for a-actin were (5-3'): 
CACA CTG TGC CCA TCT ACG A (forward) and CAC AGG ATT CCA TAC 
CCA AG (reverse). The sequences of primers for p38MAPK were (5’-3’): CCG 
GAT CCT GGA AGA TGT CGC AGG AGAG (forward) and CCG GAT CCC 
CAG GTG CTC AGG ACA CCAT (reverse). In order to verify that amplification 
of each gene was within the linear range, p38MAPK was amplified for 25, 28, 
31, 34 cycles and a-actin for 16, 19, 22, 25 cycles. Quantitative analysis was 
made comparing the band of product of 28 cycles for p38MAPK and of 19 
cycles for a-actin. Dénaturation was reached at 94°C for 1 minute, annealing at
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58°C for 1 minute and extension at 72°C for 1 minute. Each sample was run on 
1% agarose gel and the optical density of bands was quantified by Image Quant 
analyzer (Molecular Dynamics, Sunnyvale, CA, USA).
7.3.3 Chronic treatment of mice with SB 239063
Non transgenic and S0D1®®^  ^mice (10 each group, 3 per cage) received 
the drug mixed in a defined diet formulation provided by Glaxo Smith Kline 
(Brentford, Middlesex, UK). The amount of drug in the diet was calculated in 
such way to reach the dose of 10 mg/Kg mouse body weight per day. The mice 
had free access to the drug mixed diet from the manger, starting from the 
seventh week of age through the entire experiment. The same diet formulation 
without the drug was used as control. The food intake for each cage was 
measured every week when the diet in the manger was refilled.
7.3.4 Motor behavioral and neurological tests during chronic treatment 
with ZK 187638
Quantitative assessment of the motor behavioral deficit, carried out by 
measuring the stride length and rotarod performance, and the evaluation of 
survival were performed as described in section 4.3.3.
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7.4 Results
7.4.1 Study of the expression of p38MAPK protein in the spinal cord of 
So d i®®3a mice
In order to explore the hypothesis, we investigated the levels of pSBMARK 
and its phosphorylated (activated) form (P-p38MAPK) in spinal cord extracts 
from non transgenic (control) and mice using Western blot technique.
Immunobloting analysis revealed a single specific band of about 40 KDa 
corresponding to the band obtained from human monocytes stimulated with 
fMLP, used as positive control for activated p38MAPK (Figure 7.1 A).
In SODI®^^^ mice at 8  and 19 weeks of age corresponding to 
presymptomatic and late stage of the disease, the levels of total p38MAPK in 
the spinal cord were, respectively, 1.5 and 2.2 fold those found in the non 
transgenic mice (Figure 7.1 B). By contrast, immunoblot analysis of the 
phosphorylated p38MAPK showed a specific moderately intense band in spinal 
cord extracts from 19 weeks old SODI®^^^ mice. No signal was found in the 
spinal cord extracts from controls while in tissue from 8  weeks old SODI®^^^ 
mice we observed a very faint specific band, which was under the threshold for 
quantitative detection. No differences were observed in the level of another 
intracellular kinase involved in cell signalling cascade, Akt, which is also 
activated by stimuli such as cytokines, stress, etc. (Figure 7.21 A).
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7.4.2 Study of the expression of p38MAPK mRNA In the spinal cord of 
S o d i ® 9 3 a  m i c e
We then examined the expression of pSBMARK mRNA by semiquantitative 
RT-PCR analysis. The increase of pSBMAPK protein was not associated with 
changes in the levels of mRNA (Figure 7.2), suggesting that this protein is 
under post-translational regulation in the SODI^^^^mice.
7.4.3 Effect of p38MAPK activation inhibitor on symptoms and survival 
of 8001°®^'^ mice
In order to verify whether the inhibition of pSBMAPK activation may 
determine the improvement of symptoms and extension of life span in 
SOdiG93a mice, in this part of the study we examined the effect of treatment 
with SB 239063, a second generation pSBMAPK inhibitor, on the motor 
dysfunction and survival of these mice.
The drug was mixed in a defined diet formulation which was given to 
and non transgenic mice every day, starting from the seventh week 
of age until the death of mice, reaching approximately the dose of 1 0
mg/Kg day. The same diet formulation without the drug was used as control 
(vehicle). Motor dysfunction was tested by measuring the stride length and by 
evaluating the performance on rotarod of the mice. Body weight of non 
transgenic mice progressively increase from the seventh week of age until the 
end of experiment. However the rise was slightly, but significantly, lower in mice
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Figure 7.1: Expression of p38MAPK protein in the spinal cord of mice
(A) Representative immunobiots for total p38MAPK, its phosphorylated form (P- 
p38MAPK), Akt and actin. The analysis was performed on transgenic mice at early (8 
weeks) and late (19 weeks) stage of the disease in comparison to non transgenic mice 
(control). First lane (+) represent the positive control for P-p38MAPK (human 
monocytes treated with f-MLP, 50pg proteins). Other lanes are spinal cord 
homogenates (120 pg protein per lane). (B) Quantitative analysis of the immunobiots 
for p38MAPK and P-p38MAPK levels. The optical density was evaluated for each 
autoradiographic band and the values corresponding to the ratio between p38MAPK or 
P-p38MAPK and actin. Each column is the mean ± S.E.M. (n = 3-5).
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Figure 7.2: Levels of p38MAPK mRNA In the spinal cord of mice
(A) Representative RT-PCR analysis of pSSMAPK and f3-actin mRNA from spinal 
cord of mice at 8 and 19 weeks of age and controls. (B) Histograms of the
quantitative analysis of p38MAPK mRNA relative to p-actin mRNA show no significant 
differences among groups. Each column is the mean ± S.E.M. (n = 3).
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receiving the drug compared to mice fed with normal diet. Body weight of 
mice also progressively increased but at a slower rate in respect to 
non transgenic mice. The maximal body weight in these mice was reached at 
about 15 weeks of age and then it progressively declined. SODI®®^^ receiving 
the drug showed a significant lower body weight during the entire experiment 
(Figure 7.3). Surprisingly, while a constant food intake was observed in non 
transgenic mice that received either normal or drug mixed diet, the SODI®®^^ 
receiving the drug ate about 10-13% more in respect to all other groups.
In non transgenic mice the stride length reached the maximal value around 
1 2  weeks of age, which was maintained stable for the entire time of 
observation. No remarkable differences were observed between SB 239063 
and vehicle groups. Transgenic mice receiving normal diet showed a decline in 
their stride length after 16 weeks of age whereas, in the group treated with the 
drug, the onset of gait impairment started at the week 1 2 , maintaining a 
significant lower stride length in respect to vehicle group (Figure 7.4).
SODI®®^^ mice starting at 14 weeks of age showed a progressive decline in 
their capability to stay on rotating bar. No differences were found between the 
group receiving the SB 239063 and vehicle group in both transgenic and non 
transgenic mice (Figure 7.5). No difference was found in the comparison of 
survival curves of transgenic SODI^®^^ mice treated with SB 239063 with those 
treated with vehicle (Figure 7.6).
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Figure 7.3: Effect of SB 239063 on body weight of and non transgenic
mice
Data from mice treated with vehicle (red diamonds, n=10) or SB
239063 (blue squares, n=10) and non transgenic mice (control) treated with vehicle 
(green triangles, n=10) or SB 239063 (black circles, n=10) are presented as mean ± 
S.E.M. Data were analyzed by ANOVA for repeated measures followed by post-hoc 
Dunnett’s test between treatments. Group non transgenic: F (treatment) 7.3 (df1) 
p=0.01. Group S0D1^^^^ : F (treatment) 17.0 (dfl) p<0.001
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Figure 7.4: Effect of SB 239063 on stride length of and non transgenic
mice
Data from mice treated with vehicle (red diamonds, n=10) or SB
239063 (blue squares, n=10) and non transgenic mice (control) treated with vehicle 
(green triangles, n=10) or SB 239063 (black circles, n=10) are presented as mean ± 
S.E.M. Data were analyzed by ANOVA for repeated measures followed by post-hoc 
Dunnett’s test between treatments. Group non transgenic: F (treatment) 0.9 (df1) NS. 
Group S0D1^^^^ : F (treatment) 25.9 (df1) p<0.001.
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Figure 7.5: Effect of SB 239063 on rotarod performance of and non
transgenic mice
Data from mice treated with vehicle (red diamonds, n=10) or SB
239063 (blue squares, n=10) and non transgenic mice (control) treated with vehicle 
(green triangles, n=10) or SB 239063 (black circles, n=10) are presented as mean ± 
S.E.M. Data were analyzed by ANOVA for repeated measures followed by post-hoc 
Dunnett’s test between treatments. Group non transgenic: F (treatment) 0,7 (df1) NS. 
Group SOD1G93A : F (treatment) 0,7 (df1) NS.
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Figure 7.6: Effect of SB 239063 on survival of
Administration of SB 23906370 did not extende the mean survival of 
animals in respect to vehicle treated mice. Data on survival were analysed by the log 
rank test (n=10 for each group). No significant differences were found.
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7.5 Discussion
The involvement of p38MAPK pathway in ALS pathology has been 
suggested by studies indicating that treatment with minocycline, a semi­
synthetic tetracycline with p38MAPK inhibitor properties, improves 
symptomatology and extend life expectancy of S0 D1 ^^^^ and mice
(Kriz et al., 2002; Van Den Bosch et al., 2002a; Zhu et al., 2002b). More 
recently, activation of p38MAPK has been indicated as key factor implicated in 
selective death process mediated by FAS and occurring in cultured motor 
neurones (Raoul et al., 2002). The results obtained in this part of the study 
demonstrated a prominent increase of p38MAPK protein expression and its 
activated form in the spinal cord of ALS mice carrying SOD1®^^^ mutant. This 
was not associated with augmentation of mRNA transcription. 
Immunohistochemical studies carried out in our laboratory have also 
demonstarted that spinal motor neurones of transgenic mice selectively show 
higher levels of phosphorylated p38MAPK already evident at 8  weeks of age, 
when clinical symptoms are not obvious, which persist till the final stage of the 
pathology (Figures 7.7). Moreover, double immunostaining for glial fibrillary 
acidic protein (GFAP), a selective marker for astrocytes (Figure 7.9), or CD11b, 
a surface molecule that identifies microglial cells (Figure 7.10), and P- 
p38MAPK revealed a progressive activation of p38MAPK in reactive glial cells 
during the progression of the disease. This probably explains why Western blot 
analysis could only reveal the presence of activated p38MAPK at 19 week of 
age (end phase) but not at presymptomatic stage of the disease. In fact, it can
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Figure 7.7: Immunolocalization of P~p38MAPK in the lumbar spinal cord 
SODI^^^^mice
mice (G93A) were analysed at early (dweeks), intermediate (14 weeks) 
and late (19 weeks) stage of the disease in comparison SODI'^ (WT) and non 
transgenic mice used as control (CTR). (A-E) In control and SODI'^ mice the labelling 
is present at a moderate level in the grey matter and it is particularly intense in the 
substantia gelatinosa (sg) of the dorsal horn. In SODI^^^  ^mice a remarkable increase 
of immunoreactivity is observed in the motor neurones at all ages examined as shown 
at higher magnification (a-e). No remarkable changes are observed in other regions 
except for an increase of immunofluorescence in the whole grey matter of SODI^^^  ^
mice at 19 weeks of age. Scale bars: (A-E)= 200 pm; (a-e)= 30 pm.
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Figure 7.8: Colocalization of P-p38MAPK and SMI31 in the lumbar spinal cord 
SODI^^^^mice
High magnification of laser scanning confocal micrographs of P-p38MAPK and 
SMI31 immunofluorescence in the ventral horn spinal cord of mice at
different stages of the disease. In non transgenic controls (CTR, A-C) there Is a lack of 
immunostaining for SMI31 in the cell bodies of motor neurones (asterisks in A) and the 
diffuse immunoreactivity in the neuropil. No colocalisation is observed with P-p38MAPK 
(asterisks in C). In mice, at all ages examined, there is an intense
immunofluorescence of SM 131 in the vacuolized motor neuronecell bodies (arrows) and 
the colocalisation of the two antibodies in these cells (arrowheads). In the inserts of 
panels J,K,L, it is shown at high magnification a vacuolized neurite with almost 
complete overlapping of SMI 31 and P-p38MAPK immunoreactivity. Scale bar: 20 pm.
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Figure 7.9: Colocalization of P~p38MAPK and GFAP in the lumbar spinal cord 
SOD1G93A mice
High magnification of laser scanning confocal micrographs of P-p38MAPK and 
GFAP immunofluorescence in the ventral horn spinal cord of mice at
different stages of the disease. In control (CTR), GFAP immunoreactivity is in the thiny 
processes of astrocytes (arrows in A) and there is no overlapping with P-p38MAPK 
immunostaining (arrowheads in 0). In mice, GFAP immunoreactive
astrocytes show a remarkable hypertrophy which increases with the age (arrows in D,G 
and J). Panels I and L show a progressive increase of overlapping P-p38MAPK and 
GFAP immunoreactivities in hypertrophic astrocytes (arrowheads) whereas such 
colocalization does not appear in hypertrophic astrocytes of 8 weeks old
mice (arrowhead in F). Scale bar: 20 pm.
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Figure 7.10: Colocalization of P-p38MAPK and 0X42 in the lumbar spinal cord 
SODI^^^^mice
High magnification of laser scanning confocal micrographs of P-p38MAPK and 
Cd11b (0X42) immunofluorescence in the ventral horn spinal cord of 19 weeks old 
SODI^^^^ mice. Panel A shows the low GDI 1b staining for microglia in control mice. 
Panel D shows activated microglial cells with multiple hypertrophic processes (arrows) 
in which there is an almost complete overlapping with P-p38MAPK 
immunofluorescence (arrowheads). Scale bar: 30 pm.
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be assumed that the detection threshold of the antibody used for 
immunoblotting of the whole protein extract of spinal cord does not permit to 
see the increased level of P-p38MAPK when selectively present only in the 
motor neurones. At the final stage of the disease, marked astrocytosis and 
microgliosis cause a general prominent increase of activated p38MAPK levels 
and this allowed to reveal the band in the whole spinal cord homogenate. 
Western blotting also showed progressive accumulation of total p38MAPK, 
even without increase of mRNA levels. Thus, it is plausible that pathological 
processes occurring in motor neurones of ALS mice cause the recruitment of 
higher levels of p38MAPK protein obtained by slowing its turnover and 
consequently retarding protein degradation. As a result, the level of 
phosphorylated and active form of the kinase also results increased. These 
changes were specific for p38MAPK pathway since no differences were 
observed in the expression of total Akt, another intracellular kinase involved in 
the signaling following stress stimuli on the cells.
Our data are in line with those recently published by another group. Using 
multi-immunoblotting technique, they performed a wide range screening of 
numerous protein kinases expressed in symptomatic mice finding,
among others, 51% elevation of total p38MAPK and more than ten fold 
increased level of its phosphorylated form, when compared to normal mice (Hu 
et al., 2003). Reinforcing these findings, in our laboratory, we have recently 
demonstrated intense immunoreactivity for activated p38MAPK in degenerating 
motor neurones and reactive astrocytes of ALS patients (Bendotti et al., 2004).
254
This result gives further and important support to the possible involvement of 
p38MAPK in ALS.
On the basis of numerous studies that demonstrated the link existing 
between activation of p38MAPK pathway and neuronal degeneration mediated 
by glutamate in different experimental models (Kawasaki et al., 1997; Ferrer et 
al., 2001; Legos et al., 2001; Giardina and Beart, 2002; Chen et al., 2003), it is 
reasonable to assume that excitotoxic processes and activation of p38MAPK 
may be also correlated in ALS pathology. In our studies, both decreased 
expression of AMPA receptor subunit GluR2 and increased level of 
phosphorylated p38MAPK have been found in spinal motor neurones of 
SODI^®^^ mice at early stage of the disease, when the symptoms are not 
already manifest. This suggest that these two phenomena may be related and 
represent initial events in the outbreak of the symptomatology. However, 
whether dysfunction of glutamatergic neurotransmission can trigger p38MAPK 
cascade activity or be, in its turn, the consequence of the direct or indirect 
action of this kinase is not yet clear.
Increased P-p38MAPK immunoreactivity has been revealed in dying 
cortical neurones of rats occurring after toxic intracortical injection of the 
glutamate analogue quinolinic acid (Ferrer et al., 2001). Kawasaky and 
colleagues found that glutamate-induced death of cultured cerebellar granule 
cells was associated with activation of p38MAPK pathway and that SB 203580, 
a specific inhibitor for p38MAPK, inhibited this process. Furthermore, activation 
of p38MAPK resulted mediated by calcium influx (Kawasaki et al., 1997). 
Another p38MAPK inhibitor, SB 239063, provided neuroprotection against cell
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death in vitro induced by moderate excitotoxic exposure (Legos et al., 2002). 
Taken together, these finding suggest that abnormal calcium influx through 
glutamate AMPA receptors, due to decreased expression of GluR2, may induce 
p38MAPK pathway activation, which, in turn, triggers death pathways in motor 
neurones in ALS. Although studies in vitro associate activation of p38MAPK in 
neurones with apoptotic processes (Kawasaki et al., 1997; Kummer et al., 
1997), our previous results showed that morphological changes occurring in 
motor neurones of SODI^®^^ mice were never associated with ultrastructural 
apoptotic features of the nuclei nor with nuclear DMA fragmentation and 
cytoplasmic leakage, as demonstrated by in situ end-labelling (ISEL) technique, 
even at the later stages of the disease (Migheli et al., 1999; Bendotti et al., 
2001a). Therefore, these in vivo results indicate that an increase of 
phopsphorylated p38MAPK may precede motor neurone death not associated 
with apoptotic mechanisms. This is in line with the observations reported by 
Ferrer et al. showing rapid overexpression of activated p38MAPK in the rat 
cortex injured by intracerebral injection of quinolinic acid, which is consistent 
with excitotoxic necrosis (Ferrer et al., 2001).
On the other hand, the concomitant decrease of GluR2 protein levels and 
increase of phosphotylated p38MAPK in the motor neurones of transgenic mice, 
also gives rise to the hypothesis that other precocious and deleterious factors 
may trigger the activation p38MAPK pathway, which in turn may negatively 
influence the glutamatergic neurotransmission, for instance affecting AMPA 
subunit expression. Zhu and collaborators have demonstrated that AMPA 
receptor subunits are constantly added to and removed from synapses during
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normal activity of neurones. Particularly, removal of GluR2 requires the 
involvement of Rap, a small GTPases belonging to Ras superfamily, and the 
activation of p38MAPK (Zhu et al., 2002a). In addition, it has been showed that 
p38MAPK activation mediates the decrease of GluR2 occurring in neonatal 
cortical neurones of rats after treatment with glutamate (Rivera-Cervantes et al., 
2004). According with these observations, it might be hypothesized that 
activation of p38MAPK, due to pre-existent harmful stimuli, can cause AMPA 
receptor disorganization because of augmented internalisation and degradation 
of GluR2 subunit in motor neurones of ALS mice. Consequently, increase of 
number of calcium-permeable AMPA receptor would determine excitotoxic firing 
on motor neurones, contributing to their degeneration.
This theory presumes that earlier pathogenic events lead to p38MAPK 
recruitment. It is well established that p38MAPK is effectively activated by 
proinflammatory cytokines such as IL-1 and tumor necrosis factor alpha 
(TNFa)(Lee et al., 2000). Up regulation of proinflammatory factors, such as the 
presence of activated microglia, IgG and its receptor for Fc portion 
(FcgammaRI), ICAM-1 and T lymphocytes in the spinal cord of transgenic 
mice at the presymptomatic stages of the disease, strongly suggests 
that immune-inflammatory factors may be actively involved in the disease 
process occurring in ALS (Alexianu et al., 2001). Examining a wide range of 
mRNAs expression by microarray techniques, Yoshihara and collaborators 
reported that TNFa is one of the earliest factors to be induced in the spinal cord 
of SODI^®^^ mice (Yoshihara et al., 2002). Therefore, an increased TNFa 
production might contribute to the early and persistent activation of p38MAPK in
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motor neurones. During the progression of the disease, activated p38MAPK 
accumulates not only in degenerating motor neurones but also in hypertrophic 
astrocytes as demonstrated by colocalization with GFAP. TNFa and/or IL-1 
were also reported to strongly activate p38MAPK in mouse astrocytes in vitro 
(Lee et al., 2000). It has been demonstrated that p38MAPK pathway is 
specifically involved in the activation of inducible nitric oxide synthase (iNOS) 
expression in mouse astrocytes, resulting in sustained release of large amounts 
of nitric oxide (NO) (Da Silva et al., 1997). It has been shown that peroxynitrite, 
which is formed from the reaction between superoxide anions and NO, potently 
inhibits glutamate uptake (Trotti et al., 1996). Thus, it is possible that p38MAPK 
activation in astrocytes can affect glutamate system indirectly reducing activity 
of glial glutamate transporters. Activation of p38MAPK in microglia can also be 
induced by excess of glutamate and this mechanism has been proposed to play 
a role in the excitotoxic neuronal death in mixed spinal cord cultures. Tikka et al. 
reported that neuroprotective effect of minocycline against excitotoxicity in 
spinal cord cultures is due to the inhibition of proliferation and activation of 
microglia and to inhibition of p38MAPK pathway (Tikka et al., 2001). All these 
results suggest the existence of a close relation between p38MAPK pathway 
and glutamate neurotransmission that, in pathological conditions, can generate 
an autosubstained feedback, which results deleterious to motor neurones.
A possible mechanism related to p38MAPK neurotoxicity involves its 
interaction with cytoskeleton structure. It has been reported that phosphorylated 
neurofilaments accumulate in the cell bodies and proximal axons of motor 
neurones in both sporadic and familial ALS (Hirano et al., 1984a; Hirano et al..
258
1984b). Studies performed on mouse models of ALS have shown that 
neurofilament content and organization strongly influence motor neurone 
disease induced by mutant S0D1 (Couillard-Despres et al., 1998; Williamson et 
al., 1998; Couillard-Despres et al., 2000; Kong and Xu, 2000). Among its 
several biological functions, p38MAPK is involved in phosphorylation of 
cytoskeletal proteins (Mielke and Herdegen, 2000; Ono and Han, 2000). More 
recently, Ackerley and its group demonstrated the ability of active p38MAPK in 
phosphorylating middle and heavy chains of neurofilaments on their side-arm 
domains in vitro (Ackerley et al., 2004). Our results showed that P-p38MAPK 
colocalized with phosphorylated neurofilaments, labelled with SMI31 antibody 
that reacts with the phosphorylated epitope of neurofilament H and 
neurofilament M, in motor neurones of SGDI^®^^ mice (Figure 7.8). We have 
also shown that in motor neurones of ALS patients, intracellular aggregates 
containing ubiquitin and neurofilaments are strongly immunostained for 
activated p38MAPK (Bendotti et al., 2004). Therefore, activation of p38MAPK 
pathway, due to pathological circumstances, can determine phosphorylation 
and consequent disorganization of cytoskeleton architecture, which, in turn, 
may result in cell death.
Despite the early activation of p38MAPK pathway in the motor neurones of 
SODi G93a and its probable role in the pathogenesis of ALS, treatment of 
these mice with p38MAPK inhibitor did not produce any benefit in the course of 
the disease. In fact, chronic administration of SB 239063 did ameliorate neither 
the progressive motor impairment nor the survival of transgenic SODI^^^'^mice. 
The lack of neuroprotective effect of SB 239063 is in disagreement with the
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recent study showing a dose response protective effect of this drug in two rat 
stroke models after oral administration (Barone et al., 2001b). The doses 
showing the protective effect in this study (5-30 mg/Kg) are comparable to those 
received by our mice in the diet (10 mg/Kg). However the concentrations of drug 
reached in the nervous system might be dissimilar in the two studies, 
considering the different neurodegenarative model used. The stroke model 
implicates a disruption of the blood brain barrier at the site of lesion whereas it 
has not been proved in chronic degenerative pathologies like motor neurone 
disease. Moreover, the modality of administration (two bolus per day in respect 
to a diluted intake by diet) was also different. Therefore, it is plausible that this 
kind of administration in mice does not allow to reach effective concentration in 
the spinal cord. Thus, the negative result obtained does not give definite clues 
about the effectiveness of p38MAPK inhibitors in the treatment of ALS and 
cannot be excluded that the activation of this enzyme plays a role in the 
mechanism of motor neurone degeneration in this pathology. In our laboratory 
we are planning further studies using a different administration that permits to 
obtain good bioavailability in the central nervous system.
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CHAPTER 8
GENERAL DISCUSSION
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Amyotrophic lateral sclerosis is the most common disease affecting the 
motor system. Despite the profuse effort produced in many years of clinical and 
basic research, this pathology still remains orphan of an effective therapy. In 
fact, the pathogenetic mechanisms underlying the development of ALS have not 
yet been clarified. The discovery of mutations in the S0D1 gene carried by a 
subset of patients affected by familial ALS has represented an important clue 
about the processes occurring in ALS and has allowed the creations of useful in 
vitro and in vivo models of the disease. Transgenic mice expressing some of 
the S0D1 mutants discovered in ALS patients display symptoms and 
neuropathological features that closely resemble the human disorder, 
representing a reliable model of study. Clinical symptoms and neuropathological 
characteristics showed by patients affected by familial ALS are very similar to 
those occurring in sporadic case of the disease. This suggests that the same 
final event represented by selective motor neurone death can be triggered by 
different events, which affect, however, the same intracellular pathways. Thus, 
the comprehension of the death processes that lead to the pathology in FALS 
mice will also be useful to the treatment of sporadic form of ALS. However, ten 
years after the landmark breakthrough, how mutated S0D1 can trigger the 
selective motor neurone death still remains unknown.
Studies carried out on post mortem human tissues and mouse models of 
ALS have revealed the involvement of a large number of different intracellular 
pathways and alteration of several biochemical systems in motor neurones and 
surrounding glial cells. Even so, the general picture of the disease and of its 
pathogenesis still results uncertain, since almost every alteration found can be
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consequence or cause of the others. In this regard, a great support comes from 
the study of the animal models that can give information about which event can 
trigger or contribute to the motor neurone degeneration. In this study, I have 
used the transgenic mice to investigate the role of excitotoxicity and
intracellular related pathways in ALS and evaluate the time course of the 
changes observed during the progression of the disease, in the attempt to 
establish whether they can be pathogenetic or represent an epiphenomenon 
(Figure 8.1).
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Figure 8.1: Time course of the neurophatologicai alterations concerning 
glutamatatergic system that occurs in SODI^^^  ^mice
In red, the changes observed in this study
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As reported in the scheme of Figure 8.1, the first changes observed in the 
motor neurones of SODI®®^^ mice, before they display motor dysfunctions, are 
the downregulation of AMPA receptor subunit GluR2 (see chapter 3) and the 
activation of p38MAPK (see chapter 7), suggesting that these alterations can 
represent trigger events of motor neurone degeneration in S0D1®^^^ mice. 
Whether these phenomena are linked or if they represent simultaneous 
unrelated mechanisms in the motor neurone death process needs to be 
demonstrated. However, several evidences indicates interplay between AMPA- 
mediated excitotoxicity and the activation of intracellular signalling, including 
p38MAPK pathway. Decreased levels of GluR2 generate AMPA receptors 
highly permeable to divalent ions and to calcium in particular, leading to 
excitotoxic processes. As demonstrate by previous reports, abnormal Ca^ "^  
influx through AMPA receptors in neurones can determine activation of 
p38MAPK pathway, which, in turn, may contribute to activation of death 
processes. On the other hand, the action of phosphorylated p38MAPK has also 
been correlated to internalisation of GLUR2 AMPA subunit, thus suggesting that 
exceptional activation of p38MAPK can be causative of the decreased GluR2 
subunit expression on the cell surface. Over activation of p38MAPK in motor 
neurones can be consequence of several stimuli. This MAP kinase is activated 
by the action of TNFa and it has been demonstrated that TNFa is activated in 
ALS mice at the presymptomatic stage. Preliminary results obtained in our 
laboratory show that TNFa receptors are over expressed in the motor neurones 
of presymptomatic SODI®^^^ mice. Therefore, a precocious activation of TNF 
pathway might result in activation of p38MAPK in motor neurones, which in turn
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may lead to decreased expression of GluR2 subunit in these cells. Although 
suggestive, this hypothesis needs to be demonstrated.
Increased number of GluR2-lacking AMPA receptors causes the excessive 
influx of calcium in the motor neurones. However, this kind of receptors is also 
highly permeable to Zn^ .^ Zinc-mediated excitotoxicity requires much lower 
intracellular concentrations of zinc than calcium and cause a prominent 
mitochondrial dysfunction in neurones. One of the earliest neuropathological 
feature observed in the motor neurones of mice is represented by
mitochondrial swelling. Since motor neurones are in contact with numerous 
glutamatergic terminals rich in zinc, excessive influx of this ion through GluR2- 
lacking AMPA receptors could be a possible cause of motor neurone death in 
ALS. An excess of intracellular zinc is usually counteracted by the activation of 
a zinc transporter, ZnT-1, that favour the expulsion of the ion from the 
cytoplasm. Here, we have found a very low expression of ZnT-1 in spinal motor 
neurones of SODI®®^^ mice as well as in non transgenic mice (see chapter 5). 
As this transporter plays a neuroprotective role, our results suggest that the 
almost absent expression of ZnT-1 can represent a risk factor that predisposes 
motor neurones to AMPA-mediated toxicity. However, the evaluation of free 
zinc accumulation in degenerating motor neurones needs to be demonstrated.
With the progression of the disease, a massive activation of glial cells, 
both astrocytes and microglia, occur in the ventral horn of lumbar spinal cord of 
SODI®^^^ mice. Our results show that p38MAPK is remarkably activated also in 
these cells during the progression of the pathology (see chapter 7). Activation of 
p38MAPK in glial cells of ALS mice could derive from several factors such as
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excitotoxic stimulation, interaction with inflammatory cytokines or undiscovered 
neuronal factors released by affected motor neurones. On the other hand, it has 
been demonstrated that activation of p38MAPK in astrocytes and microglia is 
implicated, in its turn, in the production of inflammatory mediators such as TNFa 
and IL-ip, originating a positive feedback which can result detrimental to motor 
neurones. Activation p38MAPK pathway has also been associated to the 
activation of inducible nitric-oxide synthase (iNOS) transcription in astrocytes 
that result in sustained release of large amounts of nitric oxide (NO). NO can 
generate harmful oxidant species that can affect glutamate transporters and 
their uptake capability. Thus, p38MAPK activation in astrocytes could indirectly 
lead to excitotoxicity on motor neurones.
Although the prominent astrocytosis occurring in the spinal cord of 
S0D1®^^^ mice during the development of the pathology, we showed that the 
expression of the main glial glutamate transporter GLT-1 is selectively 
decreased in lumbar spinal cord of SODI^®^^ mice at the advanced state of the 
disease, without significant changes in its mRNA levels. Since expression of 
glutamate transporters is strictly regulated by neuronal factors, these results 
suggest that the downregulation of GLT-1 levels can represent an 
epiphenomenon deriving from the motor neurone loss occurring at the end 
stage of the pathology rather than a trigger factor involved in the motor neurone 
degeneration.
To better understand the mechanisms underlying the decreased 
expression of GLT-1 in SODI^®^^ mice, we transfected cultured astrocytes with 
human SODI®^^^ mutant and we evaluated levels and function of GLT-1 (see
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chapter 6). In line with the in vivo studies, the results showed that the levels of 
a glutamate transporter GLT-1 were downregulated in astrocytes transfected 
with SODI^®^^, without alterations of its mRNA level. This effect was selective 
to GLT-1, since the protein and mRNA levels of another glutamate transporter, 
G LAST, were not altered. Reflecting the decrease of GLT-1 protein, ^H-D- 
aspartate uptake in transfected astrocytes was also reduced. Interestingly, both 
the effects were not reverted by the use of antioxidants and there was no 
evidence of increased reactive oxygen species in transfected astrocytes. These 
data suggest that the decreased GLT-1 expression can be also due to a direct 
action of mutated S0D1 on the protein levels of the transporter and that the 
reduced uptake capability is a consequence of the decreased transporter 
availability rather than oxidative processes. It is noteworthy that the over 
expression of wild type human S0D1 also produces effects similar to those 
induced by the mutant form, even if with less intensity. It has been reported that 
mice overexpressing wild type enzyme showed some neuropathological 
alteration in motor neurones without developing of the disease. This suggests 
that, although the gain of a new adverse function by the S0D1 mutants is 
necessary to induce clinical signs of motor neurone disease in ALS mice, the 
overexpression of human wild type protein can also have some harmful 
properties, which are not enough to produce massive motor neurone death in 
mouse models but that become evident when expressed in a particular cell 
culture model like the one used in our study.
In conclusion, we have demonstrated that altered composition of 
glutamate AMPA receptors in motor neurones of SODI®^^^, associated to
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activation of p38MAPK pathway, represents an early event that probably plays 
a pivotal role in the trigger of motor neurone death. The vulnerability of these 
neurones, in respect to glutamate-induced degeneration, is likely exacerbated 
by the low expression of zinc transporter ZnT-1. Decreased levels of glutamate 
transporter GLT-1 in astrocytes, caused by the expression mutant SOD1, 
become evident only at the late stage of the pathology, contributing to 
excitotoxic insult to motor neurones but probably not representing a causative 
factor of their death.
The hypothesis regarding the involvement of AMPA glutamate receptors in 
ALS pathology is reinforced by our results showing the positive effects of the 
treatment with a new AMPA receptor antagonist, ZK 187638, on symptoms and 
survival of S0D1®®^  ^ mice (see chapter 4). This observation is in line with 
previous studies reporting similar effects obtained treating different mouse 
models of motor neurone disease with other AMPA antagonists. However, the 
compound used in our study offers a better bioavailability associated to an 
easier administration and shows a good efficacy also when administrated after 
the appearance of symptoms. Moreover, it works as an allosteric modulator of 
the glutamate binding site, minimizing the side effects.
The hope is that the results obtained in this study may contribute to the 
development of future new therapeutic strategies, which can help people 
affected by this devastating pathology.
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